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STELLINGEN 
1. Analyse van het genoom met behulp van specifieke DNA 
probes kan een belangrijke bijdrage leveren aan de 
diagnose van chronische myeloide en acute lymfoblastische 
leukemie. 
(Dit proefschrift) 
2. Twardzik en medewerkers concluderen ten onrechte, dat de 
aanwezigheid van "transforming growth factor ce" (TQEto) in 
de urine van kankerpatiënten een goede tumormarker is. 
(Twardzik et al., Cancer Research 45, 1934-1939, 1985) 
De conclusie van Bolen en medewerkers, dat in dikke darm 
carcinomen de pp60 c-src protéine kinase activiteit is 
verhoogd, wordt niet voldoende ondersteund door hun 
waarnemingen. 
(Bolen et al., P.N.A.S. 84, 2251-2255, 1987) 
4. Wanneer met in vitro analyse van kernextracten binding van 
eiwitten aan DNA aangetoond kan worden, betekent dit nog 
geenszins dat die binding ook bij genregulatie in vivo 
van belang is. 
(Becker et al., Cell 51, 435-443, 1987) 
Het lijkt hoogst onwaarschijklijk, dat de blastcrisis van 
CML patiënten gepaard gaat met een verandering van het 
breukpunt in het bcr gebied van het Philadelphia 
chromosoom, zoals gesuggereerd wordt door Schaefer-Rego en 
medewerkers. 
(Schaefer-Rego et al., Blood 70, 448-455, 1987) 
6. In tegenstelling tot wat gesuggereerd wordt door Carpenter 
en medewerkers, lijkt de tyrosine kinase activiteit van de 
"epidermal growth factor (EGF) receptor" geen rol te 
spelen bij de stimulering van de celgroei. 
(Carpenter et al., Cell 37, 357-358, 1984; Prywes et 
al., The EMBO Journal 5, 2179-2190, 1986) 
7. Het rapport waarin gesteld wordt dat aspirine de kans op 
een hartaanval kan verkleinen, zou niet door de 
farmaceutische bedrijven in advertenties gebruikt mogen 
worden. 
(The Steering Comnitee of the Physicians' Health Study 
Research Group, N.Engl.J.Hed. 318, 262-264, 1988) 
Een land dat bekend is om zijn ••hollanditis" zou geen bom 
moeten gebruiken om de eindronde van het Europees 
voethalkampioenschap te bereiken. 
Stellingen behorende bij het proefschrift: The genetic basis 
of chronic myelogenous and acute lymphoblastic leukemia. 
Kees Stam, Hageningen, 15 april 1988. 
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CHAPTER 1 
SCOPE OF THE INVESTIGATION 
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Scope of the Investigation 
The Ph' chromosome is a cardinal feature of chronic myelogenous 
leukemia (CML). Originally described by Nowell and Hungerford (1960) 
as a small chromosome 22 it was later demonstrated by de Klein and co-
workers(1982) to typically result from a reciprocal translocation 
t(9;22)(q34.1;qll.2). In approximately 5 percent of patients, the Ph' 
chromosome results from anomalous complex translocation. Detailed 
studies using in situ hybridization have demonstrated that chromosomes 
9 and 22 are usually involved in such translocations. Translocations 
between chromosome 22 and a chromosome other than 9 rarely occur. 
The human c-abj. sequences represent the cellular homologue of the 
transforming gene of Abelson Murine Leukemia Virus (A-MuLV). This 
retrovirus is a recombinant between Moloney Murine Leukemia virus and 
mouse cellular c-abj. sequences (Goff et al., 1980). A-MuLV induces 
lymphoid tumors following In vivo inoculation of the mouse (Potter^ 
1983; Prekumar et al., 1975). Southern blot analysis of a series of 
somatic cell hybrids demonstrated that the human c-abl gene is 
localized on chromosome 9 (Heisterkamp et al., 1982). The finding 
that a small region of chromosome 9 is translocated to chromosome 22 
in CML prompted studies to elucidate whether the abj gene was involved 
in this disease (de Klein et al., 1982). Bartram and colleagues (1983) 
first reported that the c-abj. gene is translocated in Ph' positive but 
not in Ph' negative patients while Heisterkamp and co-workers (1983) 
reported a CML patient with a breakpoint 14 kb 5' of the c-abl 
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sequences homologous to v-abj.. This data suggested a role for c-abl in 
CML, a theory supported by the presence of an abnormally sized abl 
messenger RNA (Collins et al., 1984; Gale and Canaani, 1984) and abl 
protein in the CML cell line K562 (Konopka et al., 1984). 
The region of chromosome 22 involved in the translocation has also 
been identified. Cloning of a chimeric breakpoint fragment from a CML 
patient (Heisterkamp et al., 1983) enabled the use of a chromosome 22 
specific probe. Subsequent Southern blot analysis of the DNA of a 
number of CML patients showed that chromosome 22 breakpoints map to a 
stretch of 5.8 kb of DNA (Groffen, et al., 1984). This area on 
chromosome 22 was designated breakpoint cluster region or bcr. 
The investigation described in this thesis was undertaken to gain 
further insight into the genetic organization of the c-abj. gene on the 
Ph' chromosome and the consequence of the Ph' translocation at the 
transcription and translation level. Chapter 2 is an extensive review 
of the genetic basis of CML and acute lymphoblastic leukemia (ALL). 
Discussed is the cytogenetic and molecular aspects of CML and ALL and 
the activation of the c-abl protein kinases as a consequence of the Ph' 
translocation. In Chapter 3, we show that the breakpoint cluster 
region on chromosome 22 is part of a gene, called pM- Molecular 
characterization demonstrates that p M is a large gene oriented with 
its 5' end towards the centromere and with its 3' end toward the 
telomere of chromosome 22. As a consequence of the Ph' translocation 
the 3' end of this gene is translocated to chromosome 9, whereas the 5' 
sequences remain on the Ph' chromosome. Following translocation, the 
remaining p_hl sequences become fused to the c-abl gene in a head to 
tail fashion on chromosome 22. We hypothesized that this genomic 
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configuration could result in the transcription of a chimeric mRNA 
consisting of 5' ehl and 3' abj. sequences. In the study presented in 
Chapter 4, we analyzed the RNA of CML patients and found strong 
evidence for this model. Direct proof for the hypothesis was provided 
by cloning of a chimeric phl/c-abl cDNA in the CML cell line K562, 
described in Chapter 5. The experiments described herein have also 
contributed to more information about the genomic organization of the 
phi and c-ab_l genes on the Ph' chromosome. 
Reports by Konopka et al. (1985) showing the presence of a larger 
210K c-abj. protein in the leukemic cells of CML patients initiated the 
studies described in Chapter 6. We demonstrate that this abnormal c-
abl protein is a fusion protein containing amino terminal £hl and 
carboxy terminal abj. sequences. This phl/c-abl protein has an elevated 
tyrosine kinase activity when compared to the normal c-abj. protein. In 
addition, we show in this chapter that the normal ßhj. gene encodes for 
a 160 K phosphoprotein exhibiting an associated kinase activity. 
A better understanding of the Ph' chromosome at the molecular 
level has allowed us to develop a probe for the detection of the Ph' 
translocation. In Chapter 7, we report the results of the clinical 
trials done at seven medical centers involving more than 400 clinical 
samples. In this report we demonstrate that the use of DNA probe 
analysis in the CML diagnostics has several advantages over cytogenetic 
methods. 
CHAPTER 2 
THE GENETIC BASIS OF CHRONIC MYELOGENOUS AND 
ACUTE LYMPHOBLASTIC LEUKEMIA 
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I. Introduction 
In 1890, David Hansemann first drew attention to the frequent 
occurrence of mitotic irregularities in malignant tissues. He 
associated them with the origin and development of malignancy and 
suggested that such nuclear abnormalities could be used as a criterion 
for diagnosis of the malignant state. Such notions formed the basis of 
the mutation theory of cancer, presented in 1914 by Theodore Boveri in 
his book "Zur Frage der Entstehung Maligner Tumoren", in which 
chromosomal aberrations were suggested as the cause of the change from 
normal to malignant growth. This long remained a theoretical idea 
because of the technical difficulties in chromosome preparation 
throughout the first half of the century. 
During the 1950s and 1960s, the application of methods developed 
for the study of chromosomes in plants and insects, coupled to the 
availability of mammalian tissue culture made it possible to work out 
detailed karyotypes. Clear-cut correlations were established between 
specific chromosome abnormalities and a number of disease states, 
laying a firm foundation for modern cancer cytogenetics. The results 
obtained, clearly demonstrated that the chromosome changes observed 
were an integral part of tumor evolution. However, most of this early 
work employed metastatic tumor cell populations, in which the 
chromosomal picture can be assumed to have changed considerably since 
the primary oncogenic process. Few, if any, conclusions, therefore, 
could be drawn as to the role of chromosome changes in etiology of 
neoplasia. The early chromosome studies on malignant cells have been 
summarized in detail previously (Atkin, 1976; Levan and Mittelman, 
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1977; Hsu, 1979; Sandberg, 1980). 
In 1960 Nowell and Hungerford (1960) reported the first consistent 
chromosome abnormality in a human cancer; they observed an unusually 
small G group chromosome in leukemic cells from patients with chronic 
myelogenous leukemia (CML). This chromosome, which appeared to have 
lost about one half of its long arm, was named the Philadelphia (Ph') 
chromosome in honor of its city of discovery. The question of whether 
the deleted portion of the long arm was missing from the cell or 
whether it was translocated to another chromosome could not be answered 
at that time because it was impossible to identify each human 
chromosome precisely with the techniques available. The discovery of 
the Ph' chromosome in CML seemed to be the conclusive verification of 
Boveri's idea: a malignant disorder strictly correlated to a specific 
chromosomal change. However, results obtained after a search for 
similar abnormalities closely associated with other types of malignant 
hematologic diseases were quite disappointing. Although the 
abnormalities seemed to be consistent in any particular patient, the 
patterns varied greatly from one patient to another. Moreover about 
one-half of the patients with acute leukemia of both the myeloid and 
lymphoid types appeared to have a normal karyotype in their leukemic 
cells (Rowley and Testa, 1982; Mitelman and Levan, 1981; Sandberg, 
1980). Thus, the accepted notion was that the Ph' chromosome was a 
unique example of a consistent karyotypic abnormality, and the general 
rule was one of marked variability in karyotype. This in turn led most 
investigators to assume that chromosome changes were a secondary 
phenomenon, rather than being fundamentally involved with the process 
of malignant transformation. 
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Evidence obtained during the 1980s showed that these assumptions 
were incorrect. The introduction and consistent refinement of 
chromosome banding techniques (Hagemeijer et al., 1979; Yunis, 1981; 
Testa, 1984) made it possible to identify and define tumor specific 
chromosomal aberrations. Combination of these sophisticated 
cytogenetic techniques with cytological, cytochemical and immunological 
studies revealed that the malignant cells of most human tumors have a 
clonal karyotypic defect (Yunis et al., 1982; Yunis, 1983; Berger and 
Flandrin, 1984). A major breakthrough in cancer research came with the 
development of recombinant DNA techniques which made it possible to 
localize, clone and characterize the individual genes involved in 
tumorigenesis. 
It is well known that cancer has myriad causes, but many of these 
may act in a common way by damaging DNA, resulting in the activation, 
mutation or loss of distinct genes. At least three major functional 
groups of such genes can be discerned. The oncogenes represent the 
first group (Bishop, 1983, 1985, 1987; Duesberg, 1983, 1985; Slamon et 
al., 1984; Weinberg, 1985; Land et al., 1983). They seem to act 
dominantly in the sense that they can induce transformation when 
transferred to cultured cells. Oncogenes are present in the human 
genome as normal cellular genes (proto-oncogenes) frequently involved 
with the control of normal cell growth; so far more than 50 proto-
oncogenes have been identified. 
A second group of genes are called "tumor suppressors" or "anti-
oncogenes". These genes act recessively in the sense that both alleles 
need to be deleted or functionally incapacitated before a tumor can 
arise. The most thoroughly analyzed example of such a gene is rb-1, 
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both alleles of which are lost in retinoblastoma tumor cells (Cavenee 
et al., 1983; Murphree and Benedict, 1984; Benedict et al., 1983). It 
has been suggested that the rb-1 gene may have a normal regulatory 
function, possibly in the induction of an essential step in the 
terminal differentiation of this tissue (Murphee and Benedict, 1984; 
Knudson, 1971; Knudson and Strong, 1972; Comings, 1973; Robertson, 
1984). Certain other neoplasms such as Wilms' tumor, familial renal 
cell carcinoma, neuroblastoma and small-cell carcinoma of the lung 
(SCLC), may also arise from the loss of both alleles of a single gene. 
This evidence for recessive anti-oncogenes is consistent with much 
earlier reports of the suppression of tumorigenic behavior in hybrids 
derived from the fusion of malignant with normal cells (Harris, et al., 
1969; Klein et al., 1981; Wiener et al., 1973; Stanbridge et al., 
1976). Cytogenetic analysis of such hybrids and their malignant 
segregants suggests the existence of different suppressor genes on 
different chromosomes (Jonasson et al., 1977; Spira et al., 1981; Evans 
et al., 1982; Klinger and Shows, 1983). There is now evidence that the 
transforming effect of certain retroviral oncogenes can be counteracted 
by different suppressor genes. For instance, revertants of in vitro 
Kirsten-murine sarcoma virus-transformed fibroblasts have been found to 
suppress ras, fes, and sis, mediated transformation after somatic 
hybridization (Noda et al., 1983). Eventually, the suppressor genes 
may turn out to be as diverse as the oncogenes. 
The third group of genes that influence neoplastic behavior are 
designated modulators. They do not, on their own, transform normal 
into neoplastic cells, but they modify their spread in the organism. 
They probably constitute a large and heterogenous group. For example, 
24 
metastatic spread may be influenced by the genes of the major histo-
compatibility complex (MHC) (Katzav et al., 1983; Sandersson and 
Beverley, 1983) and invasiveness by those genes controlling proteolytic 
and homing mechanisms (Nicholson, 1982; Dano et al., 1985). Cellular 
resistance to immune rejection (Dalianis et al., 1979; Fenyö and Klein, 
1976) may also play a part. 
Data concerning the molecular basis of the Ph' translocation in 
CML have accumulated rapidly over the past few years. The Ph' 
chromosome is observed in high frequency in CML (approximately 95 
percent of patients with typical CML have this marker [Sandberg, 1980; 
Rowley, 1973, Heim et al., 1985]). In addition, the Ph' chromosome is 
also found in both acute lymphoblastic leukemia (ALL) and, more rarely, 
in acute nonlymphocytic leukemia (ANLL) (Le Beau and Rowley, 1984; 
Chessells et al., 1979; Priest et al., 1980; Abe and Sandberg, 1979; 
Yunis et al., 1984). It offers one of the most clearly documented 
examples of a translocation which leads to the activation of a human 
cellular oncogene. The fusion of the c-abj. and pjhj. gene result in the 
production of an activated abj. protein (Ben Neriah et al., 1986b; Stam 
et al., 1987; Hermans et al., 1987), which is probably directly 
involved with the malignant process. In the following review I will 
discuss the genetic basis of chronic myelogenous and acute 
lymphoblastic leukemia. 
25 
II. Chronic Myelogenous and Acute Lymphoblastic Leukemia: 
Disease and Treatment 
a) Leukemias 
Cancer is the leading cause of death in the Western world, after 
heart disease. In the United States alone, 500,000 people die per year 
of cancer (source Surveillance, Epidemiology and End Results (SEER) 
from the National Cancer Institute). Lung cancer is responsible for 
most of the cancer deaths, with 36 percent in man and 20 percent in 
women (Table 1). Leukemias and lymphomas are responsible for 10 
percent of the cancer deaths. The annual mortality of leukemia varies 
from three to seven per 100,000 in different countries. In the United 
States the estimated new cases of leukemias for 1987 is 26,000. 
Leukemia is not a single disease entity but refers to a 
heterogenous group of neoplastic disorders involving the cells of the 
blood-forming organs. The leukemias are usually classified as acute or 
chronic, based on length of survival and degree of maturation of the 
cells. They are further subclassed according to the predominant cell 
line involved. This classification broadly divides them into 
lymphocytic and myelogenous forms. Acute leukemias are characterized 
by a predominance of immature myeloid or lymphoid precursors (blasts or 
blast forms). The blasts progressively replace normal bone marrow, 
migrate and invade other tissues. In the acute state, production of 
normal erythrocytes, granulocytes (neutrophils, eosinophils and 
basophils), and platelets is diminished leading to anemia, infection 
and hemorrhage. If untreated, the acute leukemias are fatal within a 
period of twelve months. 
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The acute leukemias are divided into two major types called acute 
lymphoblastic leukemia (ALL) and acute nonlymphoblastic leukemia 
(ANLL). The latter is divided into several subtypes depending on the 
predominant cell types present. The different subtypes, 
erythroleukemia, acute monocytic leukemia, acute myelomonocytic 
leukemia, acute promyelocytic leukemia (APL), acute megakaryoblastic 
leukemia, acute eosinophilic and acute basophilic leukemia are 
collectively called acute myelogenous leukemia (AML). 
Chronic leukemias are hematologic malignancies in which the 
predominant leukemic cell will differentiate normally. The chronic 
leukemias include chronic lymphocytic leukemia (CLL) and chronic 
myelogenous leukemia (CML). CLL is a malignant hematologic disorder 
characterized by a persistent, absolute increase in morphologically 
mature lymphocytes in the peripheral blood and bone marrow. It is a 
rare disorder in persons less than 30 years of age and gradually 
increases in incidence with each decade. The median age of CLL 
patients is 60 years. The median survival of CLL patients varies from 
24 months for patients with anemia and thrombocytopenia to eight to ten 
years for patients whose primary symptoms are lymphocytosis and 
lymphadenopathy. 
CML is a clonal myeloproliferative disorder arising from 
neoplastic transformation at the level of the pluripotent stem cell. 
It is characterized by a greatly elevated leukocyte count with all 
stages of granulocytic development in both peripheral blood and bone 
marrow. Within a mean of three years after diagnosis, the relatively 
benign chronic phase of CML gives way to a phase known as blast crisis. 
CML accounts for 20 to 30 percent of cases of leukemia and can occur at 
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any age. It is rare in childhood and peaks in the middle 40's. 
b) Chronic myelogenous leukemia 
Clinical characterization 
CML, originally described by Craigie (1854), Bennett (1845) and 
Virchow (1845), is a hematologic malignancy characterized by excessive 
growth of myeloid cells and their progenitors (Koeffler and Golde, 
1981; Goldman and Lei, 1982). The hallmark of CML is the Philadelphia 
(Ph') chromosome. This is an acquired chromosomal defect and is 
recognized by a shortening of the long arm of chromosome 22. 
Cytogenetic studies and analysis of glucose-6-phosphate dehydrogenase 
(G-6PD) isoenzyme analysis (Beutler et al., 1962; Lyon, 1962) 
demonstrated that CML is a clonal disorder of pluripotent hematopoietic 
stem cells. The Ph' chromosome, which is present in the leukemic cells 
of over 95 percent of the CML patients (Rowley, 1973; Sandberg, 1980; 
Heim et al., 1985), has been identified in neutrophils, monocytes, 
macrophages, erythrocytes, megakaryocytes, eosinophils, basophils and 
their committed progenitors (for review, Champlin and Golde, 1985; 
Greaves et al., 1982; Koeffler and Golde, 1981). Reports by Hernandez 
et al. (1982) and Griffen et al. (1983) of cases with a T lymphocyte 
blast crisis suggest that the disease may involve a pluripotent cell 
capable of differentiating to T lymphocytes as well as to other myeloid 
and lymphoid cells. The Ph' chromosome is not present in bone marrow 
fibroblast or other mesenchymal tissues (Maniatis et al., 1969). 
The clinical features of CML are usually limited to excessive 
granulocytosis, although in many patient's blood levels of platelets, 
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monocytes and even lymphocytes are also Increased. Untreated patients 
have a high white blood cell count (WBC) generally peaking at 100 to 
400 x 109 per liter blood. The red blood cell production is often 
decreased, resulting in anemia. The patient's principal complaint is 
fatigue. Abnormal physical findings usually are limited to pallor, 
splenomegaly and sternal tenderness. 
Increase of myelopoiesis appears not to be due to an accelerated 
proliferative rate (Chervenick and Boggs, 1968), but rather the disease 
is characterized by massive expansion of pools of committed myeloid 
progenitors which have a growth advantage over normal bone marrow 
progenitors (Galbraith and Abu-Zahra, 1972; Moore et al., 1973; Goldman 
et al; 1980). The proportion of Ph' chromosome-positive cells 
progressively increases over time to ultimately representing more than 
99 percent of dividing bone marrow cells. Philadelphia chromosome-
negative cells persist in the bone marrow but this growth is eventually 
suppressed by the malignant clone (Gupta et al., 1984; Dube et al., 
1984). 
Myeloid cells mature normally during the chronic phase of CML. 
There are subtle abnormalities of granulocyte (Broxmeyer et al., 1977; 
Olofsson et al., 1976) and platelet (Schafer, 1984) function, but these 
rarely lead to symptomatic complications. The mature cells have 
usually a decreased leukocyte alkaline phosphatase (LAP). The 
malignant cells are minimally invasive in the chronic phase and 
generally remain retracted to the hematopoietic tissues (the marrow 
and spleen). Release of immature cells to the blood often indicates 
evolution to the acute phase (Theologides, 1972; Barton et al., 1979). 
The chronic phase of CML is unstable. At some point, the disease 
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undergoes transformation to an aggressive leukemia. Transformation may 
be clinically manifest as in acute leukemia (acute phase or blast 
crisis) or by progression of symptoms and resistance to chemotherapy 
(termed accelerated phase) (Karanas and Silver, 1968). Features 
associated with transformation include systemic symptoms (fever, 
sweats, or weight loss) increasing organomegaly, or extramedul1ary 
leukemias. The granulocyte and/or platelet count typically becomes 
less responsive to chemotherapy while the proportion of blasts and 
promyelocytes increases, often associated with the development of 
anemia and/or thrombocytopenia. In more than 75 percent of patients, 
transformation is accompanied by karyotypic evolution with development 
of abnormalities superimposed upon the Ph' chromosome, most commonly 
trisomy 8 or, isochromosome 17 or duplication of the Ph' chromosome 
(Spiers and Baikie, 1968; Rowley, 1975). 
Most patients ultimately develop acute phase (blast crisis), in 
which the disease resembles acute leukemia. The cells no longer 
differentiate to mature granulocytes; maturation arrest occurs at the 
level of the blast or promyelocyte (Golde et al., 1974). This phase 
can be divided into two general forms: lymphoid and myeloid (Rosenthal 
et al., 1977; Boggs, 1974; Janossy et al., 1979). Lymphoid blast 
crisis develops in approximately 30 percent of the patients (Catovski, 
1979). In this variant, the blast cells are phenotypically similar to 
the common form of acute lymphoblastic leukemia. Myeloid blast crisis 
is heterogenous. The blasts appear to be morphologically similar to 
myeloblasts and express myeloid antigens and cytoplasmic enzymes. 
Erythroid and megakaryocytic variants of blast crisis also occurs (Bain 
et al., 1977; Rosenthal et al., 1977). 
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Several factors present at the time of diagnosis are associated 
with early transformation to blast crisis, including a high WBC count, 
a large proportion of immature cells, large spleen or liver size and 
large number of eosinophils or basophils. Patients with an apparently 
normal karyotype generally have an extremely poor prognosis compared to 
patients with the typical Ph' chromosome abnormality. Patients 
presenting with other chromosome abnormalities may also have a worse 
prognosis (Ezdinli et al., 1970; Whang-Peng et al., 1968). After the 
first year, there is a relatively constant risk of transformation to 
blast crisis; approximately 25 percent of patients surviving at any 
point will evolve into blast crisis over the ensuing year. Medium 
survival is three to four years. Less than 30 percent of patients 
survive five years (Fialkow et al., 1981). 
Treatment 
Several different strategies have been developed for the treatment 
of CML. The treatment of CML is mainly palliative (Koeffler and Golde, 
1981; Goldman and Lei, 1982; Wiernik, 1984; Priesler and Raza, 1982), 
being hampered by the lack of differential sensitivity to chemotherapy 
between the malignant cells and their normal hematopoietic counter 
parts (Goto et al., 1982). Treatment with an alkylating agent like 
busulfan or an anti-metabolite (DNA-synthesis inhibitor) like 
hydroxyurea is generally effective in controlling the granulocytosis 
and thrombocytosis. Other therapeutic approaches have included 
intensive leukapheresis, splenic irradiation and radioactive phosphorus 
(Reinhard et al., 1959). 
Such methods usually suppress the growth of the malignant clone 
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but fail to eradicate the disease. Patients who achieve "clinical 
remission", i.e., normal blood cell counts, continue to have 
predominantly Ph' chromosome-positive cells in the bone marrow. 
Although chemotherapy will relieve the symptoms of the disease, there 
is no evidence that treatment with any chemotherapeutic agent delays 
the development of blast crisis or prolongs patient survival (Minot et 
al., 1924; Medical Research Council, 1968). 
For CML patients in the early benign phase of the disease, 
recombinant human interferon alpha-A has recently been shown to induce 
hematologic remission (as reviewed by normalization of the WBC count, 
normalization of differential cell counts with no immature forms and 
the disappearance of all clinical symptoms)(Talpaz et al., 1986). 
Therapy with interferon also appears to result in the suppression of 
the Ph' chromosome in some of these patients. Yoffe et al. (1987) 
reported 2 cases where interferon therapy resulted in the restoration 
of normal bone marrow, whith apparently complete remission monitored, 
•to date, for 6 months in one case and 9 months in the other. Molecular 
analysis of these patients after treatment, showed (with a probe 
sensitivity of 5 percent Ph' positive cells) that no Ph' positive cells 
were present. However, interferon has sometimes strong side effects of 
fever and malaise. Further studies are needed to assess the effect of 
interferon on the course of Ph' positive CML and to determine the 
effect of combining it with other chemotherapeutic and biologic agents 
that may have antitumor activity in this disease (Kurzrock et al., 
1985). 
The most encouraging results have been obtained with high dose 
combination chemo-radiotherapy, followed by syngeneic or allogeneic 
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bone marrow transplantation. This is the only treatment so far capable 
of eradicating the leukemic clone. Fever et al. (1982) initially 
reported prolonged disease-free survival in patients with CML receiving 
high-dose cyclophosphamide, total body irradiation and syngeneic bone 
marrow transplants. Approximately 65 percent of patients receiving 
syngeneic transplants in chronic phase and 20 percent of those treated 
while in blast crisis have achieved complete remission free of Ph' 
chromosome-positive cells and have survived for over five years free of 
disease. 
Similar results have been obtained with allogeneic marrow 
transplantation with marrow from HLA-identical sibling donors (Goldman 
et al., 1986). The actuarial two year survival among patients given 
transplants in the chronic phase of their disease was 72 percent, a 
figure that contrasts with an actuarial survival of 18 percent among 
those treated in later phases of the disease. The actuarial risk of 
relapse at two years in these two categories of patients was 7 and 42 
percent, respectively. Unrelated donor bone marrow transplantation is 
possible when a suitable matched sibling donor is not available and 
when performed before the onset of advanced disease (Ganesan et al., 
1987). Unfortunately, only a minority of patients are currently 
candidates for bone marrow transplantation as most patients either lack 
an HLA-identical sibling donor or are too old to be considered. 
c) Acute lymphoblastic leukemia 
Clinical characterization 
Acute lymphoblastic leukemia (ALL) is a hematologic malignant 
34 
disease characterized by an uncontrolled proliferation of immature 
lymphocytes and their progenitors. The fundamental defect appears to 
be an unregulated proliferation of early precursor cells that have lost 
their capacity to differentiate. Studies with glucose-6 phosphate 
dehydrogenase and chromosome markers provided evidence that ALL is a 
disease in which normal and malignant cells coexist and compete for 
ascendancy within the bone marrow. This is in contrast to CML, in 
which only few normal hematopoietic progenitors are detectable at the 
time of diagnosis. Although ALL is most common in children, a 
substantial proportion of cases occur in adolescents and adults. The 
clinical symptoms of ALL relate to decreased numbers of hematopoietic 
cells. The signs and symptoms may have been present for several weeks 
to months before diagnosis and are usually nonspecific, consisting of 
mild fatigue, malaise and anorexia. With the development of anemia, 
the symptoms generally progress to more marked fatigue and pallor. 
Classification 
The complex array of hematopoietic differentiation suggests that 
the acute leukemias are extraordinarily heterogenous. Both 
morphological and immunological features are used to classify patients 
with ALL. A French-American-British (FAB) morphologic classification 
of ALL has been developed that recognizes three types of lymphoblasts 
termed LI, L2 and L3 (Bennett et al, 1976). The FAB classification is 
based on a spectrum of cell properties, such as the ratio of nucleus to 
cytoplasm, the number and size of nucleoli, and the degree of 
cytoplasmic basophilia. In childhood ALL, 85 percent of patients have 
LI morphology. In contrast, adults with ALL have a predominance of the 
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L2 morphology. The L3 morphology, resembling that in Burkitt's 
lymphoma is occasionally present in adults with ALL. 
A second approach to the classification of ALL is based on the 
immune features of the leukemic cells, in this system subtypes are 
termed common, T, B or null phenotypes, based on the detection on the 
cell surface of the common ALL antigen (a polypeptide with a molecular 
weight of 100,000), receptors for ovine red blood cells, T-cell 
antigens, or immunoglobulin molecules, respectively. Null cells have 
none of these surface features. In children, approximately 75 percent 
of cases are of the common ALL phenotype which may belong to the B-
lymphocyte lineage (Korsmeyer et al., 1983). The remainder consist of 
T-cell or null cell phenotypes: B-cell ALL accounts for less than 1 to 
2 percent of cases. In adults, the distribution of immunophenotypes is 
significantly different. Only 50 percent of cases are the common 
phenotype. Null cell ALL accounts for up to 40 percent in some 
studies, while the incidence of B-cell ALL also increases (Greaves and 
Lister, 1981). The increased frequency of phenotypically 
undifferentiated or null-cell ALL in adults is of possible prognostic 
importance. Recent data suggest that in some cases of null-cell ALL 
the cells may represent myeloid or hybrid leukemias rather than typical 
ALL (Desforges, 1981). 
Chromosomal abnormalities 
Data indicate that up to two thirds of adults with ALL have 
chromosomal abnormalities, including hypodiploidy, pseudodiploidy, and 
hyperdiploidy, as well as specific chromosome translocations. 
Approximately 17 to 25 percent of adults with ALL (LeBeau and Rowley, 
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1984) and 2 to 6 percent of children with ALL (Chessels et al, 1979; 
Priest et al, 1980) have the Ph' chromosome. Patients with Ph' 
positive ALL are heterogenous; up to 20 percent have a disease best 
characterized as lymphoid transformation of CML (Pittman et al, 1979). 
These patients may have a remission after treatment with vincristine 
and prednisone. They, nevertheless, retain the Ph' chromosome while in 
remission (as do patients with typical CML) and usually relapse within 
a short time with either lymphoid-blast or, less typically, myeloid-
blast crises (Catovsky, 1979). The second group of Ph'-positive 
patients with ALL are more typically of high-risk ALL. If these 
patients respond to chemotherapy, the bone marrow in remission is 
cytogenetically normal. Remission tends to be brief, with bone marrow 
or central nervous system relapse; myeloid transformation does not 
occur. Patients with ALL and the Ph' chromosome tend to be younger and 
have a lower white-cell count than those with lymphoid transformation 
of CML (Raza et al, 1982). Patients with L3 or the B-cell form of ALL, 
which is related to Burkitt's lymphoma or leukemia, have a high 
frequency of the t(8;14) translocation (Zech et al, 1976). Less 
commonly, translocations involving chromosome 8 and either 2 or 22 are 
found (t(2;8) and t(8;22)) (Van den Berghe et al, 1979). Other even 
less frequent aberrations found in ALL are t(4;ll), a deletion of the 
long arm of chromosome 6(6q-) and trisomy of chromosome 12(12+) (Jacobs 
and Gale, 1984). The result of cytogenetic studies suggest that ALL 
patients with chromosomal abnormalities have a worse prognosis. For 
example, over 70 percent of adults with a normal karyotype have 
remission with conventional chemotherapy, as compared with only 45 
percent of those with chromosomal abnormalities (Third International 
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Workshop, 1983). Abnormalities associated with a poor prognosis 
include t(9;22), t(4;ll) and t(8;14). In contrast, hyperdiploidy and 
6q- are both associated with a relatively good prognosis. 
Treatment 
The treatment of ALL is generally divided into two phases, called 
induction and continuation. The latter is subdivided into 
consolidation or intensification, and maintenance. The objective of 
induction chemotherapy is to achieve remission, i.e., the eradication 
of leukemia that is detectable by conventional techniques. 
Consolidation or intensification refers to the use of high-dose 
chemotherapy in patients who are in remission. These are aimed at 
completely eliminating residual clinically undetectable leukemia and 
preventing relapse and the emergence of drug resistant cells. 
Maintenance usually involves less intensive chemotherapy. Its purpose 
is to reduce the leukemia cell burden further. 
Approximately 50 percent of patients less than 15 years of age 
with ALL are experiencing long-term leukemia-free survival. This 
success has evolved during the past two decades by improving the rate 
of induction of complete remission, establishing the necessity for 
continued combination chemotherapy during remission with maximally 
tolerated doses of drugs, and prophylactically treating the central 
nervous system. 
The combination of vincristine and prednisone induces complete 
remission in more than 90 percent of pediatric patients. These drugs 
result in minimal suppression of normal regenerating bone marrow and 
allow for rapid induction of remission with minimal morbidity. 
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Patients more than 15 years of age and rare individuals with 
morphologically undifferentiated leukemia remain relatively resistant 
to this induction therapy. The addition of L-asparaginase or an 
anthracycline, such as daunomycin or adriamycin, may increase the 
proportion of patients who enter remission and may also result in lower 
relapse rates. 
Methotrexate and 6-MP have been the most effective agents for 
prolonging hematologic remission in ALL. Treatment in remission with 
drug combinations different from those employed in induction has become 
a standard part of the complete program. Combined with central nervous 
system prophylaxis it has, in the last decade, produced apparent cures 
in about 50 percent of children with ALL. Duration of maintenance 
therapy has varied from 2 1/2 to 5 years. 
Recent advances in understanding the biology and therapy of ALL 
have had a considerable effect on survival in this heterogeneous group 
of diseases; long term disease free survival rates of 50 to 75 percent 
are now observed in patients who receive chemotherapy (George et al., 
1979; Nesbit et al., 1983; Niemeyer et al., 1985; Hoelzer et al., 
1984). Some patients who have a first remission lasting more than 18 
months will have a prolonged second remission by chemotherapy alone 
(Rivera et al., 19851; Chessels et al., 1986). Chemotherapy followed 
by bone marrow transplantation from matched sibling donors has been 
used successfully in several centers to treat patients with leukemia in 
whom chemotherapy fails or who are at very high risk for relapse after 
primary therapy (Chessels, 1986; Johnson et al., 1981; Dinsmore et al., 
1983; Blume et al., 1980). In the 60 to 70 percent of patients that do 
not have a matched allogeneic marrow donor, autologous marrow 
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transplantation has been used (Ritz et al., 1982; Ramsay et al., 1985). 
The reports by Kersey et al. (1987) are encouraging, suggesting that in 
high risk group patients with a first remission lasting less than 18 
months, long-term survival can be obtained. 
III. Oncogenes, Mechanism of Activation and Biochemical Function 
a) Oncogenes 
The search for genetic damage in neoplastic cells now occupies a 
central place in cancer research. The belief that genetic damage might 
be responsible for cancer is based on a number of different findings: 
the recognition of hereditary predispositions to cancer (Lynch, 1976; 
Schimke, 1978; Ponder, 1980), the detection of damaged chromosomes in 
cancer cells (Rowley, 1983, 1984; Yunis, 1983), the apparent connection 
between susceptibility to cancer and impaired ability of cells to 
repair damaged DNA (Lehmann, 1982; Hanawalt and Sarasin, 1986), and 
evidence that relates the mutagenic potential of substances to their 
carcinogenicity (Ames, 1979). The discovery of cellular genes (proto-
oncogenes) that in another form (oncogenes) can be clearly demonstrated 
to induce neoplastic growth implicated DNA in the genesis of human 
tumors. 
To date more than 50 (proto) oncogenes (Table 2, Figure 1) have 
been identified. Several of the oncogenes have been associated with 
specific forms of human cancer (Bishop, 1983, 1985). They are believed 
to act individually or in concert; the interaction of oncogene-encoded 
proteins possibly accounts for the multi-stage nature of cancer. 
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Oncogenes are present in the human genome as normal cellular genes 
(proto-oncogenes) with normal cellular functions. Proto-oncogenes have 
been highly conserved throughout vertebrate evolution suggesting that 
they play a critical role in cellular metabolism or at particular 
developmental stages. 
Activation to oncogene activity can result from either qualitative 
or quantitative changes in the protein product encoded by an altered 
proto-oncogene. The activation could be caused by the expression of a 
normal proto-oncogene product in the wrong tissue or at the 
inappropriate development stage. The cellular processes affected by 
the conversion of a proto-oncogene into a transforming activated 
oncogene are not fully understood. 
b) Mode of discovery 
Viral transduction 
Cellular oncogenes were first identified as the homologues (c-onç) 
of the transforming genes of acute RNA tumor viruses (Bishop, 1983; 
Varmus, 1982, 1983). In contrast to the slowly transforming RNA tumor 
viruses, these acute transforming RNA tumor viruses were found to 
contain extra host cell derived sequences, responsible for the acute 
form of transformation. Typically, the viral oncogenes were found to 
represent truncated and/or mutated forms of normal cellular genes 
(Bishop, 1983; Duesberg, 1983). The genesis of retroviral oncogenes 
from cellular proto-oncogenes has been called transduction. 
Two different possibilities have been proposed to explain why the 
transduced oncogenes of retroviruses are pathogenic, even though they 
derive from seemingly harmless cellular genes. First, expression of 
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the transduced genes is driven by potent viral regulatory elements. 
Thus sustained and abundant expression of an otherwise normal gene 
might cause neoplastic growth. Efforts to test this possibility have 
given ambiguous results and remain incomplete. When expressed at high 
levels by experimental means, most of the proto-oncogenes tested to 
date can transform established lines of cells but not primary expiants 
of normal tissues. There may be exceptions in both regards: the 
proto-oncogene c-src has not elicited a completely neoplastic phenotype 
in established cells (Iba, et al, 1984; Parker et al., 1984; Johnson et 
al., 1985), whereas over expression of the normal c-mvc and c-H-ras 
proto-oncogenes transform primary as well as established cultures 
(Baumbach et al., 1986; Martin et al., 1986; Patchinsky et al., 1986; 
Cichutek and Duesberg, 1986). 
Second, transduced genes generally acquire mutations while en 
route from proto-oncogene to oncogene (Bishop, 1983; Varmus, 1984). 
Comparisons of retroviral oncogenes with their cellular progenitors 
have uncovered point mutations, deletions and genetic substitutions in 
the viral alleles. In two instances, this genetic damage appears to 
release the biochemical activities of the gene products from allosteric 
controls. Firstly, the mutations in v-src (Coussens et al., 1985; Iba 
et al., 1985; Cooper et al., 1986, Levy et al., 1986) and v-erb B 
(Gilmore et al., 1985; Kris et al., 1985; Lax et al., 1985) confer 
higher constitutive activity on the protein-tyrosine kinases encoded by 
these genes (they might also alter substrate specificities of the 
enzymes, but there is no evidence for this as yet). Secondly, mutations 
present in the oncogenic versions of c-ras reduce the GTPase (GTP is 
guanosine 5' triphosphate) activity compared to the activity of the 
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normal c-ras protein. Since the GTP-ras complex is the active 
version, this could imply that the oncogenic version may transmit a 
continuous signal rather than a regulated, transient one (Gibbs et al., 
1984; McGrath et al., 1984; Sweet et al., 1984; Manne et al., 1985; 
Colby et al., 1986; Levinson, 1986). Transformation by these 
retroviral oncogenes may therefore result from sustained levels of 
otherwise normal biochemical activities. 
Insertional mutagenesis 
A second mechanism of activation is called insertional 
mutagenesis. Integration of viral DNA into genomic DNA can influence 
expression of cellular genes by bringing them under control of powerful 
regulatory elements in the viral genome (Varmus, 1982; Nusse, 1986) or 
damage them directly (Bishop, 1983; Varmus 1982; Varmus, 1983). 
Besides previously identified cellular oncogenes like c-mvc (Hayward et 
al., 1981; Payne et al., 1982; Corcoran et al., 1984), c-mos (Rechavi 
et al., 1982; Cohen et al., 1983, Gattoni-Celli et al., 1983); c-mvb 
(Shen-Ong et al., 1984; Rosson and Reddy, 1986) and c-erbB (Fung et 
al., 1983; Raines et al., 1985), other cellular genes can serve as 
targets for activation by proviral or transposon-like integration, like 
int-1 (Nusse and Varmus, 1982; Nusse et al., 1984), pim-1 (Cuypers et 
al., 1984; Selten et al., 1985) or Mvli-1 (Tsichlis et al., 1983). 
There is as yet no direct evidence that activation of proto 
oncogenes by insertional mutagenesis is tumorigenic, but the argument 
nevertheless has considerable logical force. First, several of the 
genes attached by integration are known to be progenitors of retroviral 
oncogenes. Second, integration of retroviral DNA displays little (if 
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any) specificity within the cellular genome, yet integration in the 
tumors affects specific proto-oncogenes, presumably the consequence of 
selection for cells that have undergone neoplastic transformation. 
Third, retroviral vectors have been used to demonstrate that such 
mutant proto-oncogenes have transforming activity. Examples include c-
mvc and c-erbB (Baumbach et al., 1986; Martin et al., 1986; Patschinsky 
et al., 1986; Keath et al., 1984); and the proto-oncogene int-1. first 
identified at the integration site of MMTV (Brown et al., 1986). 
Translocation 
Cancer cells have provided clues to oncogenes in the form of 
microscopically visible damage to chromosomes. Three types of damage 
can be recognized: translocations between (or inversion within) 
chromosomes, deletions affecting discrete portions of chromosomes, and 
abnormal amplifications of large domains within chromosomes. Deletions 
on occasion may signal the existence of a different type of genetic 
element the so called "anti-oncogenes". 
Specific translocations have been shown to affect known c-
oncogenes such as c-myç and c-abl in the Burkitt's lymphoma and chronic 
myelogenous leukemia specific translocations respectively, or lead to 
the identification of new putative c-oncogenes as bc_l-l and bel-2 
(Nowell et al., 1984; Cleary and Sklar, 1985) or pvt-1 (Webb et al., 
1984; Cory et al., 1985). Like c-myç these latter genes are joined to 
the immunoglobulin genes following translocation. 
Although karyotypic instability of cancer cells is commonplace, 
and could represent effect rather than cause, several observations 
suggest that the translocation of proto-oncogenes plays a crucial role 
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in tumorigenesis. Some translocations occur with great consistency in 
particular tumors (Rowley, 1983; 1984; Yunis, 1983) and can affect the 
same proto-oncogene in different species, for example, c-mvc in B cell 
tumors (Varmus, 1984). Three of the proto-oncogenes first recognized 
during the study of retroviral oncogenes (c-abl, c-ets and c-mvb) have 
now been implicated in translocations that exemplify various forms of 
malignancy (Klein, 1983; Leder et al., 1983; Nowell et al., 1985 
Shtivelman et al., 1985; Bartram et al., 1983; Groffen et al., 1984 
Stam et al., 1985; Grosveld et al., 1986; Rovigatti et al., 1986 
Sacchi et al., 1986). Translocation of a proto-oncogene can damage 
both the structure and the function of the gene in ways that echo those 
found in the transduced and overtly oncogenic version of the same gene 
(Davis et al., 1985). Finally, mice carrying a translocated c-mvc gene 
in their germinal DNA develop lymphoid tumors (Adams et al., 1985). 
Amplification 
Amplification of proto-oncogenes has been shown in two patterns: 
as an occasional feature of diverse tumors (Varmus, 1984; Ali tal o and 
Schwab, 1986) and as a recurrent abnormality of specific proto-
oncogenes in particular tumors (Kohl et al., 1983; Little et al., 1983; 
Schwab et al., 1983b, 1984, 1985a; Schwab, 1985; Nau et al., 1985, 
1986; Escot et al., 1986; Wong et al., 1986; Libermann et al., 1985; 
Yamamoto et al., 1986). Investigation of amplified DNA sequences in 
tumor cells showed the involvement of previously identified oncogenes: 
c-mvc (Alitalo et al., 1983) and K-ras (Schwab et al. 1983a) and has 
also lead to the discovery of new, related oncogenes: N-mvc (Schwab et 
al., 1983b) or L-myç (Nau et al., 1985). 
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There are three reasons why amplification may be of significance 
in cancer cells. First because amplification frequently affects known 
proto-oncogenes (Varmus, 1984; Schwab et al., 1985b; Yancopoulos et al. 
1985; Alitalo and Schwab, 1986), secondly, the amplification of a 
proto-oncogene sometimes correlates with a particular feature of cancer 
cells, as if one were cause and the other effect (Winter and Perucho, 
1986), and thirdly, because amplified DNA persists in mammalian cells 
only if it provides a selective advantage to the cells (Stark and Wahl, 
1984; Schimke, 1984), it must be necessary in the cancer cells, where 
it has survived countless rounds of cell division. 
Transfection 
DNA-mediated gene transfer, led to the characterization of 
transforming genes present in tumor cells, competent to transform 
appropriate recipient cultured cells, e.g. the mouse fibroblast cell 
line NIH-3T3 (Cooper et al., 1980). Approximately 20 percent of the 
DNA's extracted from primary human tissue or human tumor cell lines 
were able to induce focus formation in cultures of this immortalized, 
rodent cell line. The isolated transforming genes are generally 
mutated members of the ras gene family: H-rjs, K-ras or N-ras (Cooper, 
1982; Der et al., 1982; Shimizu et al., 1983; Hall et al., 1983; Cooper 
and Lane, 1984). Despite obvious limitations, probably due to the 
recipient cell line used, occasionally new and often truncated 
transforming genes have been isolated like met (Cooper et al., 1984; 
Dean et al., 1985; Park et al., 1986), trk (Martin-Zanca et al., 1986), 
B- and T-lvm (Lane et al., 1982) or neu (Schechter et al., 1984; 1985; 
Bargmann et al., 1986a, 1986b). 
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c) Biochemical function 
Although a variety of proto-oncogenes and oncogenes have been 
discovered, only four biochemical mechanisms have been identified by 
which this rich diversity of proteins may act; control of gene 
expression by influencing the biogenesis of mRNA (Kingston et al., 
1984, 1985; Setoyama et al., 1986); participation in the replication of 
DNA (Studzinski, 1986); metabolic regulation by proteins that bind GTP 
in the manner of the familiar G or N proteins (Hurley et al., 1984); 
and protein phosphorylation with either tyrosine, serine or threonine 
as substrate amino acids (Hunter and Cooper, 1985). For a more 
detailed review of the different mechanisms see Weinberg (1985), Bishop 
and Varmus (1985) and Bishop (1985). 
The oncogene products of fos, my_ç, my_b, ski» E53, erb-A and iun 
are all found in the nucleus of the cell (Klempnauer et al., 1984; 
Verma et al., 1984; Bishop, 1985; Weinberger, et al, 1986; Struhl, 
1987) and are implicated in control of gene expression and replication 
of DNA. The exact mechanisms by which these proteins induce 
transformation is not known. 
Activation of ras oncogenes in human tumors is most commonly due 
to point mutations in the ras coding sequence (Bos et al., 1985; Fasano 
et al., 1984; Reddy et al., 1982; Tabin et al. 1982). Activated ras 
oncogenes are found in 10-20% of human tumors and have been detected in 
carcinomas, sarcomas, and hematopoetic malignancies (Der et al., 1982; 
Eva et al., 1983; Pulciani et al., 1982). Mammalian ras gene products 
are associated with the inner face of the plasma membrane, bind GTP, 
and exhibit a low GTPase activity (Sefton et al., 1982; Sweet et al., 
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1984). On the basis of sequence homology and biochemical properties, 
it has been suggested that Ü S proteins may be members of the G protein 
family that serve to transduce information from cell surface receptors 
to internal effector molecules in a variety of systems (Gibbs et al., 
1984; Hurley et al., 1984), e.g. hormonal regulation of adenylate 
cyclase (Gilman, 1984) and phosphoinositide turnover (Berridge and 
Irvine, 1984). Although there are few data concerning the normal 
function of p21 ras in mammalian cells, in yeast, one role of the ras 
protein may be to integrate nutritional information with intracellular 
cAMP levels via the adenylate cyclase system (Fraenkel, 1985; Toda et 
al., 1985). The GTPase activity of the oncogenic versions of p21 ras 
is considerably reduced compared to the normal product (Gibbs et al., 
1984; Sweet et al., 1984). Since the GTP-G protein complex is the 
active version of the G protein family, this could imply that the 
oncogenic version of p21 may transmit a continuous signal rather than a 
regulated, transient one. In the case of adenylate cyclase, this would 
lead in to activition of the cAMP-dependent protein kinase and would 
thereby increase the phosphorylation state of its protein substrates. 
IV. Protein Kinases 
For nearly thirty years phosphorylation has been recognized as a 
means of reversibly modulating the function of proteins. Over this 
period many protein kinases specific for serine and threonine residues 
in their substrates have been identified and characterized. The first 
protein kinase to be purified was Phosphorylase kinase in 1959 (Krebs 
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et al., 1959) followed in 1968 by the cAMP-dependent protein kinase 
(Walsh et al., 1968). Only recently have enzymes with specificity for 
tyrosine been reported. Tyrosine phosphorylating activity was 
originally detected in partially purified preparations of two viral 
transforming proteins (Eckhart et al., 1979; Witte et al., 1980). 
Since that time it has become clear that there is a large family of 
protein tyrosine kinases (Table 3). The group of oncogenic protein 
kinases account for approximately one third of all known oncogene 
products (Bishop, 1985, 1987, Table 2). Eight such cellular enzymes 
were first recognized in altered guises as parts of the transforming 
proteins of a series of acutely oncogenic retroviruses; these are v-
src. v-ves. v-fqr. v-fps/fes. v-abl, v-ras. v-erbB. and v-fms. Some 
tyrosine kinases are growth factor receptors. The proto-oncogenes c-
mos, c-raf. A-raf, pjcs and pim-1 show homology with protein 
serine/threonine kinases. 
All protein kinases have a striking sequence similarity in their 
catalytic domains. The first demonstration of this similarity came 
when the cAMP-dependent protein kinase subunit was shown to be related 
to pp60v-src over a region of about 300 amino acids (Barker and 
Dayhoff, 1982) an unexpected finding given the different amino acid 
specificities of these enzymes. This relatedness implies that the 
cAMP-dependent protein kinase and pp60c-src are descended from the same 
ancestral protein kinase. Based on sequence similarities, it appears 
that most if not all eukaryotic protein-serine/threonine and protein-
tyrosine kinase genes arose from a single archetypal gene. 
A comparison of a large number of catalytic domains reveals a 
series of short sequence motifs that are highly conserved. Starting 
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from the N-terminus, these include Gly-X-Gly-X-X-Gly followed by a Lys 
15-20 residues downstream both of which form part of the ATP binding 
site. At a distance varying from 80-180 residues further C-terminal, a 
second conserved region is observed, consisting of a sixty amino acid 
region which contains the sequences Arg-Asp-Leu, Asp-Phe-Gly and Ala-
Pro-Glu (Hunter and Cooper, 1985, 1986). Although the protein-
serine/threonine kinases and protein-tyrosine kinases are closely 
related, they are distinguished from one another by a number of primary 
sequence features in their catalytic domains. Among these is the 
region between the Asp-Phe-Gly and Ala-Pro-Glu elements, which contains 
the major autophosphorylation site. The existence in this region of a 
Tyr surrounded by acidic amino acids is, so far, a perfect prediction 
that a protein will be a protein-tyrosine kinase (Hunter and Cooper, 
1986). 
The screening of cDNA and genomic libraries with different probing 
techniques revealed new protein kinases in the srç gene family (Semba 
et al., 1986; Kawakami et al., 1986, Quintrell et al., 1987; Yamanashi 
et al., 1987; Ziegler et al., 1987), ab_l and fp_s_ gene family (Kruh et 
al. 1986; Foster et al., 1986) and new members of the protein 
serine/threonine family (PSK-J3, PSK-HI, PSK-C3, Hanks, 1987). In 
addition, well characterized protein kinases that were thought to be 
single catalytic entities proved to be encoded by multiple genes. 
Four mammalian protein kinase C genes have been identified, one of 
which gives rise to two alternately spliced mRNAs encoding proteins 
with different C-termini; this places at least five distinct protein 
kinase isozymes in this subfamily (Coussens et al., 1986; Knopf et al., 
1986; Ono et al., 1986a, 1986b; Parker et al. 1986; Housey et al., 
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1987; Ohno et al., 1987). Likewise, the cAMP dependent protein kinase, 
although known to have multiple regulatory subunits, was believed to 
have a single type of catalytic subunit. Now it has emerged that there 
are at least two genes encoding different, although highly related, 
catalytic subunits (Uhler et al., 1986; Showers and Maurer, 1986). The 
generation of multiple protein kinases from a single gene by alternate 
splicing, exemplified by protein kinase C, is also found with the c-abl 
gene, whose products can have one of two different N-termini (Ben-
Neriah et al., 1986a; Shtivelman et al., 1986a), as well as the srç 
gene, which encodes two forms of pp60 c-src differing by the presence 
or absence of an internal amino acid exon (Martinez et al., 1987). 
Although protein-serine kinase activity has been shown in 
prokaryotes, protein-tyrosine kinase activity has not yet been 
demonstrated. Protein phosphorylation seems to have become common in 
parallel with the increase in complexity of eukaryotic organisms. In 
yeast a total of 14 serine/threonine kinases but no tyrosine-kinases 
have been discovered. This is in contrast to Drosophila were at least 
9 protein tyrosine-kinases have been found (Hunter, 1987b). Probably, 
the first protein kinase originated from a nucleotide binding protein 
and had specificity for serine and/or threonine, subsequently a 
protein-tyrosine kinase evolved. The expansion in the number of 
protein tyrosine kinase genes may have coincided with the evolution of 
multicellular differentiated organisms. Many protein tyrosine kinases 
serve as receptors and signal transducers for circulatory peptide 
hormones and growth factors, a function that is largely unnecessary in 
unicellular organisms. The existence in mammals and Drosophila of so 
many growth factor receptor protein tyrosine kinases implies that 
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tyrosine phosphorylation plays an important role in mitogenic response 
pathways. However, the fact that both in mammals and in Drosophila 
several of the protein-tyrosine kinases are expressed at the highest 
levels in terminally differentiated neural tissue suggest that 
specific types of protein phosphorylation are essential for the 
functioning of differentiated as well as growing cells. 
Hunter (1987b) compares protein kinases with sophisticated 
transistors in electronic circuits. Protein kinases can be envisaged 
as components of biological feedback and amplification pathways, as 
well as switching or signalling systems, serving as major components of 
the essential regulatory circuitry of the cell. Their activity can be 
regulated positively or negatively by several types of input such as 
specific ligands or by phosphorylation of the protein kinases 
themselves. Most protein kinases have multiple substrates as outputs. 
For the cell to use protein phosphorylation as a regulatory 
mechanism, this modification must be reversible. Dephosphorylation is 
brought about by protein phosphatases. It has yet to be shown whether 
the protein phosphatases are as diverse as the protein kinases or 
whether fewer phospatases with broad specificity will suffice. To 
date, little is known about phosphotyrosyl-protein phosphatases, but 
there appears to be multiple forms, all of which are distinct from the 
better characterized phosphoseryl-phosphothreonyl phosphatases 
(Foulkes, 1983). 
The discovery of a protein kinase activity associated with pp60 v-
src (Collett and Erikson, 1978), the product of the Rous sarcoma virus 
(RSV) sr£ gene, suggested that transformation might be due to aberrant 
protein phosphorylation events which would modulate the functions of 
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critical cellular proteins. Abnormal patterns of tyrosine 
phosphorylation are manifest in cells transformed by the viral protein-
tyrosine kinases. However, little real progress in identifying cellular 
proteins phosphorylated on tyrosine have been made. First it has been 
difficult to demonstrate that cellular proteins phosphorylated on 
tyrosine in transformed cells are direct substrates of the kinase. 
Second, it has not yet been possible to firmly establish a causal 
relationship between tyrosine phosphorylation of any particular 
cellular protein and cell transformation. This raises the possibility 
that many of the known or suspected cellular substrates could be the 
result of simply adventitious phosphorylation with no physiological 
relevance. 
Although the exact mechanism through which phosphorylation is 
involved in cell transformation is unknown, the correlation between 
protein-tyrosine kinase activity of certain oncogene products and their 
ability to transform cells is significant. Mutation experiments with 
v-abl and v-src/c-src have shown that tyrosine kinase activity is 
necessary for transformation (Prywes et al., 1983, 1985; Coussens et 
al., 1985; Hanafusa et al., 1984; Levy et al., 1986; Jove and Hanafusa, 
1987). Overexpression of c-erbB-2 has been reported in approximately 30 
percent of human breast carcinomas (Slaraon et al., 1987; Venter et al., 
1987; Kraus et al., 1987) and activated c-abl proteins are present in 
the leukemic cells of Ph' positive CML and ALL patients. 
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V. The Ph' Chromosome 
The Ph' chromosome or 22q" is a cytogenetic abnormality usually 
resulting from a reciprocal translocation t(9;22) (q34; qll). This 
marker chromosome is found in the leukemic cells of more than 95 
percent of patients with chronic myelogenous leukemia (Rowley, 1973; 
Heim et al., 1985). A Ph' chromosome indistinguishable by cytogenetics 
is observed in the leukemic cells of about 17 to 25 percent of adults 
with a suspected diagnosis of ALL (Le Beau and Rowley, 1984). A lower 
incidence has been reported for childhood ALL (2 to 6 percent) 
(Chessels et al., 1979; Priest et al., 1980) and AML (less than 1 
percent, Abe and Sandberg, 1979; Yunis et al., 1984). The presence of 
the Ph' chromosome in CML usually means a better prognosis than when 
the Ph' chromosome is absent (Ezdinli et al., 1970; Pugh et al., 1985; 
Travis et al., 1986). However, Ph'-positive ALL patients have a worse 
prognosis than the Ph'-negative ALL patients (Bloomfield et al., 1986; 
Seeker Walker, 1984). 
The Ph' chromosome is the result of either a standard t(9;22) 
translocation (90 percent of the CML cases) (Rowley, 1973) or a variant 
translocation (3 to 8 percent, Heim et al., 1985). A minority of the 
CML cases (3 to 7 percent) are without a Ph' chromosome (Ph'-negative 
CML, Rowley and Testa, 1982). The standard Ph' translocation is the 
result of reciprocal exchange between chromosome 9 and 22, shown by de 
Klein et al. (1982) and Bartram et al. (1983) with the help of in situ 
hybridization. The translocation juxtaposes c-abl proto-oncogene 
sequences on chromosome 9 (Heisterkamp et al., 1982, 1983b; de Klein et 
al., 1982) with a gene of unknown function denoted ßhl_> on chromosome 
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22 (Groffen et al., 1984; Heisterkamp et al., 1985). The translocation 
breakpoints are within a 5.8 kilobase (kb) region of ßhl, designated 
bcr (breakpoint cluster region) (Groffen et al., 1984). Transcription 
of the phl/c-abl gene gives rise to a spliced 8.5 kb mRNA (Stam et al., 
1985; Shtivelman et al., 1985, Heisterkamp et al., 1985; Grosveld et 
al., 1986) encoding a fusion protein of relative molecular mass 210,000 
called P210 phl/c-abl (Ben-Neriah et al., 1986b; Stam et al., 1987). 
Molecular analysis of Ph'-positive ALL reveals two classes of 
rearrangements involving c-abl. One group (designated Ph'-positive, 
bcr-negative) comprises phl/c-abl translocations indistinguishable from 
those found in CML, as shown by chromosomal breakpoints within bcr and 
synthesis of the P210 phl/c-abl fusion protein. The second group 
(designated Ph'-positive, bcr-negative) has breakpoints lying outside 
of the bcr region (Rodenhuis et al., 1985; Erikson et al., 1986; de 
Klein et al., 1986b) but still in the PJLL gene (Hermans et al., 1987). 
The Ph'-positive, bcr-negative ALLs are associated with the 
transcription of a 7.0 kb chimeric mRNA (Hermans et al., 1987) and 
expression of a P190 c-abl protein (Clark et al., 1987; Chan et al., 
1987; Kurzrock et al., 1987; Hermans et al., 1987). Sequential 
immunoprecipitation with antisera against abj. and ßhl peptides 
confirmed that the P190 is a fusion protein consisting of p_h_l and a M 
sequences (Walker et al., 1987). Very occasionally, CML patients 
positive for the Ph' chromosome but negative for bcr have also been 
reported (Leibowitz et al., 1985; A. Hermans, personal communication). 
It is not known whether these patients have a breakpoint in the phi 
gene. 
Variant translocations have been found in CML, ALL and in AML, 
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although the incidence of variant translocations in ALL is higher 
(Whang-Peng and Knutsen, 1982; de Klein et al., 1986b). Three forms of 
cytogenetic variants have been reported in CML: firstly; simple 
translocations between chromosome 22 and another chromosome, without 
visible involvement of chromosome 9, secondly; complex translocations 
involving 9, 22 and at least one other chromosome (in this case the 
third chromosome is recipient of the deleted part of 22q", while 9 is 
recipient of the deleted part of the third chromosome). Thirdly; a 
rare type of variant called masked Ph' chromosome where the Ph' 
chromosome is the recipient of a part of another chromosome (de Klein 
and Hagemeyer, 1984). Studies showed that the c-aM oncogene is 
consistently translocated to the proximal (5') p_hl sequences on the Ph' 
chromosome. This is also the case in patients with a simple 
translocation variant where there was no visible alteration of 
chromosome 9 (Bartram et al., 1983; Hagemeyer et al., 1984; Hagemeyer 
et al., 1985). Simple variant translocations may be complex variant 
translocations affecting the terminal bands of the chromosomes 
(Mittelman and Levan, 1981; Heim and Mittelman, 1987). The small 
fragments involved masks the 9q34 involvement. 
A consistent fusion of c-abj. and p_hl sequences is not only found 
in variant translocations but also in the leukemic cells of some Ph'-
negative CML patients (Bartram et al., 1985; Morris et al., 1986; 
Ganesan et al., 1986; Kurzrock et al., 1986). Clinical and 
hematological features of Ph'-negative CML patients are 
indistinguishable from Ph'-positive CML patients. This is in contrast 
to the Ph'-negative CML patients who lack the phl/c-abl juxtaposition 
and probably represent myelodysplasia and reactive myeloproliferative 
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conditions other than CML, with an overall poorer prognosis (Pugh et 
al., 1985; Travis et al., 1986). Applying a strict set of clinical and 
hematological criteria, Wiedemann et al. (submitted) defined bcr 
positive CML as chronic granulocytic leukemia (CGL). Other 
myeloproliferative disorders including atypical CML (aCML), chronic 
myelomonocytic leukemia (CMML), juvenile CML, (JuCML) and chronic 
neutrophilic leukemia (CNL) do not express elevated levels of abl 
protein tyrosine kinase activity and therefore must rely on other 
mechanisms of leukemogenesis. 
Approximately 75 to 80 percent of chronic phase CML patients 
develop additional aberrations when entering the acute, blastic phase 
(Alimena et al., 1979; First International Workshop, 1978; Lawler, 
1982; Mittelman et al., 1976; Rowley, 1980; Sandberg, 1980a, 1980b). 
Chromosomes 8, 17 and 22 are those most often involved in secondary 
changes, with the frequent occurrence of trisomy 8, isochromosome 17, 
an extra Ph' chromosome, and less frequent trisomy 19 (Mittelman et 
al., 1976; Heim and Mittelman, 1987). The extra Ph' chromosome is the 
result of a second translocation in a different hematopoietic stem cell 
as described for a patient by Shtalrid et al. (submitted), or is the 
result of a duplication of the primary Ph' chromosome (Collins, 1986; 
Seiden et al., 1983; Grosveld et al., 1986). The pattern of secondary 
changes can be found both in the CML patients with standard and variant 
translocations. In CML patients without the Ph' chromosome trisomy 8 
and isochromosome 17 are the most frequent cytogenetic hallmarks. 
Trisomy 19 is less frequent, while rearrangements of chromosome 3 and 
monosomy 7 seem to be common changes in Ph'-negative CML (Heim and 
Mittelman, 1987). The latter feature is reminiscent of the chromosome 
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7 involvement in acute t(9;22) associated leukemias (Heim and 
Mittelman, 1986). The absence of trisomy 8 and 19 and a second Ph' 
chromosome in acute leukemia will help to distinguish between the acute 
phase of CML and Ph'-positive ALL. 
The fact that the t(9;22) abnormality is such a specific and 
regular feature of CML argues forcefully that it is an important step 
in leukemogenesis. Likewise, the finding of Ph'-positive bone marrow 
cells preceding the leukemia (Canellos and Whang-Peng, 1972) supports 
this interpretation. However, in spite of the attractiveness of the 
t(9;22) oncogene rearrangement hypothesis, the evidence favoring this 
model is still circumstantial and it remains possible that earlier 
submicroscopic changes elsewhere in the genome are crucial. For 
example, Fialkow et al. (1978) showed that long term bone marrow 
cultures containing blood lymphocytes arising from Ph'-positive CML 
clones, were Ph'-negative. This led to the hypothesis that at least 
two steps were involved in the leukemogenesis; one causing growth of a 
clone of pluripotent hematopoietic cells, the other inducing Ph' in 
descendants of these progenitors (Fialkow, 1984; Fialkow et al., 1978). 
Compatible with this, are reports of six CML patients who developed the 
Ph' chromosome only late in their disease (Hayata et al., 1975; Lisker 
et al, 1982, 1980; Tanzer, 1977). Heim and Mittelman (1987) suggest a 
three step scheme for the pathogenesis of CML. Step 1 involves a 
clonal proliferation of pluripotent Ph'-negative bone marrow cells. 
These are genetically unstable but have a growth advantage over normal 
stem cells. This step, which would involve an, as yet, unidentified 
primary event, might be equivalent to initation in experimental 
tumorigenesis. Step 2 would involve the acquisition of the Ph' 
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chromosome (or a functionally equivalent cytogenetic rearrangement), 
in a suitable primed cell, presumably a pluripotent stem cell, for CML 
to evolve. The key effect in molecular terms of the translocation 
would be a deranged c-abl protein. This stage might be analogous to 
tumor promotion in experimental systems. Step 3 is the blast crisis. 
The increased genetic instability now results in additional chromosomal 
abnormalities, thereby enhancing the malignant potential of the 
abnormal clone. This stage might cover the same development which in 
experimental carcinogenesis is termed tumor progression. 
VI. Involvement of the c-abl and p M gene in CML and ALL 
a) The c-abl gene 
The cellular gene c-abl represents the progenitor of the 
transforming gene (v-abj.) within the genome of Abel son leukemia virus 
(Goff et al., 1980). This genome was formed by a process of 
recombination between a Moloney murine leukemia virus and the DNA of 
the host cell. The v-abl gene confers to this virus the capacity to 
rapidly transform a broad range of hematopoietic cell types such as B-
lymphoid cells, plasma cells, macrophages, and promyelocytes as well as 
NIH 3T3 fibroblasts (for review, see Konopka and Witte, 1985a). 
Transformation is mediated by a protein tyrosine kinase activity 
encoded by the v-abl polypeptide attached at its N-terminus to a viral 
gag polypeptide. 
c-abj is a highly conserved gene and is present not only in 
vertebrates but also in Drosophila (Hoffman et al., 1983). The human 
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gene is localized on chromosome 9 (Heisterkamp et al., 1982) and spans 
more than 230 kb of DNA (Bernards et al., 1987, Heisterkamp et al., 
1983, Figure 2). It is transcribed into two major mRNAs of 6 and 7 kb 
(Canaani et al., 1984; Gale and Canaani, 1984; Stam et al., 1985), each 
initiated by independent promotors (Shtivelman et al., 1986a; Bernards 
et al., 1987). Cloning of human c-abj. cDNA (Shtivelman et al., 1986a) 
showed the presence of two alternative first exons (1A and IB) each 
spliced to a common set of ten 3' exons. Exon 1A, homologous to the 
mouse first exon type I, is present in the 6 kb mRNA, while exon IB, 
equivalent with mouse first exon type IV, is part of the 7 kb c-abl 
transcript. The region of homology with v-abl starts within the third 
exon and extends to the 5' part of the last exon (exon 11). The most 
3' 2 kb of exon 11 contains untranslated sequences. Exons 2 through 11 
cover approximately 48 kb of genomic DNA (Groffen et al., 1986, 1987) 
preceded by the two alternative exons 1A and IB at a distance of 19 and 
200 kb, respectively (Shtivelman, 1985, 1986a; Bernards et al., 1987). 
It is not known whether in the human genome more N-terminal coding 
exons are present. In the mouse, 4 such exons exist (Ben-Neriah et 
al., 1986a) of which the expression may be restricted to specific cell 
types or developmental stages. 
Alternative splicing can affect the level of gene expression by 
selection of different promotors (Young et al., 1981; Benyajati et al., 
1983) or can generate different proteins (Early et al., 1980; Breitbart 
et al., 1985; Basi et al., 1984; Rozek and Davidson, 1983; Nabeshima et 
al., 1984; Amara et al., 1982). In the case of c-abl. selection is at 
the level of the transcriptional promotor. Since the coding regions 
begin within the first exon, selection of different exons will result 
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in different protein products. Both c-abj. mRNAs are detected in all 
tissues analyzed (Wang and Baltimore, 1983; Westin et al., 1982); 
differential expression of either mRNA has not been observed. The low 
expression of c-abl in many tissues is common with some genes 
considered "housekeeping genes" such as hypoxanthine phosphoribosyl 
transferase (HPRT), 3-hydroxy-3 methyl glutaryl coenzyme A (HMGCoA), 
reductase, and adenosine deaminase (ADA). Like these genes (Melton et 
al., 1986; Reynolds et al., 1984; Val erio et al., 1985), c-abl lacks 
TATA boxes, its two promotor regions are G+C rich and contain multiple 
GGGCGG repeats (Shtivelman et al. 1986a). This repeat was identified 
as the core within the consensus binding site of the Spl factor, which 
has been shown to regulate transcription in vitro (Dynan et al., 
1986). RNase protection experiments showed four transcription 
initiation sites in the exon IB promotor region and two in the exon 1A 
promotor region (Shtivelman et al. 1986a). The presence of CAAT boxes 
and a sequence resembling the CATAAAAGG element, which functions as a 
TATA box in the rabbit beta-globin gene (Dierks et al., 1983), have 
been demonstrated in the IB promotor region (Bernards, 1987). 
In addition to the 6 and 7 kb c-abl mRNA a 4.5 kb c-abl transcript 
was shown to be present in haploid spermatoids in the testis of the 
mouse (Ponzetto and Wolgemuth, 1985). Kretser (1986) described 
additional mRNAs of 2.5 and 10 kb in human leukemic lymphoblasts. In 
addition, at least one abj. related gene, termed arg, has been reported 
(Kruh et al., 1986). This gene was identified in human placenta and 
mapped on chromosome lq 24-25. A 12 kb mRNA is transcribed from this 
gene and is present both in normal and tumor cells. 
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b) The Ehl gene 
Analysis of the Ph' translocation identified a 5.8 kb "hot spot" 
region on chromosome 22 containing the translocation breakpoints. This 
region was designated the breakpoint cluster region or bcr (Groffen et 
al., 1984). The isolation of cDNA clones with bcr probes demonstrated 
that bcr is part of a gene called ßhl (Figure 2, Heisterkamp et al., 
1985; Mes-Masson et al., 1987; Hariharan et al., 1987). The ßhl gene 
encompasses approximately 90 kb and is oriented with its 5' end towards 
the centromere of chromosome 22 (Heisterkamp et al., 1985, unpublished 
information). Southern hybridization identified a minimum of 18 exons 
of which 9 have been mapped and sequenced (Heisterkamp, et al., 1985; 
Hermans et al., 1987; unpublished information). Exon 1 is 1.7 kb which 
is relatively large in comparison to the 4 exons which are present in 
bcr, which vary in size from 76 to 140 bp. The intron between exon 1 
and 2 is at least 30 kb (Hermans et al., 1987). 
Two messengers of 4.5 and 7 kb are transcribed from the ßhl gene 
(Stam et al., 1985). Transcription occurs at low level in different 
cells and tissue type (Stam et al., 1985; Heisterkamp et al., 1985, 
Shtivelman et al., 1985; Grosveld et al., 1986; M. von Lindern personal 
communication). The relationship of the 4.5 kb and 7 kb transcripts is 
not clear. Hariharan et al. (1987) showed that sequences present in 
the 4.5 kb transcript are also present in the 7 kb mRNA. Additional 
sequences in the 7 kb transcript might occur at its 5' end, internally 
or at its 3' end. The 7 kb mRNA may be generated by a more distal 
polyadenylation signal or as alternative splice in the 3' region. 
Promotor regions in the ßhj. gene have not yet been identified. 
Although no sequence homology with other known genes has been 
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found (Heisterkamp et al., 1985; Mes-Masson et al., 1987; Hariharan et 
al., 1987) a few ßhl related genes have been reported (Croce et al., 
1987; Heisterkamp et al., unpublished). Three genes homologous to the 
3' end of the p_h_l gene have been mapped on chromosome 22, both 5' and 
3' of the p_hl gene. A fourth related gene showing homology with the 
exons in bcr is located on chromosome 17. From this gene, cDNAs have 
been isolated, and approximately 25 kb of genomic DNA has been cloned 
and mapped for restriction enzyme sites (Heisterkamp et al., 
unpublished). Present in the p M related gene are two so called 
variable regions of approximately 1.5 kb containing repeats of 43 bp. 
The variable regions are prone to deletions resulting in heterozygosy 
for this region. Currently this gene is being screened for 
translocations or rearrangements specifically associated with various 
neoplastic and hereditary disorders. Screening of a variety of 60 
different tumors (including two acute promyelocytic leukemia samples 
with t(15;17), Stam et al., unpublished) did not show translocations in 
this gene. It might still be worthwhile, however, to determine the 
exact location of this p_h_l related gene on chromosome 17, making it 
possible to screen disorders with known specific translocations in this 
region. 
c) The Fusion of p_hl and abl on the Ph' chromosome 
The discovery of a breakpoint 14 kb 5' of the v-abl homologous c-
abl exons in a CML patient (Heisterkamp et al., 1983) indicated the 
possibly active involvement of the c-abj. gene in CHL. To date, the 
breakpoints of 6 patients have been mapped between c-abl exon 1A and 2 
(15 percent of total amount of samples studied)(Figure 2)(Collins, 
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1986; Leibowitz et al., 1985; Heisterkamp et al., 1983), and the 
breakpoint of 4 patients (Heisterkamp et al., unpublished) and the CML 
cell lines K562 and BV173 (Grosveld et al., 1986; Bernards et al., 
1987; Westbrook, personal communications) between exon IB and 1A. From 
one patient the breakpoint lies 5' of exon IB (Bernards et al., 1987) 
while from another patient the break occurs between exon 2 and 3 
(Grosveld, Berlin Human Genetics meeting 1986, Proc. of International 
Congress Human Genetics Springer Verlag, 428-434). It is expected that 
the majority of the breaks occur in the 200 kb intron between exon IB 
and 1A. Summarizing, the amount of c-abl sequences that are 
translocated can vary from the whole c-abl locus (patient with 
breakpoint 5' of exon IB) to only the v-abl homologous part (patient 
with breakpoint between exon 2 and 3). However, in all cases of CML 
studied to date, the protein-tyrosine kinase domain of c-ibj. is 
translocated to the Ph' chromosome. 
All breakpoints in the pjhl gene are clustered in bcr (Figure 2) 
(Groffen et al., 1984). Of more than 400 reported CML patients 
positive for the Ph' chromosome (Groffen et al., 1984, 1986, 1987; 
Collins, 1986; Chan et al., submitted; Wiedeman et al., submitted; 
Blennerhassett et al., submitted; Stahlrid et al., submitted) only 4 
have a breakpoint outside bcr (Leibowitz et al., 1985; A. Hermans 
pers. comm.). Breakpoints are always in an intron primarily between 
bcr exons 2 and 3 or 3 and 4 (Collins, 1986; Heisterkamp et al., 1985). 
Some cases have been described where the break occurs between bcr exon 
4 and 5 (Shtalrid et al. submitted) or between exon 1 and 2 (Schaefer-
Rego et al., 1987). Schaefer-Rego and co-workers (1987) found a 
correlation between a 3' bcr breakpoint and blast crisis. However, 
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this observation is in contrast to results obtained by Shtalrid and 
colleagues (submitted) who found the distribution of the breakpoints in 
bcr to be similar in blast and chronic phase patients. 
In a group of Ph' positive ALL patients the break occurs in the 
phi gene, but outside bcr. Hermans et al. (1987) showed that in these 
patients the break is in an intron between p_h_l exon 1 and 2. Although 
the exact size of this intron (minimum of 30 kb) and location of the 
breakpoints have not been determined, it is possible that there is a 
second breakpoint cluster region, in the pJü. gene. 
In most cases of CML, the 3' end of the p_h_L gene is translocated 
to chromosome 9 and forms part of the 9q+ chromosome. Several studies 
have demonstrated that 3' p_hl deletions occur in the sequences on 9q+. 
Popenoe et al. (1986) found large deletions in 4 of 14 Ph' positive CML 
patients and suggested that more proximal deletions occurred in 4 other 
patients. In the CML cell line K562, 3' p_hl sequences are also deleted 
(Grosveld et al., 1986). In contrast, de Klein et al. (1986b) found 
only small deletions in Ph' positive CML patients. Large deletions may 
occur in 10 to 20 percent of patients and are independent of the size 
of breaks within bcr (Shtalrid et al. submitted); no unique features 
are associated with these Ph' positive CML patients. Incidence of 3' 
phi deletions is higher in Ph'-positive ALL patients (de Klein et al. 
1986b). Deletions probably occur at the time of translocation and may 
be involved in the mechanism of Ph' chromosome recombination (Showe and 
Groce, 1986). 
Comparison of DNA sequences of several breakpoints showed that 
there is no apparent homology between the chromosome 9 and 22 
sequences, making homologous recombination unlikely (Heisterkamp et al. 
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1985, de Klein et al. 1986a). However, since most of the breakpoints 
occur within Alu-repeats (Schmid and Jelinek, 1982) or Alu-repeatlike 
sequences (Rogers et al. 1985; Groffen et al. 1986, 1987; de Klein et 
al. 1986a), it is possible that Alu repetitive sequences are hot spots 
of recombination. 
The fusion of genomic p M and c-abl sequences results in the 
expression of an abnormal c-abl gene product. In the leukemic cells of 
CML patients and CML-derived cell lines an abnormal 8.5 kb mRNA is 
present (Canaani et al., 1984; Gale and Canaani, 1984; Collins et al., 
1984; Blick et al., 1984). Stam et al. (1985) and Grosveld et al. 
(1986) showed that this mRNA is a chimeric mRNA consisting of 5' fihl 
(3.2 kb) and 3' c-abl (5.3 kb) sequences. This 8.5 kb mRNA is specific 
for Ph' positive cells, (Gale and Canaani, 1984; Romero et al. 1986; 
Grosveld et al. 1986) and its expression has been reported in both the 
myeloid and lymphoid acute phase of CML (Romero et al., 1986), in 
erythroleukemia or lymphoid CML derived cell lines (Collins et al., 
1984; Konopka et al., 1986), and in somatic cell hybrids retaining the 
Ph' chromosome (Kozbar et al., 1986). Direct proof for the presence of 
a chimeric mRNA was provided with the cloning of chimeric cDNA 
(Shtivelman et al., 1985, Grosveld et al., 1986; Mes-Masson et al., 
1986). 
The mature 8.5 kb mRNA lacks the first exon of c-abl. It is 
produced by splicing of the precursor RNA, in which the versatility of 
the splicing system accommodates for the large variation in intron size 
present between the pjil and c-abj. exons in different patients. The 
breakpoint on chromosome 22 defines whether bcr exon 2 or 3 will be 
spliced to the first available c-abl exon, usually exon 2 (Figure 2). 
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In either case, however, this results in a hybrid transcript with one 
long open reading frame coding for a protein of 902 or 927 amino acids 
from the p_hl gene plus 1104 amino acids from c-abj. (Figure 3). 
Shtivelman et al. (1987) reported the presence of hybrid transcripts 
with the bcr exon 3/abl exon 2 junction but also with bcr exon 2/abl 
exon 2 junction in the leukemic cells of a few CML patients with a 
breakpoint between bcr exon 3 and 4. Alternative splicing may be 
responsible for this finding. In the few rare cases where breakpoints 
occur between bcr exon 1 and 2 or the one reported case with a 
breakpoint between abj. exon 2 and 3 result in a long phl/c-abl open 
reading frame as well. The bcrl/abl2 and bcr2/ab!3 junction 
transcripts code for polypeptides of 1971 and 1948 amino acids, 
respectively (bcr exon 2 codes for 35 amino acids, abj. exon 2 for 58 
amino acids). However, junctions between bcr exon 4 and abj. exon 2 are 
not in frame. Ben-Neriah et al. (1986b) and Stam et al. (1987) 
demonstrated that the 8.5 kb hybrid transcripts translate into a 210 K 
phl/c-abl fusion protein. 
In Ph' positive, bcr negative ALL patients, the fusion of the pJVL 
and c-abl genes result in a 7 kb hybrid transcript (Hermans et al., 
1987). This transcript, which is the result of a junction between p M 
exon 1 and c-aJü. exon 2 and contains 1.7 kb of {El and 5.3 kb of c-abl 
sequences, codes for 1530 amino acids (Figure 3). The P190 c-abl 
protein found in the leukemic cells in the Ph' positive, bcr negative 
ALL patients has been shown to be the transiational product of the 7 kb 
phl/c-abl mRNA (Walker, et al., 1987; Clark et al. 1987; Kurzrock et 
al.; 1987; Chan et al., 1987). 
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VII. Activation of c-abl Protein Kinase 
a) The phi/c-abl aberrant proteins 
The human c-abl gene encodes a 145 K protein as shown by 
immunoprecipitation (Konopka et al., 1984). Both the human P145 c-abl 
protein and its mouse counterpart P150 have been shown to possess a low 
protein tyrosine kinase activity (Konopka and Witte, 1985b). In 
addition, the c-abl protein is phosphorylated in vivo on serine but not 
on tyrosine (Konopka et al., 1984). cDNA cloning of the 6 and 7 kb 
human c-ab_L transcripts (Shtivelman et al., 1986a) showed that although 
2 protein subtypes exist (Figure 3), neither contains a transmembrane 
region nor a signal peptide, indicating that the abj. protein is not a 
classical membrane receptor for extracellular factors and is therefore 
distinct from a number of protein-tyrosine kinases such as the EGF 
receptor (Ullrich et al., 1984), the insulin receptor (Ebina et al., 
1985) and CSF-1/fms (Sherr et al., 1985). Of the two predicted c-abl 
proteins, the one encoded by the 7 kb mRNA (1148 amino acids versus 
1130 amino acids encoded by the 6 kb mRNA) has the sequence Met-Gly at 
the N-terminus. It is possible that the methionine will be removed in 
processing. If so, this is significant because the N-terminal Gly of 
murine gag protein (Henderson et al., 1983), the catalytic subunit of 
cyclic AMP dependent protein kinase (Carr et al., 1982), protein 
phosphatase 2B (Aitkin, 1982) and v-src and c-src (Buss and Sefton, 
1985) are linked to myristic acid, which is thought to stabilize the 
interaction of proteins with the lipid bilayer of cell membranes. 
Myristyllation is required for membrane association of p60 src and for 
its capacity to induce cell transformation (Cross et al., 1984; Kamps 
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et al., 1986). The extreme conservation between the human and mouse 
polypeptides coded by exons 1A (100 percent homology with the 26 amino 
acids of mouse type I) and IB (90 percent homology, with 42 amino acids 
out of 44 amino acids of mouse type IV) makes it likely that the two 
abl proteins have distinct functions, depending on their myristillation 
status, and their targets could be found in both the cytoplasm and in 
the membrane. Human homologues of the mouse type II (20 amino acids) 
and type III (21 amino acids) peptides have not been described. 
Computer analysis of the predicted amino acids sequences showed 
four potential asparagine-1inked glycosylation sites (Asn x Ser/Thr) in 
position 146, 478, 770 and 812 of the protein. However, there is no 
evidence for the glycosylation of either mouse or human abl protein. 
The tyrosine kinase domain spans amino acids 235-485 (Feng et al., 
1985) and includes the ATP binding site (Kamps et al., 1984) composed 
of the conserved 9 amino acid peptide at position 248-256 and lysine at 
position 27. The major tyrosine phosphorylation site in vitro (Konopka 
and Witte 1985b) is position 393. There are 13 cysteine residues in 
the molecule with no obvious clustering. The region spanning amino 
acids 800-1000 is proline rich (17.5 percent), while the rest of the 
protein averages 5.5 percent proline. 
Comparison of the predicted amino acid sequence of the human c-abl 
kinase with the mouse enzyme shows an overall homology of 85 percent 
(Shtivelman et al., 1986a; Lee et al., 1985; Ben-Neriah et al., 1986a). 
Remarkably the 500 amino acids at the N-terminus and 130 amino acids at 
the C-terminus show homologies of 99 percent and 96 percent, 
respectively. Although the extreme conservation of the catalytic 
domain is not surprising, the conservation of the two termini of the 
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protein is unexpected and suggest that these regions also play an 
essential role in the function of c-abl protein, perhaps via 
interactions with other cell proteins. Comparison of c-abj. protein 
with other tyrosine kinases shows most similarity with the srç and y_e_s 
proteins (Ben-Neriah et al., 1986a). However, the c-abl protein is 
distinct from phosphotyrosine kinases described to date in that the 
catalytic domain is in the amino terminal domain of the protein. 
In addition to the normal P145 c-abl protein, leukemic cells from 
CML patients contain, a large c-abl protein of 210 K (Kloetzer et al., 
1985, Konopka et al., 1984, 1985, 1986, Konopka and Witte 1985a&b; 
Davis et al., 1985). This c-abj. related protein was shown to be the 
translational product of the 8.5 kb hybrid phl/c-abl transcript (Ben-
Neriah et al. 1986b, Stam et al., 1987). The P210 phl/c-abl protein 
contains 902/927 amino acids from p_hl (depending on presence of 25 
amino acids of bcr exon 3) and 1104 amino acids derived from c-abl 
(exon 2 through 11). 
The predicted molecular weight of the p M polypeptide based on the 
sequence of the cDNA of the 4.5 kb transcript is 143 K (Hariharan et 
al., 1987). This polypeptide consists of 1271 amino acids, and 
represents a relatively hydrophilic protein, with no obvious regions of 
marked hydrophobicity that are characteristic of transmembrane domains. 
Several investigators demonstrated by immunoprecipitation, with phi 
antiserum, the presence of 190K (Ben-Neriah et al., 1986b) and 160 K 
(Stam et al., 1987, 0. Draezen pers. comm.) phosphoproteins. These 
proteins exhibited an associated protein-serine kinase activity. 
However, it has not been demonstrated whether this kinase activity is 
intrinsic to the pjü. gene product or whether it derives from a protein 
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coprecipitated in a complex with the pjil protein. A detailed 
comparison of the p_h_l amino acid sequences with other protein kinases, 
fails to reveal any sequence homology (Hariharan et al., 1987, 
Heisterkamp et al., 1985). 
The replacement of N-terminal c-abl sequences with p_hl sequences 
in the P210 fusion protein is reminiscent to the replacement of N-
terminal c-abl sequences by gag sequences following viral transduction 
of the abj. oncogene in A-MuLV. The resulting P160 aag-abl protein 
contains 236 amino acids of gag fused with 1008 amino acids of the 
mouse c-abj. protein (encoded by part of exon 3 through 11, Figure 3). 
There is no sequence homology between gag and p_h_l (Heisterkamp et al., 
1985, Hariharan et al., 1987, Mes-Masson et al., 1987). However, both 
P160 and P210 exhibited elevated tyrosine kinase activity compared to 
P145 (Konopka et al. 1984; Davis et al. 1985). In addition, in 
contrast to P145 c-abl. both proteins are phosphorylated on tyrosine in 
vivo (Davis et al., 1985; Stam et al., 1987; Konopka et al., 1984). 
In the subgroup of Ph'positive, bcr negative ALL, a P190 c-abl 
protein is expressed (Clark et al., 1987; Chan et al., 1987; Kurzrock 
et al., 1987; Hermans et al., 1987; Walker, et al., 1987). This 
protein is the translational product of the 7 kb phl/abl hybrid 
transcript, and contains 1530 amino acids, 426 from PJLL and 1104 from 
c-abl. P190 is mainly phosphorylated on tyrosine (> 95 percent of 
total phosphate), with very little Pi on serine, in the immunocomplex 
assay and has like P210 elevated tyrosine kinase activity. 
Phosphoamino acid analysis of the different c-abl proteins showed 
different patterns of in vivo and in vitro tyrosine phosphorylation 
(Konopka and Witte, 1985b; Clark et al., 1987). The P145 and P150 c-
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abl proteins are predominantly phosphorylated on a single site 
corresponding to the human c-abl amino acid 393 (v-abl residue 
514)(Shtivelman et al., 1986a). P190 phosphotyrosine was found on a 
single major site similar to the site in P145 and P150, and on three 
minor sites. P210 and P160 are each phosphorylated at several major 
sites, distinct from the major c-abj. and P190 phosphorylation site. A 
P160 minor site corresponds with the P150 and P145 major site while the 
major sites have been mapped to the amino terminal gag sequences 
(Konopka and Witte, 1985b; Clark, et al., 1987). The exact location of 
the P210 phosphorylation sites have not yet been determined. However, 
its pattern of in vitro phosphorylation is distinct from the P160 
pattern. in vivo studies demonstrated that P145 and P150 are not 
phosphorylated on tyrosine in vivo. P160 is phosphorylated on tyrosine 
514 (major site) and on tyrosine 385 (minor site). The P210 
phosphorylation site has not been localized, but is apparently 
different from v-abl tyrosine 514 (Konopka and Witte, 1985b). In vivo 
studies have not been reported for P190. 
The different manner in which the abj proteins utilize themselves 
as substrates for phosphorylation in vitro suggest that they may 
interact differently with substrates in vivo. This idea is supported 
by the fact that P150 and P145 are not detected by phosphorylation on 
tyrosine in vivo but P160 and P210 are. Quantitative and qualitative 
changes, like altered substrate specificity, of the P210 kinase may be 
important in the leukemogenesis of Ph' positive bcr positive CML and 
ALL. A more similar phosphorylation pattern between P190 and P145 
suggest that a quantitative change in abl kinase activity may be 
important for the pathogenesis in Ph' positive bcr-negative ALL. Of 
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interest is the report of enhanced tyrosine kinase activity or elevated 
levels of P145 in a Ph' negative ALL patient (Chan et al., 1987). 
Different mechanisms of c-abl activation could result in clinically 
distinctive leukemias. 
b) Regulation of kinase activity and transformation 
To address the question of how the c-abl kinase activity could be 
affected by the viral transduction or translocation, it is important to 
understand the mechanisms of which protein kinases are regulated. The 
precise mechanisms involved in regulating protein kinase activity are 
quite diverse. Protein kinases are often multisubunit enzymes, either 
of homo or hetero-oligomeric nature. Such oligomeric structures allow 
for cooperative and highly sensitive responses to regulatory inputs. 
Monomeric protein kinases commonly have discrete regulatory domains, 
which may contain pseudo substrate sequences involved in negative 
regulation (Hunter, 1987b). In general it appears that protein kinases 
exist in the cell in the off-state. Many protein kinases are 
positively regulated by ligands, which bind to regulatory domains or 
subunits. For instance, growth factor receptor protein tyrosine 
kinases are stimulated by binding their cognate peptide growth factor. 
Other protein kinases are activated by second messengers. The activity 
of cyclic nucleotide regulated protein kinases is increased through 
elevation of cyclic nucleotide levels generated by hormone-dependent 
membrane-associated cyclases, whereas the protein kinase C family is 
stimulated by diacylglycerol turnover of phosphoinositides. There are 
also protein kinases regulated by changes in Ca 2 + concentration through 
the agency of calmodulin. 
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Kinase activity can also be regulated through a positive or 
negative mechanism of autologous or heterologous phosphorylation. 
Autophosphorylation, generally, results in activation as is the case 
with the insulin (Rosen et al., 1983) and probably the EGF receptor 
(Bertics and Gill, 1985). Autophosphorylation could also provide a 
negative feedback mechanism to down regulate the phosphorylation 
signal. Regulation by heterologous phosphorylation can occur both 
between protein-tyrosine and protein-serine kinases or within one 
class. For example, the activity of the EGF receptor protein-tyrosine 
kinase is decreased upon phosphorylation by protein kinase C (Cochet et 
al., 1984; Friedman et al., 1985). The activity of the protein-
tyrosine kinase pp60c-src is suppressed by a tyrosine phosphorylation 
event, which appears to be mediated by another protein-tyrosine kinase 
(Cooper et al., 1986; Cooper and King, 1986; Jove et al., 1987). An 
example of positive regulation is the increase in activity of 
Phosphorylase kinase following phosphorylation by cAMP-dependent 
protein kinase (Walsh et al., 1968). 
Several cellular protein tyrosine kinases are subject to tight 
negative regulation by noncatalytic domains. A good example is the 
regulation of pp60v-src and pp60c-src. Comparison of the predicted 
amino acid sequences of v-src with that of c-srç shows that the 
residues 1-514 differ only in a few amino acids but starting at residue 
518, the proteins diverge completely due to a deletion of the coding 
sequences for the C-terminal nineteen amino acids of pp60c-srç (Takeya 
and Hanafusa, 1983). pp60v-src has a novel C-terminus of twelve amino 
acids derived from a sequence believed to originate from the 3' 
untranslated region of the c-srç gene. The protein kinase domain of 
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pp60v-srç has been localized to its C-terminal half, approximately 
between residues 260 and 516 (Yacuik and Shalloway 1986; Wilkerson et 
al., 1985). 
Courtneidge et al. (1985) demonstrated that dephosphorylation of 
Tyr 527 in pp60c-src increases the protein kinase activity by 5-10 
fold. Tyr 527 is deleted in pp60v-src explaining the increased 
tyrosine kinase activity of v-srç. pp60c-src is phosphorylated in the 
cell on Tyr 527 and can be activated in vitro to nearly the pp60v-src 
level by phosphatase treatment or by an antibody directed against a 
synthetic peptide corresponding to the C-terminus of pp60c-src (Cooper 
and King, 1986). 
Phosphorylated Tyr 527 could inhibit pp60c-src by acting as 
product analog or in some allosteric fashion. Little is known about 
how phosphorylation of Tyr 527 is regulated; it does not appear to be 
an effective autophosphorylation site. The absence of the C-terminal 
domain in pp60v-src, however, prevent negative regulation of the kinase 
leading to unscheduled tyrosine phosphorylation and transformation. 
Phosphorylation of Tyr 527 can play a role in transformation as 
shown by different groups. It has been found that for polyoma 
transformation it is necessary that the polyoma middle T antigen binds 
to pp60c-src (Bolen et al. 1984). The binding of polyoma middle T 
prevents phosphorylation of Tyr 527 and therefore activates the kinase 
activity. Other groups (Piwnica-Worms et al., 1987; Cartwright et al. 
1987; Kmiecek and Shalloway, 1987) demonstrated that mutations 
preventing phosphorylation of Tyr 527 in pp60c-src (Tyr — > Phe) is 
sufficient to activate pp60c-src oncogenically. Although the mutated 
proteins transform NIH-3T3 cells, the transforming ability is weaker 
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than that of pp60v-src. Additional activating mutations acquired by 
pp60v-srç may be necessary to increase the tumorigenic potential of the 
mutated c-srç proteins. 
Other protein kinases especially those from the c-srç gene family 
(Table 3) also have a highly conserved C-terminal extension beyond the 
catalytic domain including a Tyr equivalent to Tyr 527. The deletions 
of these C-terminal sequences in v-fes and v-fgr could lead to 
oncogenic activation. The v-fms protein lacks the C-terminal fourty 
residues of c-fms (alias the receptor for colony stimulation factor 
CSF-1) which include a Tyr 969. Restoration of the normal c-fms C-
terminus of the v-fms gene reduces its transforming activity 20 fold 
implying that this region has a negative regulatory role (Hunter, 
1987a; Roussel et al., pers. comm.). 
The elimination of negative regulatory elements could also be 
responsible for the activation of the different aberrant c-abl kinases 
(Figure 3). As a consequence of viral transduction or translocation 
new sequences are juxtaposed to c-abl sequences. Additionally, these 
events result in a loss of c-abl sequences at the 5' end. It is 
possible that deletion of these sequences result in activation of the 
c-abl kinase activity. Wang et al. (pers. commun.) expressed a full 
length cDNA of human c-abl in E. coli cells. This protein had low 
kinase activity. Deletions of 5' sequences of the cDNA resulted in the 
expression of a protein with elevated tyrosine kinase activity. 
Deregulation of phosphorylation may not be sufficient for 
transformation. For example, there is no direct correlation between in 
vitro tyrosine kinase activity of the different âbl proteins and their 
transforming capacity in the cell. Although, the tyrosine kinase 
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activity of P210 is very similar to P160, expression under several 
promotors (SV40, MMuLV-LTR, bcr promotor) of the 8.5 kb full length 
ßhl/c-abj. cDNA fails to transform NIH 3T3 fibroblast, while the MMuLV-
LTR driven v-abl gene does induce transformation (Daley et al., 1987; 
Hermans et al.,1987) P210 phl/c-abl may not transform fibroblasts in 
culture because of an inability to bind to cellular membranes. The gag 
portion of v-abl. like v-src. contains an ^-terminal myristic acid 
moiety thought to determine membrane association (Schultz and Oroszlan, 
1985; Sefton et al., 1982). ^-terminal mutants of v-abl and v-src 
that lack a myristylation site no longer localize to membranes and are 
transformation-defective (Garber et al., 1983, Cross et al., 1984; 
Pellman et al., 1985). It is significant therefore, that spontaneous 
recombinants in which ^-terminal viral gag sequences have fused to 
the phl/c-abl protein, result in a gag/phl/c-abl protein that readily 
transforms NIH 3T3 cells (Daley et al., 1987). Daley and co-workers 
have demonstrated that for fibroblast transformation not only membrane 
localization is important but deletion of abj. sequences as well. 
Deletions in the normal c-abl type IB that remove sequences near the 
NH2-terminus, but preserve the glycine at position 2 (a putative 
myrystilation site) produce transforming c-abl proteins. Although P210 
phl/c-abl appears not to transform NIH 3T3 fibroblasts, data from 
Whitlock/Witte culture systems suggest that the P210 phl/c-abl protein 
can stimulate growth of cells of hematopoietic lineage but is not 
sufficient for full oncogenic behavior (McLaughlin et al., 1987) 
Questions as what is the role of P210 and P190 in CML, and what 
defines their specificity have to be answered in the future. For v-abl 
it has been shown that deletions in the P15 region of gag can 
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specifically abolish lymphoid transforming activity (Prywes et al., 
1985a, 1985b). The P15 deleted proteins demonstrated a marked 
instability in lymphoid cells. p M sequences present in P210 but 
removed in P190 may be involved in controlling the action of the c-abl 
moiety and/or be responsible for host cell specificity resulting in 
different clinical manifestations. 
What are the molecular events that connect the kinase activity of 
the aberrant kinases with the myriad and complex changes collectively 
termed transformation? The answer will undoubtedly be found at many 
different levels. A critical step is identification of primary 
cellular substrates involved in transformation. To date this quest has 
met with little success, although phosphorylated proteins specific for 
CML cells have been found (Huhn et al., 1987). However, it has yet to 
be established whether they are specific abl substrates. 
Phosphorylation of some substrates may directly trigger gross 
phenotypic alterations. Other phosphorylated substrates may represent 
an initial step in a cascade or a series of reactions that are involved 
in signal transduction and amplification. The observation that a 
putative phosphatidyl inositol kinase represents a substrate for both 
the PDGF receptor and polyoma middle T/pp60 c-src tyrosine kinase 
activities (Kaplan et al. 1987; Courtneidge and Heber, 1987) is 
significant in this regard. This links protein tyrosine kinases to the 
phosphoinositide pathway with its important secondary messengers 
diacylglycerol and inositoltriphosphate. 
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VIII. Conclusion 
Since the days of Hansemann and Boveri, chromosomal aberrations 
have been associated with malignant growth. The Philadelphia (Ph') 
chromosome is the cytogenetic hallmark of CML and is the product of a 
specific translocation between chromosomes 9 and 22. The c-abl 
oncogene on chromosome 9 is translocated into a 5.8 kb breakpoint 
cluster region (bcr) in the p M gene on chromosome 22. Although the 
breakpoints on both chromosomes are variable, RNA splicing generates a 
unique 8.5 kb phl/c-abl chimeric message. This chimeric message 
encodes a phosphoprotein (P210 phl/c-abl) that contains p_bl encoded 
NHg-terminal sequences and a c-abl derived COOH-terminal segment. The 
P210 phl/c-abl protein has, in comparison to the normal P145 c-abl 
protein, elevated tyrosine kinase activity. 
A Ph' chromosome, cytogenetically indistinguishable from the Ph' 
chromosome in CML, is present in a percentage of acute lymphoblastic 
leukemia (ALL) patients. Molecular analysis reveals two classes of 
rearrangements. The first of these has a breakpoint in bcr resulting 
in the expression of P210 phl/c-abl. In the second class, the 
breakpoint lies outside bcr, in an intron between phi exon 1 and 2. 
Transcription results in a 7 kb phl/c-abl message that translates into 
a P190 phl/c-abl fusion protein with, like P210, an elevated tyrosine 
kinase activity. 
Although the evidence is circumstantial, the translocation of the 
c-abl oncogene to the p M sequences appears to represent a critical 
event in the pathogenesis of CML and ALL. The Ph' chromosome, or 
better, the expression of P210 phl/c-abl or P190 phl/c-abl. are 
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important diagnostic and prognostic markers. It has been shown that 
CML patients with the phl/c-abl juxtaposition have identical clinical 
and hematological features. This is in contrast to the real Ph' 
negative CML patients who are considered to represent myelodysplasia 
and reactive myeloproliferative conditions other than CML with an 
overall poorer prognosis. 
The presence of the Ph' chromosome in ALL is associated with 
extremely poor prognosis. Patients expressing the P210 phl/c-abl 
protein could represent a lymphoid blast crisis of CML, evolving from a 
clinically silence, or short chronic phase. ALL patients expressing 
the P190 phl/c-abl are more typical of high-risk ALL. However, the 
assumptions made are based on the partial analysis of leukemic cells 
from a limited number of Ph' positive ALL patients. A more extensive 
study will be required in order to corroborate the clinical and/or 
biological importance of these molecular differences among the Ph' 
positive leukemia patients. 
The Ph' translocation results in different activated c-abl protein 
kinases. Although implicated in CML and ALL, the exact role of the 
aberrant abj. kinases is not known. The next step will require the 
identification of crucial substrates for the phosphotyrosine kinases 
and the demonstration of functional effects of tyrosine 
phosphorylation. In the last few years, we have come a long way. The 
understanding of the genome of the leukemic cell helps to acquire new 
devices for the prevention, diagnosis and therapy of chronic 
myelogenous and acute lymphoblastic leukemia. 
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The Philadelphia (Ph') chromosome, an abnormal chromosome 
22 (ref. 1), is one of the best-known examples of a specific human 
chromosomal abnormality strongly associated with one form of 
human leukaemia, chronic myelocytic leukaemia (CML). The 
finding1 that a small region of chromosome 9 which includes the 
c-abl oncogene is translocated to chromosome 22 prompted studies 
to elucidate the molecular mechanisms involved in this disease. 
Wé have demonstrated previously that the chromosome 9 of one 
patient with CML contains a breakpoint 14 kilobases (kb) 5' of 
the most 5' v-aM-homologous exon3. These data suggest a role for 
c-abl in CM L, a theory supported by the presence of an abnormally 
sized abl messenger RNA4,5 and protein6 in the CML cell line 
K562. The region involved in the translocation on chromosome 22 
has also been identified: all Ph'-positive patients examined to date 
bave a breakpoint within a 5.8-kb region, for which we have 
proposed the name 'breakpoint cluster region' (bcr)7. To determine 
whether bcr contains protein-encoding regions, probes from bcr 
were tested for their ability to hybridize to complementary DNA 
sequences. A 0.6-kb /findlll/BamHI bcr restriction enzyme frag-
ment proved suitable for isolating several cDNA clones from a 
human fibroblast cDNA library*. Using bcr cDNA sequences, we 
obtained data strongly suggesting the presence of a chimaeric 
bcr/abt mRNA in the leukaemic ceils of Ph'-positive CML 
patients. The recent isolation of cDNA clones containing bcr and 
abl sequences confirms this finding12. Because the bcr part of the 
chimaeric mRNA could be required to induce the transforming 
activity of the human c-abl oncogene, we have now initiated studies 
to characterize the normal *bcr gene* and to determine the effect 
of a translocation within its coding domain. We demonstrate that 
as a result of the Ph' translocation, a variable number of bcr exons 
are included in the chimaeric bcr/abl mRNA. The bcr gene sequen-
ces in this mRNA could be responsible for the transit too of the 
abl cellular proto-oncogene into an oncogene. 
The largest cDNA, Vl-3, containing an insert of 2.2 kb, was 
characterized in detail by restriction enzyme mapping (Fig. la) 
and sequence analysis (Fig. 16). The cDNA contains one long 
open reading frame, starting at the poty(G) tail at the 5' end 
and continuing to nucleotide 1,770, where a stop codon is 
encountered. All other reading frames have many stop codons 
within the entire region. The long open reading frame has the 
coding capacity for 589 amino-acid residues, corresponding to 
a protein of relative molecular mass (Mf) —65,000; at the 3' 
end, a polyadenylation signal occurs at nucleotide 2,182 fol-
lowed by a poly(A) tail beginning at base 2,208 indicating that 
the cDNA contains the complete 3' end of the gene. Although 
transtational start sequences are encountered at the 5' end, it is 
unlikely that this cDNA contains a complete copy of the mRNA, 
as Northern blpt hybridizations indicate the presence of bcr 
mRNAs of —4.0 and —6.5 kb. Computer searches of newly 
isolated protein sequences derived directly from proteins or 
deduced from cDNA nucleotide sequences frequently result in 
the identification of proteins with partial homology. Such infor-
mation is valuable, frequently allowing the assignment of a 
preliminary function to an unknown protein. Therefore, the PIR 
FASTP program10 was used to search for bcr-homologous pro-
teins; no proteins with significant homology were found, indicat-
ing that the bcr protein exhibits an as yet unidentified cellular 
function. 
To determine the orientation of the bcr gene on chromosome 
22, 5' and 3' probes were prepared from the Vl-3 cDNA and 
hybridized to cosmids7 containing human chromosome 22 
sequences. This established that the 5' end of the bcr gene is 
towards the centromere of chromosome 22 and is retained after 
the Ph' translocation; the 3' end of the bcr gene lies in the 
direction of the telomere and is translocated to chromosome 9 
in the t(9; 22) translocation. The cDNA hybridizes to restriction 
enzyme fragments distributed over a region of up to 45 kb of 
chromosome 22 DNA (Fig. 2a). Within this region, a minimum 
of 13 exons are present. To determine the exact position and 
number of exons within the breakpoint cluster region, all 
hybridizing regions in bcr were sequenced and compared with 
the Vl-3cDNA. Four relatively small exons, designated 1-4, 
were present within bcr, varying in size from 76 to 105 base 
pairs (bp) (Fig.26); in the cDNA, these exons correspond to 
nucleotides 483-836 (Fig. 16). As 6cr was defined as the area 
on chromosome 22 in which the Ph' breakpoints are found, we 
conclude that the breakpoints occur within a gene. 
Having determined the position of the exons within 6cr, we 
investigated whether the breakpoints occur in exon or intron 
regions. For CML DNA such as that of CML patient C481, this 
was readily determined. We had previously demonstrated7 a 
breakpoint within a 1.2-kb H/Bg bcr fragment in several CML 
DNA samples, including that of patient C481. As no coding 
sequences are located within this region (see Fig. 2), patients 
such as C481 must have a chromosomal breakpoint in the intron 
between the exons designated 3 and 4. 
A less simple situation was encountered in the DNA of 
patients 0311068 and 7701C. Nonetheless, cloning of 9q+ break-
point fragments from these DNAs (data not shown) and restric-
tion enzyme analysis followed by Southern hybridization 
enabled us to locate the breakpoints between exons 2 and 3 (see 
Fig. 2). The'breakpoints in the previously cloned3,7 9q* break-
point fragments of patients 0319129 and 02120185 were analysed 
by DNA sequencing. In addition, we cloned the 22q" breakpoint 
fragments of patient 0319129 (unpublished results) and of the 
cell line K562. DNA sequence analysis of the breakpoint regions 
of these fragments and that of the sequence of the corresponding 
chromosome 22 regions enabled us to define the point of translo-
cation for these DNAs (see Fig. 2). None of the breakpoints 
analysed here could be located within an exon, indicating that 
in the Ph' translocation, breakpoints occur within intron regions 
of 6cr. For four of the six DNA samples analysed, the transloca-
tion would result in the transcription of a mRNA that includes 
ocr exons 1 and 2 (see Fig. 2); in two CML DNAs the third 
exon would be additionally incorporated in the chimaeric 6cr/c-
abl mRNA. Exon 3 encodes only 25 amino acids, not substan-
tially increasing the size of the chimaeric protein. 
A knowledge of the DNA sequence of the translocation junc-
tion point may provide additional information about the 
mechanism of chromosomal translocation. Figure 3a shows the 
sequence of the region containing the crossover point for translo-
cation in the DNA of patient 0319129 and compares this with 
norma! chromosome 22 and 9 DNA sequences. In 0319129 
DNA, the chromosomal break has occurred in a rather 'precise' 
manner, leading to the generation of a 22q" and 9q+ sequence 
exactly reflecting the sequence of the normal chromosome 22 
and 9 DNA sequences. However, at the breakpoint, a C nucleo-
tide is found in both the 9q* and 22q" sequences, whereas the 
chromosome 22 sequence contains a G at that position. Note 
that both chromosomes 9 and 22 contain limited stretches of 
homology near the break (Fig. 3a underlined); a DNA search 
revealed homology of this region to human Alu repetitive 
sequences. 
No such similar stretches of homologous sequences between 
chromosomes 9 and 22 occur at the breakpoint in the DNA of 
patient 0212015 (Fig. 36) or in that of K562 DNA (data not 
shown). In the 9q* DNA of patient 0212015, sequences are 
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Fig. 2 Genomic organization of the bcr gene. 
a, Restriction enzyme map of chromosome 22 
sequences encompassing bcr. Exons are indi-
cated by black boxes below the restriction 
enzyme map. The position of the numbered 
exons has been determined by sequencing; all 
other exons were located by hybridization to 
the Vl-3 cDNA. The asterisk indicates a poly-
morphic BglU restriction enzyme site. 6, 
Restriction enzyme map of the breakpoint 
cluster region, with the exons as indicated in a. 
Below the map, the approximate positions of 
the breakpoints in different CML DNAs are 
indicated by horizontal or vertical arrows. 
Restriction enzymes include: A, Aval; B, 
BamHI; Bg, BglU; E, Eco RI, H, HindlII; P, 
Pstl; S, Smal; Ss, Sstl: X, Xhol. The break-
point of the 22q" chromosome from DNA 
0319129 was cloned as a 9.5-kb BglU fragment 
in Charon 30 according to previously described 
methods16.9q+ fragments were isolated by clon-
ing a 7.2-kb BamHI fragment and a 7.7-kb 
£coRI fragment into Charon 30 and Agtwes, 
respectively. 
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found between the breakpoints on chromosomes 9 and 22 
(Fig. 36) which are not present in the sequenced region of the 
normal chromosomes 9 and 22. This suggests that in the 9q+ 
chromosome a secondary event has taken place; it is possible 
that after translocation of chromosome 22 sequences to chromo-
some 9, a deletion affecting chromosome 9 sequences occurred. 
The arrow indicating the breakpoint on chromosome 9 (see 
Fig. 36) would then represent the point of deletion. In addition, 
compared with the normal chromosome 9 sequences, the 
chromosome 9 sequences of the 9q+ fragment contain 13 nucleo-
tide changes within an 8l-bp stretch. These changes may reflect 
differences between individuals (the control chromosome 9 
sequences were isolated from a human lung carcinoma cosmid 
library) ; however, the number of nucleotide substitutions would 
be very high in such an event. Moreover, the chromosome 22 
part of the 9q* fragment contains no nucleotide changes in 
either intron or exon sequences, favouring the explanation of 
inefficient DNA repair on deletion of chromosome 9 sequences. 
These results indicate that bcr is part of a gene oriented with 
its 5' end towards the centromere of chromosome 22. In the 
Philadelphia translocation, a break occurs within bcr, and 
sequences from chromosome 9 which contain the human c-abl 
oncogene in all Ph'-positive cases examined7''' are translocated 
to the 3' of the truncated bcr gene. The joining of bcr and c-abl 
sequences is highly specific for CML, as this configuration has 
been found in complex translocations9 and even in the leukaemic 
cells of one CML patient cytogenetically lacking the Ph' chromo-
some". Because the orientation of c-abl on chromosome 9 is 
also centromere-5'-3'-telomere, bcr and c-abl are joined in a 
head-to-tail fashion on the Ph' chromosome. Although the dist-
ance between the most S' v-abl homologous to v-abl and the 
physical breakpoint may vary from 14 kb (patient 0319129) to 
> 100 kb ( K562), the effect of the translocation on the expression 
of the bcr gene and c-abl seems to be very similar in different 
patients: in K.562 and in Ph'-positive CML patients, abnormal 
RNA transcripts of —8.5 kb are detected, which hybridize to 
both c-abl and 5' bcr exon probes. The molecular cloning of a 
chimaeric cDNA from K562 cells has provided definitive proof 
for the existence of chimaeric mRNA i : . The chimaeric mRNAs 
must be the result of transcription initiating at the promoter of 
the bcr gene; depending on the exact location of the breakpoint, 
the transcript will include all S' exons in addition to either exons 
1 and 2 or exons 1, 2 and 3 of bcr. Recent sequence analysis of 
K562 bcr/abl cDNA confirms the variable presence of the third 
exon. In K562 we found that, as predicted, the third exon is 
present in the cDNA, immediately preceding c-aW sequences. 
In contrast, Southern blot analysis of the molecularly cloned 
22q" genomic DNA fragment of, for example, patient 0319129 
unambiguously demonstrates that in this patient exon 3 has 
been removed from the Ph' chromosome and wil! not be included 
in a chimaeric bcr/abl transcript. Transcription continues into 
the c-abl oncogene, including, as a minimum, the most 5' v-abl-
homologous exon and all exons 3' of it, including the phos-
photyrosine acceptor site13. We do not know whether the 
inclusion of exon 3 in the chimaeric m RNA has an effect on 
the progression of the disease. 
Chromosomal aberrations may be generated by specific events 
involving recombination-prone DNA sequences. Alternatively, 
such recombination events could occur almost at random. In 
either case, a very limited number of translocations will result 
in gene alterations leading to the disruption of normal growth 
and differentiation. In the Ph' translocation, We have found that 
breakpoints on chromosome 9 are spread over a region of up 
to 100 kb. The breakpoints on chomosome 22 occur within a 
smaller region of around 5.0 kb. Nonetheless, no sequence 
homology can be found between breakpoint regions of different 
CML patients or coding regions of c-abl and bcr genes. There-
fore, we may conclude that the processes underlying the Ph' 
translocation are random recombination events. Once such re-
combinations result in a genomic configuration that allows the 
transcription of chimaeric bcr/abl mRNA, malignant prolifer-
6TTj>GG0CCTtrTCTCTCCTCCCMC«CT66«C«*GCTGIiGTT*6G*tC»6TTTercCCT6*liTC6CTGC 
CCCGGGT1 
' CCC6GGTTt*CGTG*T*eTCTIGCCTC*GCTICCTGC»TAGCTGSG*CT*C»GGC*CceACC«e*CCCC 
TG*C*eTGGCTT*CCTIGTGeCAGGC*GAIGGC*GCC»C*CAGTGTCC*CC6G*TGGTTG)lTTTTG*AGe 
CA6CTAArrITTTTGTirGTTIGT' 
' CA6CT«ATTTTET6IAT6TTT»GTi 
AGAGTTAGCTrGtCACCTGCCncCCmCUSGGAC. 
GTTTTCCTGAGACGGAGKTCACrGKACCCAGGCTGGAC 
GAGGTTTC|tCAGAAGCTGACCTCTTTGGTCTCTTGCGCAG 
CAGAAGCTGACCTCTTTGATCKTTGCGCAG 
T G C A G T G G C G ! A A T C T 7 G G C T : A C T C C » 
ATGATGAGTCTCCGGGGC1CTATGGGTT 
.ccrccAccrcccGGG 
CTGAAIGTCATCGIC 
Fig. 3 Breakpoint sequences of the DNAs of two CML patients. 
a. Sequence of 0319129 DNA; the sequences are in a 5'-3'orienta-
tion. Normal chromosome 9 sequences {first line) are from non-
CML DNA; the 9q* and 22q~ sequences (second and third lines) 
are from DNA of patient 0319129. Normal chromosome 22 sequen-
ces (fourth line) are from non-CML DNA. An arrow indicates the 
breakpoint on chromosomes 9 and 22; the nucleotide C found in 
both the 9q+ and 22q~ sequences at the breakpoint is boxed. 
Limited regions of homology between the normal chromosome 9 
and 22 sequences are underlined, b. Breakpoint sequence of 
02120185 DNA; normal chromosome 9 and 22 sequences (first and 
third lines in each set) were from non-CML DNA. The 9q* 
sequence on the second line contains an area boxed to indicate 
that it does not originate from the normal chromosomes 9 or 22 
sequenced in the present experiments. Dots above the chromosome 
9 sequences indicate nucleotide differences at those positions from 
the9q* chromosome. The beginning of exon 3 (see Fig. 2b) in the 
9q* and 22 sequence is indicated in the figure. Small restriction 
enzyme fragments containing the breakpoints were chosen for 
sequence analysis, based on restriction enzyme mapping data and 
comparison with normal chromosome 9 and 22 maps. 
ation of specific cell types may occur. It seems highly likely that 
this chimaeric mRNA is translated into protein because an 
abnormally sized 210,000-Mr c-abl protein was detected in K562 
cells. In contrast to the normal c-abl protein, the P210 has 
tyrosine kinase activity*. 
It is tempting to speculate that the bcr moiety of the fusion 
protein is responsible for this effect. However, although the 
consequences of the Ph' translocation on a molecular level are 
becoming evident, it remains to be established whether this 
phenomenon is actually the cause or merely one of the steps 
that eventually result in CML. 
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CHAPTER 4 
EVIDENCE OF A NEW CHIMERIC BCR/C-ABL MRNA IN PATIENTS WITH 
CHRONIC MYELOCYTIC LEUKEMIA AND THE PH' CHROMOSOOM 
Kees Stam, Nora Heisterkamp, Gerard Grosveld, Annelies de Klein, 
Ram Verma, Morton Coleman, Harvey Dosik and John Groffen 
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E V I D E N C E O F A N E W C H I M E R I C bcr/c-abl m R N A I N P A T I E N T S W I T H C H R O N I C 
M Y E L O C Y T I C L E U K E M I A A N D T H E P H I L A D E L P H I A C H R O M O S O M E 
K E E S S T A M , IR . , N O R A H E I S T E R K A M P , P H . D . , G E R A R D G R O S V E L D , P H . D . , ANNELIES DE K L E I N , P H . D . , 
R A M S. V E R M A , P H . D . , D . C . C . , M O R T O N C O L E M A N , M . D . , H A R V E Y DOSIK, M . D . , 
AND J O H N G R O F F E N , P H . D . 
Abstract The hallmark of chronic myelocytic leukemia is 
the presence of the Philadelphia chromosome (Ph'). In 
recent studies, we obtained data that strongly suggested 
the involvement of an oncogene, c-abl, in this type of leu-
kemia. This oncogene, normally located on chromosome 
9, is translocated to chromosome 22 as a result of the Ph1 
translocation. In addition, we identified a region on chro-
mosome 22, the breakpoint cluster region (bcr), which 
contains the chromosomal breakpoint in all patients with 
chronic myelocytic leukemia who are positive for Ph1. Re-
cent studies have suggested that the bcr is part of a gene 
that is truncated as a consequence of the Ph' transloca-
tion. The deleted part of this gene could be replaced by 
c-abl sequences; to test this hypothesis we analyzed the 
RNA of five patients with chronic myelocytic leukemia. All 
five had chimeric bcrtc-abl messenger RNA, suggesting 
that the deleterious effects of this disease can be associat-
ed with an abnormal chimeric protein encoded by the bcr 
and the c-abl oncogene. (N Engl J Med 1985; 313:1429-
33.) 
RECENT studies indicate a close association be-. tween chronic myelocytic leukemia (CML) and 
the activation of an oncogene, human c-abl. The hall-
mark of CML is the presence of an abnormal chromo-
some, the Philadelphia (Ph1) chromosome, found in 
the leukemic cells of over 95 per cent of all patients. 
This chromosome is the result of a reciprocal trans-
location involving chromosome 9 band q34 and chro-
mosome 22 band q l l . ' Since only a small region of 
chromosome 9, on which the oncogene c-abl is located, 
is translocated to chromosome 22,2 the abnormal, 
shortened chromosome 22 (22q~, or Ph') can be easily 
identified cytogenetically. In some patients with CML 
the abnormal chromosome 9 (9q+) is not detectable; 
nonetheless, we have found that in these patients, c-abl 
is also translocated to chromosome 22.3 
We have previously identified a region about 5.8 kb 
long on chromosome 22, in which the breakpoint oc-
curred in the DNA of all of more than 30 patients with 
CML who were positive for Ph'.4 We proposed the 
name "breakpoint cluster region," or bcr, for this rela-
tively small region. In recent experiments we have 
shown that the bcr is part of a gene, the bcr gene5; 
coding regions of this gene are spread over at least 
66 kb of genomic DNA including the bcr and exons 5' 
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and 3' to it. As a consequence of the Ph' translocation 
part of this gene, the 3' end is translocated to chro-
mosome 9, whereas the 5' part remains on the Ph' 
chromosome. 
The remaining bcr sequences act as an acceptor of a 
chromosome 9 gene, the c-abl oncogene; the c-abl on-
cogene is fused in head-to-tail fashion to the chromo-
some 22 sequences. This genomic configuration could 
result in the transcription of a novel chimeric mRNA 
(messenger RNA) consisting of 5' bcr sequences and 3' 
c-abl oncogene sequences. 
In the present studies we analyzed the RNA of five 
patients with CML and found strong evidence for this 
model. We demonstrated the presence of a chimeric 
bcr/c-abl transcript in RNA specimens isolated directly 
from the bone marrow of all patients studied. 
METHODS 
Patients 
Wc studied five patients with Ph'-positive CML. Four had the 
usual Ph1 translocation, and one had a complex translocation. 
Patient 2128 was a 37-year-old Asian (East Indian) man, in 
whom CML was diagnosed on June 17, 1982. He had a complex 
t(9;12),t(l2;22) translocation.6 Chromosome studies revealed a 
46,XY,Ph' karyotype. His disease is still in the chronic phase, and 
his peripheral blood is normal. 
Patient 2252 was a 45-year-old white man. He presented with 
CML on January 26, 1983 and had the usual t(9;22) translocation. 
His karyotype {46,XY,Ph') has remained unchanged, and his pe-
ripheral blood is normal. Patient 2397 was a 43-year-old white 
woman with a 46,XX,t(9;22),Ph' karyotype. CML was first diag-
nosed on October 17, 1983. She has been evaluated regularly, and 
her karyotype has not changed; her peripheral blood is normal. 
Patient 1708 was a white woman who presented with CML on 
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July 24, 1980. All 40 cells examined had the 46,XX,t(9;22),Ph1 
karyotype. At the latest bone marrow aspiration (July 9, 1984), the 
40 cells examined showed similar cytogenetic findings. Her disease 
is in the chronic phase. During the past six years cytogenetic evalua-
tion has been performed serially. Stimulation of peripheral-blood 
cells with phytohemagglutinin has given normal results. 
Patient 2172 was a 52-year-old white man, in whom CML was 
originally diagnosed on September 22, 1982. Cytogenetic analyses 
have been performed every three months. His karyotype remains 
46,XY,t(9;22),Phl, and phytohemagglutinin-stimulated peripheral 
blood is normal. 
Cytogenetic Techniques 
Initially, 20 metaphases were banded by G banding each time 
a blood sample was drawn. Afterward, 20 ceils were banded by 
R banding as described by Verma and Lubs.T Metaphases were 
photographed in color but printed in black and white. Cytogenetic 
evaluation was performed by projecting the color slides. 
RNA Isolation and Electrophoresis 
Total RNA was isolated according to the lithium chloride-urea 
method.8 Fresh bone marrow samples {1 to 2.5 ml) were homog-
enized in 25 ml of 3 M lithium chloride and 6 M urea on ice in a 
polytron homogenizer, two bursts for 30 seconds each. The homoge-
nate was kept on ice for three hours. The precipitate was pelleted 
at 10,000x^ for one hour and dissolved in 3.2 ml of a 1:1 mix-
ture of buffer (10 mM TRIS-HC1 [pH 7.5], 5 m M EDTA, and 0.2 
per cent sodium dodecyl sulfate) and phenol:chloroform:isoamyl-
alcohol (25:24:1). The water phase was extracted two times with 
phenol:chloroform:isoamyIalcohoI (25:24:1), and the RNA precipi-
tated overnight at —20°C with 2.5 volumes of absolute ethanol and 
0.1 volume of 3 M sodium acetate (pH 5.2). The RNA was rinsed 
three times in 70 per cent ethanol and stored at - 70°C. Poly A RNA 
was obtained after one passage of the RNA over oligo-dT-cellulose; 
10|tg was subjected to electrophoresis on a 1 percent agarose gel in 
the presence of formaldehyde. Blotting to nitrocellulose (Schleicher 
and Schuell filters, PH 79) was performed essentially as described 
elsewhere.9 
Hybridization 
wP-labeIed RNA probes were generated by transcription labeling 
according to the pSP riboprobe method (Promega Biotech), essen-
tially as previously described10; 1 to 5x 108 cpm of [32P]RNA was 
used per hybridization, corresponding to 0.5 to 2.5x10s cpm per 
microgram of input DNA. 
Blots were first prehybridized in 100 ml of 50 per cent formamide, 
50 mM sodium phosphate bufFer [pH 6.5], 5xSSC (1 XSSC = 0.15 M 
sodium chloride and 0.15 M sodium citrate [pH 7.0]), 1 mM 
EDTA, 0.1 per cent sodium dodecyl sulfate, 2.5-fold-concentrated 
Denhardt's solution, 250/*g of salmon-sperm DNA (per milliliter), 
250 fig of calf-liver RNA (per milliliter), and 10 u.g of poly A (per 
milliliter) for four hours at 55°C. Hybridization was performed in 35 
ml of hybridization mix (four parts prehybridization mix and one 
part 50 per cent dextran sulfate) overnight at 55°C. The filters were 
washed in 20 mM sodium phosphate buffer (pH 6.5), 1 mM EDTA, 
0.1 per cent sodium dodecyl sulfate, and 2.5X SSC, twice (20 min-
utes each time) at 55°C. They were then washed twice for 20 min-
utes in 20 mM sodium phosphate buffer (pH 6.5), I mM EDTA, 0.1 
per cent sodium dodecyl sulfate, and 0.3 x SSC at 65°C, and similar-
ly, in the same solution but with 0.1 X and 0.03X SSC, consecutive-
ly, at 65°C. Filter washings were stopped when no radioactivity 
could be detected in the washing solutions. Filters were exposed to 
XAR-2 film (Kodak) at — 70°C with intensifying screens (Dupont 
Lightning Plus). 
RESULTS 
Northern Blot Analysis 
To demonstrate the presence of chimeric bcr/c-abl 
mRNAs in the bone marrow cells of the patients, a 
number of probes were required to perform Northern 
blot analysis. 
We recently isolated a bcr cDNA clone from a li-
brary of normal human-fibroblast cDNA {comple-
mentary DNA).1 ' Upon hybridization of this clone 
with previously isolated cosmid clones encompassing 
the bcr, we demonstrated that the bcr is part of a large 
gene, the icrgene, consisting of at least 12 exons locat-
ed 5' and 3' of the bcr} Because the 5' and 3' ends of 
the bcr cDNA are known,12 the orientation of the bcr 
gene on chromosome 22 could be determined; its 5' 
end is pointed to the centromere, and its 3' end to the 
telomere of chromosome 22. As a consequence of Ph1 
translocation, the 5' part of the bcr gene remains on 
chromosome 22 while the 3' part is translocated to 
chromosome 9 in the t(9;22).5 In previous studies, the 
majority of all Ph1 breakpoints have been shown to 
occur in the intron sequences between the exons de-
noted as II and III or in the intron between exons III 
and IV (Fig. 1A).4'5 This implies that the part of the 
cDNA corresponding to probe A (Fig. IB) remains on 
chromosome 22, whereas the cDNA sequences corre-
sponding to probe B are translocated to chromosome 9 
in the Ph1 translocation. Both probes were inserted in 
reversed orientation in pSP vectors, permitting isola-
tion of [32P]RNA complementary (anti-sense) to nor-
mal bcr mRNA. Labeled probes were generated by 
means of this vector construct, since previous experi-
ments" had demonstrated that such probes enhance 
the signal by at least fivefold in Northern hybridiza-
* I Bg 
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I ,1 
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Figure 1. Exon-lntron Organization within the bcr. 
Panel A is a restriction-enzyme map of genomic bcr; the 5.8-kb 
bcr, in which all breakpoints occur on chromosome 22 in the Ph' 
translocation, is indicated above the map. The location of exons 
immediately 5',3' and within the bcr are shown (not drawn to 
scale) beneath the map. The numbered exons are 
referred to in the text. 
Panel B is a restriction-enzyme map of bcr cDNA; the num-
bers and shading of regions in the cDNA correspond to the ex-
ons similarly labeled in Pane! A. The bcr cDNA probes used in 
this study are shown beneath the map. The following abbrevia-
tions denote the restriction enzymes used in mapping: A repre-
sents Aval, 8 Sam HI, Bg BglU, Bs Ss/EII, E EcoRI, H Hind\\\, 
P Pst\, and Pv PvuW. The AAA* at the 3' end of the cDNA indi-
cates the poly A tail. 
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Figure 2. Northern Blot Analysis of RNA from Five Patients with CML. 
The lanes show results with the following probes: A denotes the 5' bcr probe (see Fig. 
1B); B, the 3' bcr probe (Fig. 1B); and C, the c-abl probe. The molecular weight of 
c-aW-hybridizing RNA (in kilobases; 1 kb = 3.3 X105 daltons) is indicated at the left: 
the position of ribosomal 28s and 18s RNA is shown at the right. 
tions, as compared with conventional, nick-translated 
DNA probes. Similarly, a human c-abl fragment en-
compassing the most V v-abt homologous exon (probe 
C) was inserted into a pSP vector.13 
Abnormal bcrtc-abl mRNA in Leukemic Cells 
If a chimeric bcrlabl mRNA exists in the leukemic 
cells of patients with CML, we would expect to detect 
an abnormally sized abt transcript; the same abnormal 
mRNA should hybridize with the 5' bcr probe (probe 
A) but not with the 3' bcr probe (probe B), since the 
genomic sequences corresponding to the latter probe 
are translocated to chromosome 9 in the t(9;22). The 
data from our experiment with these probes are shown 
in Fig. 2. 
All patients had an 8.5-kb transcript that hybrid-
ized both with the c-abl and the 5'-specific bcr probe 
(Fig. 2). The 3'-specific bcr probe did not hybridize 
with this transcript, thus excluding it as a normal 
bcr mRNA. The 8.5-kb transcript seems to be charac-
teristic of Ph'-positive cells, since it is not found 
in either normal control cells or cells of other types 
of leukemia.14,15 Three bands around 7.5, 7.0, and 4.5 
kb were detected with both the 5' and the 3' bcr 
probes, indicating that these bands may represent 
normal bcr mRNAs. The transcripts of 7.5, 7.0, and 4.5 
kb are also present in other human cell lines and tis-
sues, including several myeloid and lymphoid cell 
lines, erythroid precursor cells, skin, gut, kidney, 
PATIENT and spleen. None of the samples 
2252 tested contained the 8.5-kb bcr-rc-
C A B lated RNA.11 
The bone marrow cells from all 
the patients contained a 6.0-kb and 
a 7.0-kb c-abl transcript (Fig. 2). 
These transcripts are also present 
in normal cells14 and represent nor-
mal c-abl mRNAs. Presumably, 
both transcripts are initiated at the 
same promotor but terminate dif-
ferently at the 3' end of the abl on-
cogene. In addition, an 8.5-kb c-abl 
hybridizing mRNA was clearly 
demonstrated in all patients. Al-
though all five patients had both 
the 8.5-kb chimeric and the normal 
abl transcripts, the chimeric tran-
script was expressed at a higher 
level. 
Patient 2128 
Cytogenetic analysis of Patient 
2128 revealed a complex 
[t(9;12),t(12;22),PhI] transloca-
tion. In a patient with an analogous 
karyotype,16 both bcr and c-abl se-
quences were found on chromo-
some 12 by means of in situ hybrid-
ization techniques. This suggests 
that even in complex Ph' translocations, bcr and c-abl 
are fused, producing a chimeric bcrlabl mRNA. North-
ern blot analysis of Patient 2128 provided confirma-
tive evidence: both bcr and c-abl hybridized with the 
same 8.5-kb mRNA (Fig. 2). Interestingly, probe B 
strongly hybridized with an mRNA of approximately 
2.0 kb ( 18s) in this patient. This suggests that as a result 
of the complex Ph' translocation, the 3' part of the bcr 
gene fuses to a currently unknown gene that directs 
expression of the 3' , translocated part of the bcr gene. 
DISCUSSION 
Cells from patients with Ph'-positive CML and 
from different CML cell lines contain an abnormal 
c-aA/-related transcript of approximately 8.5 kb.14,15,17 
In the present studies, we demonstrated that this ab-
normal mRNA was present in RNA from each of five 
patients with CML and that it represents a chimeric 
bcr I'c-abl transcript. 
The specific presence of this novel transcript in leu-
kemic cells of patients with CML supports the view 
that both c-abl and bcr are involved in this disorder 
and that the fusion of bcr and c-abl sequences is a 
crucial event in the disease. The recent demonstra-
tion16 of a breakpoint within the bcr, and the location 
of genomic bcr and c-abl sequences on chromosome 12 
in a patient with a t(9;12) but without a cytogenetical-
ly detectable Ph1 chromosome, further substantiates 
this model. 
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Figure 3. Results of Ph1 Translocation at the Molecular Level. 
During the Ph1 translocation, a break occurs within an intron of 
the bcr gene on chromosome 22 and within the c-abl oncogene 
on chromosome 9; these DNA sequences are physically joined on 
the Ph' chromosome in a head-to-tail fashion, with bcr (open part 
of bar) centromeric (CEN) and c-abl (solid part of bar) telomeric 
(TEL). This configuration allows transcription of a chimeric 
mRNA, consisting of 5' bcr exons fused to 3' c-abl coding 
sequences, including the region coding for phosphotyrostne ki-
nase activity. After splicing, this mRNA is translated into a chi-
meric fusion protein with a bcr amino terminus and a c-abl 
carboxy terminus. 
In approximately 15 to 25 per cent of patients with 
acute lymphoblastic leukemia, the Ph' chromosome is 
found in the leukemic cells.18 Preliminary experiments 
indicate that these patients also have a breakpoint 
within the bcr, suggesting that a chimeric bcr/c-abl 
mRNA will be transcribed in the leukemic cells. 
Translation of a chimeric mRNA, as found in our five 
patients, would result in a bcr/abl fusion protein (Fig. 
3). Evidence for the existence of such a protein has 
been recently found in K.562, a cell line derived from 
the leukemic cells of a patient with CML in blast cri-
sis.19 In this cell line a similar bcr/'c-abl transcript 
could be demonstrated.11 In addition, a c-abl protein 
of abnormal size was detected (P210; 210,000 dal-
tons),20 suggesting that this protein is the transla-
tional product of the chimeric bcr/abl mRNA. Al-
though the tumorigenic potential of this protein is 
unknown, it involves the c-abl oncogene; v-abl — the 
result of a recombination of murine leukemia virus 
and the mouse c-abl oncogene21 — induces rapid 
B-cell lymphoma in mice.22'23 As yet, the normal 
cellular function of c-abl has not been defined; how-
ever, this gene belongs to a broader family of genes, 
some of which may encode cellular receptors. Recent-
ly, the insulin receptor was molecularly cloned and 
shown to have a marked degree of homology to v-ros 
and other members of the tyrosine-specific protein 
kinase family, such as v-abl2*; the receptor for epi-
dermal growth factor was found to be homologous to 
the v-erbB oncogene, another member of this family 
of oncogenes.25 
How the bcr part of the abnormal bcr/c-abl fusion 
protein could contribute to tumorigenic activity is un-
known at the moment. However, studies with the 
CML cell line K562 may provide insight into how the 
protein is altered: the abnormal P210 protein has tyro-
sine kinase activity, in contrast to the normal, P145 
c-abl protein.20,26 The bcr moiety of this chimeric mole-
cule could therefore have altered the structure of the 
c-abl protein and so unmasked its associated tyrosine 
kinase activity. It remains an interesting question, 
though, whether the bcr would be sufficient or neces-
sary for this effect. On analogy to the v-abl poly-
protein, which is also a tyrosine kinase,27,28 the CML-
specific bcr/c-abl protein might have transforming 
activity and could play an essential part in the causa-
tion or persistence (or both) of CML. 
Wc are indebted to Pamela Hansen and Gall Blennerhassett for 
technical assistance, to Dr. J.R. Stephenson for a critical reading of 
the manuscript, to Professor Dr. D. Bootsma for helpful discussions, 
and to Rosanne Beyer for help in preparing the manuscript. 
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In the DNAs of all Ph'-positive chronic myelocytic leukemia patients studied to date, a breakpoint on 
chromosome 22 (the Ph' chromosome) can be demonstrated with a probe Trom the bcr (breakpoint cluster 
region). Although the K562 eel) line was established from cells of a chronic myelocytic leukemia patient, we 
have been unable to detect the Ph1 chromosome by cytogenetic means. Employing a probe from the 5' region 
offre/-, we have cloned an amplified Ph1 breakpoint fragment from K562. This demonstrates that K562 contains 
multiple remnants of a Ph' chromosome with a breakpoint within bcr and thus may serve as a model system 
for the study of Ph'-positive chronic myelocytic leukemia at a molecular level. The isolation of bcr cDNA 
sequences shows that parts of bcr encode a protein. Employing K562, we demonstrate the presence of an 
abnormally sized mRNA species hybridizing to c-abl and to a bcr cDNA probe, indicating the possible 
consequence of the Ph' translocation on a transcriptional level in chronic myelocytic leukemia. The isolation 
and sequencing of a cDNA containing the breakpoint area of this mRNA provide further evidence for its 
chimeric structure. Cloning of large stretches of chromosomal DNA flanking bcr and c-abl sequences in K562 
and identification of the exons participating in the formation of the chimeric mRNA shows that a splice of at 
least 99 kilobases is made to fuse the 3' bcr exon to the 5' c-abl exon. Furthermore two chimeric cDNAs were 
isolated containing chromosome 9 sequences that map 43.5 kilobases downstream from the K562 breakpoint. 
These chromosome 9 sequences neither hybridize to the 8.5-kiIobase chimeric c-abl mRNA nor to normal c-abl 
mRNAs in Hela cells and probably represent incorrect splicing products present in the K562 cell line. 
Chronic myelocytic leukemia (CML) is a pluripotent stem 
cell disease characterized by the presence of the Philadel-
phia (PhL) chromosome in the leukemic cells of 96% of all 
CML patients. The Ph' chromosome is the result of a 
translocation between chromosomes 22 and 9 (31). The 
human c-abl oncogene (17) has been mapped to the long (q) 
arm of chromosome 9 (18). By analysis of somatic cell 
hybrids, we have shown that this oncogene is translocated to 
the Ph1 (22q-) chromosome in Ph'-positive CML, demon-
strating that c-abl is involved in the translocation between 
chromosomes 9 and 22 (8). The location of the c-abl 
oncogene adjacent to the translocation breakpoint in CML 
was shown by the isolation of a DNA fragment from the 9q* 
chromosome of a CML patient: this fragment contained 
sequences of both chromosomes 9 and 22. The breakpoint 
had occurred 14 kilobases (kb) immediately 5' of the v-abl 
homologous sequences and resulted in a 9q ' chromosome in 
which the tip of chromosome 9, including the v-abl homol-
ogous sequences, was replaced by sequences of chromo-
some 22 (20). The isolated chromosome 22 sequences of this 
chimeric DNA fragment enabled us to study their role in the 
Ph1 translocation in greater detail. A breakpoint cluster 
region (bcr) was identified on chromosome 22; the DNAs of 
all (over 30) Ph'-positive CML patients examined to date 
have breakpoints in this region of up to 5.8 kb. As a result. 
c-abl is linked to the same chromosome 22 sequences on the 
Ph1 chromosome in all patients, oriented with its 5' end 
toward and its 3' end away from bcr (14). 
In 1975, Lozzio and Lozzio (25) reported the isolation of a 
cell line, K562, from the pleural effusion of an adult patient 
* Corresponding author. 
with CML. This cell line expresses phenotypic markers of 
eythroid lineage and displays induced and spontaneous 
globin synthesis (23). We and others (5, 20. 33) have shown 
that the c-abl oncogene and the X immunoglobulin light chain 
constant region (CM are amplified at least fourfold in this cell 
line. In contrast, another human oncogene, c-sis, is not 
amplified (20) and is normally located on chromosome 22 but 
transposed to chromosome 9 in the Ph1 translocation (13). 
These data suggest that K562 contains part of a Ph' chro-
mosome which is at least fourfold amplified. However, 
cytogenetic data are not confirmative, because we cannot 
detect a Ph' chromosome in different pedigrees of this cell 
line and others (25) have suggested the presence of a single 
Ph1 chromosome. Such findings leave the question unre-
solved as to whether K562 cells may serve as a model system 
for the study of Ph'-positive CML at the molecular level. In 
the present study we demonstrate the presence of a Ph' 
chromosomal breakpoint in the DNA of K562. The 
breakpoint has occurred in bcr, confirming our previous 
results that a breakpoint in bcr is highly specific for CML. In 
addition, we have established that bcr is part of a protein-
encoding region (19). Shtivelman et al. (34) have described 
the existence of a chimeric bcrlc-abl mRNA in the CML 
derived cell lines K562 and EM-2, by cloning partial cDNAs 
for these molecules. From sequence analysis of the chimeric 
cDNAs the authors show that the mRNA can code for a 
bcrlc-abl fusion protein. In the present paper we provide 
independent confirmation for the presence of the chimeric 
bcrlc-abl mRNA in K562. We identify and sequence the 
chromosomal exons of bcr and c-abl that participate in the 
formation of the chimeric mRNA and show that they are at 
minimum 97 kb apart in K562. Furthermore we provide 
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evidence that probably alternative splicing products can be 
formed from the bcrlc-abl precursor mRNA in K562. 
MATERIALS AND METHODS 
Southern blotting and hybridization. High-molecular-
weight DNAs were isolated as described previously (22), 
digested with restriction enzymes, and electrophoresed on 
agarose gels. Blotting was as described by Southern (35) on 
nitrocellulose (Schleicher & Schuell Co.; ph 79). Nick 
translation of probes and filter hybridizations were as 
described previously (2, 10). The specific activity of the 
probes was 2 x 10H to 5 x 108 cpm/jj.g. Filters were exposed 
to XAR-2 film (Eastman Kodak Co.) at -70°C with Du Pont 
Lightning Plus intensifying screens. 
Isolation of probes. DNA probes were prepared by diges-
tion with appropriate restriction enzymes, followed by elec-
trophoresis through low-melting-point agarose gels. Desired 
bands were cut from the gel and brought into solution by 
heating at 65°C for 3Ü min. Agarose was removed by two 
extractions with phenol equilibrated with 0.3 M sodium 
acetate (pH 5.0) and one extraction with phenol-chloroform-
isoamyl alcohol (25:24:1). DNA was precipitated with 
ethanol and 0.2 M sodium acetate (pH 5.6) in the presence of 
20 jjtg of Dextran T-500 per ml as a carrier. Restriction 
enzymes and low-melting-point agarose were purchased 
from Bethesda Research Laboratories, Inc., and were used 
according to the supplier's specifications. 
Molecular cloning. A cosmid library was constructed of 
size-fractionated K562 DNA partially digested with M bol by 
previously published procedures (12) and screened with the 
0.6-kb Himllll-BumHl bcr probe (see Fig. 2) by the method 
of Grosveld et al. (15). Three positive cosmid clones were 
isolated and mapped independently by digestion of individ-
ual restriction enzyme fragments isolated from low-melting-
point agarose gels. 
Construction of k562 cDNA libraries. Total polyadenylated 
rpoly(A) + ] RNA (50 \x.g) was denatured with 1 mM 
methylmercuric hydroxide before cDNA synthesis (26). 
First-strand synthesis was primed with oligo(dT) or 120 ng of 
c-abl 27-mer primer. cDNA synthesis was performed as 
described by Gubler and Hoffman (16). The double-stranded 
cDNA was treated with 10 U of T4 polymerase (Bethesda 
Research Laboratories) for 10 min at 37°C before EcoRl 
methylation and EcoRl linker addition. After EcoKl diges-
tion, excess linkers were removed by passage of the cDNA 
over Sepharose 2B-CL (Pharmacia Fine Chemicals). The 
cDNA was ligated to XgtlO DNA cut with EcoRl, essentially 
as described by Huynh et al. (21). For the total library 4 x 
10* plaques were screened, and for the c-abl primed library 
2 x 105 plaques were screened. £toRI inserts from positive 
plaques were subcloned into the EcoRl site of pUC18 or 
PUC19. 
RNA analysis. Total RNA was isolated by the LiCl-urea 
method (1). Poly(A)' RNA was obtained after two passages 
of the RNA over oligo(dT)-celluIose, and 20 |xg of poly(A)' 
RNA of K562 was electrophoresed on a 1% agarose gel in 
the presence of formaldehyde (26). After blotting, nitrocel-
lulose filters were hybridized to the probes indicated in the 
legends to Fig. 3 and Fig. 8. 
RESULTS 
Identification of K562 chimeric DNA fragments. In the 
DNAs of all Ph'-positive CML patients examined to date, 
the presence of a breakpoint on chromosome 22 can be 
demonstrated for the majority of the DNAs by using a 1.2-kb 
Hitidlll-Bglll probe (14) (Fig. 1A); for example, abnormal 
EcoRl restriction enzyme fragments are clearly present in 
the DNAs of CML patients 02120185, 0319129, and 0311068 
(Fig. 2A). Restriction enzyme fragments containing these 
breakpoints have been molecularly cloned (14, 20; unpub-
lished results) and shown to represent 9q* fragments. In the 
K562 cell line abnormal fragments could not be detected 
either with EcoRl (Fig. 2A, lane 4) or with each of several 
other restriction enzymes tested (data not shown) after 
hybridization to the 1.2-kb //indlll-ßg/II probe. This could 
indicate that K562 does not contain a breakpoint on chro-
mosome 22 within bcr. To examine this more thoroughly, a 
probe more to the 5' (0.6-kb HtndlU-BamHl probe; Fig. 1A) 
within bcr was prepared and hybridized to the DNA of K562 
digested with different enzymes. This probe detects, in 
addition to the normal 5.0-kb Bglll fragment (Fig. 2B, lanes 
3 and 4). abnormal BglU fragments in K562 DNA (Fig. 2B, 
lane 2). Moreover, one of these fragments is amplified at 
least fourfold. Abnormal amplified restriction enzyme frag-
ments in K562 could also be detected by using other en-
zymes (Fig. 2B, lane 1). Since the 0.6-kb ///wdlll-ßamHI 
probe has detected 22q~ fragments in the DNAs of a number 
of CML patients (14), it seemed likely that the abnormal 
amplified fragments in K.562 represent amplified sequences 
on the 22q~ chromosome. 
Molecular cloning of the K562 22q~ breakpoint fragment. 
To analyze the abnormal amplified fragments in more detail, 
a cosmid library was constructed from K562 DNA partially 
digested with Mbol (12, 15). Numerous colonies of the 
approximately 100,000 recombinants hybridized with the 
0.6-kb / /mdlll-ßumHI probe; three such positive colonies 
containing overlapping portions of the same region were 
selected for further restriction enzyme analysis (Fig. ID). It 
is evident from a comparison of the detailed restriction 
enzyme maps of normal chromosome 22 sequences (Fig. IB) 
and K562 DNA (Fig. 1C) that the homology between the two 
terminates 3' to the most 5' Avul site. 
A 1.0-kb EcoRl probe prepared from K562 DNA immedi-
ately 3' to the breakpoint (Fig. ID) hybridizes to DNA 
isolated from somatic cell hybrids containing human chro-
mosome 9 in the absence of chromosome 22, but not to DNA 
isolated from hybrids containing chromosome 22 (data not 
shown). This indicates that the sequences isolated from 
K562 DNA are chimeric and contain the breakpoint of the 
22q" chromosome. The entire region is amplified at least 
fourfold; the chromosome 9-specific sequences are also 
amplified, as can be demonstrated by the strong hybridiza-
tion of the 1.0-kb EcoRl probe to K562 DNA in comparison 
with control DNA (Fig. 2C). Thus the amplification of 
chromosome 9 sequences begins at the point where the 
breakpoint has occurred on chromosome 9 in the Ph1 
translocation and extends in the direction of the telomere of 
the chromosome, including the c-abl oncogene. The ampli-
fied region may be relatively large, since the distance be-
tween the breakpoint on chromosome 9 and the most 5' v-abl 
homologous exon is, at minimum 99 kb (this paper). 
bcr is part of a gene. These results indicate that all 
Ph'-positive CML DNAs, including that from the cell line 
K562 established almost a decade ago and propagated in 
tissue culture, contain a common genetic defect, a break on 
chromosome 22 within a very narrowly defined region. This 
region was found to code for part of a gene of unknown 
function on chromosome 22 (19). Normal bcr cDNA clones 
isolated with the 0.6-kb HimMll-BamHl probe (Fig. 1A). 
such as pVl-3. were characterized by restriction enzyme 
mapping (Fig. 3) and hybridization to the genomic DNA of 
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FIG. 1. Restriction enzyme map of the K562 breakpoint region on chromosome 22. A. Restriction enzyme map of human chromosome 22 
sequences; the 5.8-kb Bglll-Bamtil (ACT) region encompasses the 0.6-kb HindlU-BumHl and 1.2-kb HindUl-BgHl probes. D. Restriction 
enzyme map of the Ph' chromosome in K562; the Ph1 chromosomal breakpoint is indicated with an arrow. B and C represent more detailed 
restriction enzyme maps of the indicated regions of A and D, respectively. The solid bars represent chromosome 22 sequences, whereas the 
open bars indicate sequences originating from chromosome 9. Probes used in the study are shown above A and below D. Abbreviations: A, 
Aval; B; BamHl; Bg, BglU; E, EcoRI; H, Himlttl; K, Kpnl; P, Pstl; S, Sstl; Xh, Xltol. 
chromosome 22. DNA sequence analysis of the cDNA and 
homologous genomic bcr sequences showed exact concor-
dance (19). 
Since the cDNA cloning procedure orients the cDNA in 
the vector (29), the transcriptional orientation of the bcr gene 
could be established; it points toward the telomere of chro-
mosome 22. This implies that bcr and the linked c-abl gene 
are transcribed in the same direction on the Ph1 chromosome 
(5' end centromeric, 3' end telomeric). 
Consequence of the Ph1 translocation on bcr and c-abl 
expression. Since the bcr gene is oriented in the same 
transcriptional direction as the c-abl oncogene, we next 
examined the influence of the Ph1 translocation on the 
transcription of these genes in K562. 
For the detection of c-abl mRNA we used a human c-abl 
riboprobe containing a 0.6-kb £t'«RI-fi«mHI fragment in 
pSP64 (28). This fragment contains the most 5' human v-abl 
hybridizing exon as identified by DNA sequencing (see Fig. 
5 and 6). This exon is homologous to the mouse c-abl exon 
containing the v-abl-gag-abl junction identified and se-
quenced by Wang et al. (37). To examine the effect of the 
amplification and translocation of the human c-abl oncogene 
on its expression, po!y(A)+ RNA was isolated from K562 
and control Hela cells. In concordance with results obtained 
by others (6, 11), the c-a&/-specific probe detects 6.0- and 
7.0-kb mRNAs both in Hela cells and in K562. In addition, a 
novel c-abl homologous mRNA of 8.5 kb is detected in K562 
(Fig. 3, left lane). An extra band of approximately 11 kb is 
also visible and may represent c-abl precursor RNA. which 
has not been studied in further detail. The abnormally sized 
mRNA seems to be characteristic of Ph'-positive cells, as it 
is not detected in either normal control cells or cells of other 
types of leukemia (4. 11). 
For experiments involving bcr gene expression, the fol-
lowing two probes were subcloned from the normal bcr 
cDNA pVl-3: probe A, Pvull-Pst\, containing sequences 5' 
of the K562 breakpoint, and probe B, Pstl-Pvull, 3' of the 
breakpoint (Fig. 3). The relative position of the breakpoint 
within the cDNA was determined by Southern hybridiza-
tion: cDNA sequences 5' of the breakpoint hybridize with 
the K.562 and normal chromosome 22 cosmid clones, 
whereas sequences 3' of it only hybridize with normal cloned 
chromosome 22 DNA sequences (Fig. 1). Both probes were 
cloned in reversed orientation in pSP64 and pSP65, respec-
tively. Hybridization of the Northern blot with bcr probe A 
shows a strongly hybridizing band of 8.5 kb that migrates at 
the same position as the 8.5-kb c-o6/-hybridizing RNA (Fig. 
4). Vague bands of around 7.0 and 4.5 kb are also detected 
and could represent the normal bcr transcripts; however the 
nature and structure of these transcripts has not been 
analyzed in detail (35a). Because the c-abl and bcr probes do 
not cross-hybridize, the nature of the 8.5-kb RNA can be 
explained in two ways: either this new RNA is a hybrid RNA 
consisting in part of bcr and in part of c-abl sequences, or 
alternatively K.562 contains a new abl and a bcr RNA that 
happen to be of the same size. When the K.562 po!y(A)+ 
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FIG. 3. Restriction enzyme map of the normal bcr cDNA, 
pVl-3. Three normal bcr cDNA clones were isolated from a 
fibroblast cDN A library (29) after screening with the 0.6-kb WimJIII-
BomHI probe (Fig. 1A). Of the largest cDNA, pVl-3, only the 
2.2-kb cDNA insert is shown flanked by poly(G) and poly(A) tails. A 
restriction enzyme map was deduced with the following enzymes: 
Pv, PvuU; Bg. BglU; H. HiniUl; Ps, Pstl; and A, Aiol. The arrow 
indicates the position of the bcr breakpoint in the cell line K562. 
Sequences to the left are linked to c-abl and are amplified in K562; 
sequences to the right are not amplified. Probe A represents a0.5-kb 
PvuU-Pml fragment, and probe B a 0.56-kb Psil-Pvull fragment, 
both cloned in reversed orientation into pSP65 and pSP65, 
respectively. 
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FIG. 2. Ph1 chromosomal breakpoint in K562. A, EcoRI digest 
of 10 u.g of DNA from CML patients 02120185 (lane 1). 0319129 (lane 
2), and 0311068 (lane 3) and from the cell line K562 (lane 4). B. K562 
DNA digested with S.\ll (lane 1) andS^/11 (lane 2): DNAs of human 
cell lines AGI732 (lane 3) and AG2655 (lane 4) digested with BglW. 
C, EcoRI digest of K562 DNA (lane 1) and DNA of human cell line 
GM3344 (lane 2). A. B. and C were hybridized with different 
molecular probes as shown at the bottom of the figures: the origin of 
the probes is as indicated in Fig. 1. 12P-labeled WmdlII-digested \ 
DNA is included in the left lane of each panel as a molecular weight 
marker. 
RNA blot is hybridized to probe B (3' of the K562 
breakpoint) no hybridization to the 8.5-kb RNA can be 
detected {Fig. 4). In longer exposures of this Northern blot, 
only faint hybridization can be seen with the normal bcr 
RNAs. This experiment suggests that the 8.5-kb mRNA is 
indeed a chimera and contains, in addition to c-abl se-
quences, the 5' region of the bcr gene. 
Cloning of a cDNA containing the chimeric part of the 
8.5-kb mRNA. To investigate the structure of the 8.5-kb 
mRNA in more detail, a K562 cDN A library was constructed 
in XgtlO (21) by using a 27-mer c-abl oligonucleotide to prime 
the first-strand cDNA synthesis. The primer was derived 
from the 5' side of the human i-ahl homologous region 
(designated exon a2 in Fig. 5), and its sequence is shown in 
Fig. 6A. After screening of this library with a combined c-abl 
0.3-kb EcoRl-Kpnl probe (specific for the 5' side of exon a2. 
Fig. 5) and bcr probe A (Fig. 3) several hybridizing plaques 
were found; one, ba 4.1, was subcloned in pUC19 and 
analyzed in detail. This cDNA contains a insert of 468 bp 
flanked by synthetic EcoRI linkers. The restriction map of ba 
4.1 is given in Fig. 5. Hybridization of the ba 4.1 insert to a 
Southern blot containing EcuRI-digested K562 DNA and 
non-CML DNA (GM3344) results in the detection of three 
amplified EcoRI fragments of 16.0. 7.0, and 2.9 kb in K562 
and single-copy fragments of 17.0 kb in K562 and 17.0. 7.0. 
and 2.9 kb in GM3344 (Fig. 7). These bands could be 
identified by hybridization of the cDNA probe to cloned 
c-abl and bcr sequences (data not shown). The 17.0-kb 
single-copy fragment in both DNAs represents the normal 
EcoRI fragment on chromosome 22, whereas the amplified 
16.0-kb band represents the bcr gene containing the Ph1 
breakpoint (Fig. ID). The 2.9-kb band contains c-aWexon a2 
(Fig. 5), and the 7.0-kb band could be mapped directly 5' to 
the 2.9-kb c-abl fragment. The exon sequences present in 
prob« 
c-abl 
probe 
A 
probe 
Kb 
8 . 5 -
7.0-
6 .0 -
-28s 
FIG. 4. Hybridization of K562 Northern blot with c-abl and bcr 
probes. Poly(A)* RNA (20 u.g) of K562 was run on a 1% agarose gel 
and transferred to nitrocellulose. As probes we used a 0.6-kb 
EcoRl-BamHl c-abl fragment (8), a 0.5-kb Pvtdl-Psll 5' bcr frag-
ment (probe A) and a 0.56-kb Pstl-Pvull 3' bcr fragment (probe B) 
cloned in pSP64. pSP65, and pSP64, respectively. The probes were 
labeled and hybridized as described in the supplier's manual 
(Promega Biotec). After hybridization the filters were washed under 
stringent conditions (0.03X SSC [IX SSC in 0.15 M NaCI plus 0.015 
M sodium citrate). 65°C). 
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TRANSCRIPTION 
- * • 3 ' 
K562 breakpoint v-abl homologous sequences 
FIG. 5. Restriction enzyme maps of two chimeric cDNAs and the positions of the exon sequences in the K562 breakpoint region. The 
upper line represents the restriction map of the Ph1 chromosome in K562. The chromosomal breakpoint is indicated by an arrow above the 
map. as is the region of c-abl that is homologous to v-abl sequences. Blocks represent exon sequences of which b2 and b3 are bcr exons and 
al and al c-abl exons. xl represents a chromosome 9-specific exon not homologous to c-abl. Symbols: / \ , mapped and cloned chromosome 
9 sequences fat the 3' side of exon x l another 10 kb of chromosome 9 sequences have been cloned and mapped, but this has been omitted 
from the figure):-^ £-, gap of unknown size. The middle line represents the restriction map of the chimeric K562 cDNA ba4.1. The relative 
positions of the ba4.1 exon sequences on K562 chromosomal DNA are indicated by the dashed lines. The lower line represents the restriction 
map of chimeric K.562 cDNA 8E. The relative positions of the 8E exon sequences on K.562 chromosomal DNA are again indicated by dashed 
lines. Only the bcr exons of interest in 8E have been indicated. The arrows under both cDNAs and chromosomal exon sequences indicate 
the sequence strategies. All sequences were done by the method of Maxam and Gilbert (27). Dots indicate the positions of the end labels. The 
arrows indicate directions and lengths of the sequences; an exception on this was the chromosomal exon x l , of which the 1.6-kb 
EcoRl-BamHl and 0.3-kb BamHl-EcoRl fragments were cloned in M13 and sequenced by the dideoxy method (32). AH sequences were 
determined from both strands, except for the 1.6-kb chromosomal EcoRl-BamHl fragments of exon x l , which was sequenced from one 
strand. Solid bars represent chromosome 22 sequences, whereas open bars indicate sequences from chromosome 9. Abbreviations: B, 
BamHl; Bg, BgtU; E, EcoRl, H. Hindlll; HI]], HindlU; K, KpnV, S, Sail: Sa, Saul. 
these fragments are located within one 2.7-kb Bglll frag-
ment, indicated in Fig. 5. From these two experiments we 
concluded that cDNA ba 4.1 contains previously identified 
bcr and c-abl coding sequences complemented with as yet 
unidentified c-abl hybridizing DNA. To determine the exact 
nature of ba 4.1, thecDNA was sequenced (27) as designated 
in Fig. 5; the sequence is shown in Fig. 6A. Comparison of 
the 5' side of the clone to the pVl-3 bcr cDNA sequence 
revealed exact concordance with the 3' pan of bcr exon 2 
and the entire bcr exon 3 (here designated b2 and b3; Fig. 5) 
(19). The bcr sequence in ba 4.1 is immediately flanked at the 
3' side by an unknown non-bcr sequence. The 3' end of the 
clone is identical to the sequence of c-abl exon a2 (Fig. 6A) 
and ends with the sequence of the 27-mer c-abl primer. The 
unknown middle part of ba 4.1 contains an Saul site (posi-
tion 147; Fig. 6A) that also seemed to be present in the 
genomic 2.7-kb Bglll c-abl fragment (Fig. 5). Sequencing of 
the genomic DNA around the Saul site (Fig. 5) identified the 
c-abl exon a l coding for the unknown ba 4.1 cDNA se-
quence (Fig. 6A). Mapping of the Saul site localizes c-abl 
exon al 0.56 kb upstream from c-abl exon a2. The genomic 
0.3-kb Saul-Sail fragment containing exon a l (Fig. 5) detects 
the c-abl mRN As of 6.0 and 7.0 kb in HeLa cells and of 6.0, 
7.0, and 8.5 kb in K562 cells (data not shown). This proves 
that exon a l is part of the c-abl gene. Comparison of the ba 
4.1 cDNA sequence to the sequence of Shtivelman et al. (34) 
shows exact concordance. 
The sequence of the genomic bcr-txon b3, as defined by 
the bcrcDNA sequence, is followed by a splice donor site (3) 
(Fig. 6A); the K.562 breakpoint has been localized to 3' of 
this splice site in the intron between bcr exons b3 and b4 
(19). The genomic sequence of c-abl exon al is immediately 
preceded by a splice acceptor and foliowed by a splice donor 
(Fig. 6A). and c-abl exon a2 again is preceded by a splice 
acceptor. Therefore in cDNA ba 4.1 these three exons are 
linked following the GT-AG rule, resulting in the open 
reading frame (Fig. 6A). This frame is in phase with the 
predicted bcr (19), v-abl, and mouse c-abl (37) reading 
frames. 
Minimal distance between bcr exon b3 and c-aWexon al in 
K562. By chromosomal walking experiments with genomic 
K562 cosmid and X libraries, we cloned and mapped 54 kb of 
chromosome 9 DNA downstream of bcr exon b3 and 45 kbof 
DNA upstream of c-aWexon al as indicated in Fig. 5. Still, 
the overlap between the two has not been found. This 
implies that in K.562 a splice of at minimum 99 kb has to be 
performed to link bcr exon b3 and c-abl exon a l . An obvious 
question is how the splice system deals with an intron of this 
size and whether alternative splices are made. Screening 
with /HT probe A (Fig. 3) of an oligo(dT)-primed K562cDNA 
library in \gt l0 produced two clones that contained bcr 
sequences linked to DNA that did not cross-hybridize to 
cDNA ba 4.1. One of these clones, 8E. is shown in Fig. 5. 
Due to incomplete EcoRl methylation of the cDNA during 
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amino acid hi — S 
• GlyPhelysGlnSerSerl. 
GGATTTAAGCAGAGTTCAA 
erArgSerPheGlyThry^A^ThrG1uProLysLeuPh«G_^GIyPheAsnThrSerAipThrVal . . . 
ysAULeuGlnAroProValAlaSêrAspPheGluProGInClyLeuSerGliiAlaAIaArgTrpAsnSei-
AAGCCCTTtAGCGGCCAGTAGCATCTGACTTTGAGCCTCAGGGTCTGAüTGAAGCCGCTCGTTGGAACTCC " 
• ThrSerProGlnArqAlaGlYAIaLeuAlaGlyGlyValThrThrPheValAlaLeur^rAspTyrGtuSerArgThrGluIhrAspLeu 
• LysGluAsnLeuLeuAlaGlyProSerGluAînAspProA5nLeuPiiL'V,ilAlaLeurvrAspPheValA1aSerGlyAspAsnThrLeu 
AAGGAAAACCTTCTCGCTGGACCCAGTGAAAArGACCCCAACCTTTTCGTrGCACTGTATCATTTTGTGGCCAGTGGAGATAACACTCTA 
• SerPHel.ysl.yiG 
• SerlleThrLysC 
AGCATAACTAAAG 
lyGUjArgLeuGIMIeValAsnAsnThrGlyGIyAspTrpTrpLeuAlaHisSerLeuThrThrGlyGjnG'yTyr 
TyGluLysLeuArgValCêÜGlyTyrAsnHisAsnGlyGluTrpCysCluAlaGlnrhrLyiAsnGlyGInGIyTro 
GTGAAAAGCTCCGGGTCTTAGGCTATAATCACAATGGGGAATGGTGTGAAGCCCAAACCAAAAATGGCCAAGGCTGG -]60-
: -ab l « o n i 
c- I.euP.roSerAtnTyrValAUProSerAspSer1 leClnAlaGluGluTrgTyrPheGlyLysl leThrArijArgGluSei-GUjArgLeu 
i l - ValProScrAsnTyrTTêrhrProValAsnSerLëiJGluLysHïsSerTrpTyrHisGlyProÛalsërArgAsnAUAlaGluTyrLeu 
GTCCCAAGCAACTACATCACGCCAGrCAACAGTCTGGAGAAACACTCCTGGTACCATCCGCCTGTGTCCCGCAATGCCGCTGA&TATCTG 
t 
• LeuLeuAïnProGluAsr; 
• LeuSefSerGly1leAsn 
CTGAGCAGCGGGATCAAT 
ATGATGACTCTCCGGGGCrCTATGGGTTTCTGAATGTCATCGTCCACTCAGCCACTGGATTTAAGCAGAGTTCAAJgtaagtactgglttg -90-
gggaggagggttgg -lQlt-
cttttttecgttcccccctctctcctecag AAGCCCTTCAGCGGCCAGTAGCATCTGACTTTGAGCCTCAGCCTCTGAGTGflAGCCCCTC -90-
;CT 
iAAGJgi 
GTTCGAACTCCAAGGAAAACCTTCTCG GGACCCACTGAAAATGACCCCAACCTrïTCGTTGCACTGTATGATrTTGTGGCCAGTGCAG -1 BO-
AT AACACTCTAAGCATAACTAA j câdaagggt [gtgggcagctagtgglqgt 
g[çT( atalglctgattcggttcctttcttctca  GTGAAAACCTCCCGGTCTTAGGCTATAATCACAAÏGGGGAATGCTTTGAAGCCCAAACCA -90-
AAAATGGCCAAGGCTGGGTCCCAAGCAACTACATCACGCCAGTCAACAGTCTGGAGAAACACTCCTGGrACCATGGCCCTGTGTCCCGCA -130-
ATGCCCCTGAGTATCTGCTGAGCAGCGGGATCAAT -2]2-
Ihe construction of the library, both clones have been the chimeric 3' part of the 8E cDNA (strategy indicated in 
truncated at their 3' end at an endogenous EcoR\ site. The Fig. 5) and the homologous genomic exon (designated x l ; 
0.3-kb BtimHl-EcoRl fragment of 8E (Fig. 5) is amplified in Fig. 5) shows exact splicing of for exon b3 to exon x l 
K562 DNA (data not shown) and hybridizes to cloned following the GT-AG rule, because x l is preceded by a splice 
genomic DNA sequences mapping 43.5 kb downstream from acceptor site (Fig. 6B). However this mRNA cannot code for 
the K562 Ph1 breakpoint (Fig. 5). DNA sequence analysis of a chimeric bcr/c-abt protein since exon x l contains transla-
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GluGlnGlnLysLysC ysPheArgSerPheS«rLeuThrSerValGlULeuClnMetLeuThraSn5erCysValt.¥*t.euClnThrVal 
GAGCAGCAGAAGAAGT GTTTCAGAAGCTTCTCCCTGACATCCGTGGAGCTGCAGATGCTGACCAACTCGTGTGTGAAACTCCAGACTGTC -90-
, b3 
MisSerlleProLeuTtir I leAsnLysGtuALpAspGluSerProGI yLeuTy rGI yPhoLeuAsnVa I I IeVaIHisSerAI«ThrGI y 
CACACCATTCCGCTGACCATCAATAAGGAAG ATGATGAGTCTCCGGGGCTCTArCGGT-TTCTGAATGTCATCGTCCACTCAGCCACTGGA - l 30-
CmGTCATATTGGGGCTGATCTTGGAGCTGTCTGGATCTGACCAGTCTCCAGGTTGAAAACTCTTGCAACTTTCGTTTTTGGATAGTGC -J6i-
TCACCrCGTATCTGTACTCGTAACTGCTArTrCTAGGCGAATTGTCCCCTTTCTCCTCCCTCTTCCCTCATCTCCCTCTCTCCTCTGCCT -I.50-
GGCrGACACCAGGAAGGAGCAGTrTTCrTITATTTAGATAAAAAAAAGTrGAGAGGAGGCAGCÏCCAGAAATGTGGGATACTCAGCACTG -j*0-
GAGACATTTGGGCTGGAATTC 
»cattttectctggctttrggctgttttag GAACAAGCCATACGGTGAACCACCTCATGCTGACCTTATCTCCATCCAC5CCATCCAGAT -90-
GAAGCCATATTTACCTTTGTGArATTGGGCCTGATCTTGGACCTGTCTGGATCTGACCAGTCTCCAGGriGAAAACTCTTGCAACTrTCG -ISO-
TTTTTGGATAGTGCTCACCTCGIATCTGTACTCGTAACTGCTATTTCTAGGCGAArTGTCCCCTTTCTCCrCCCTCTTCCCTCATCICCC -270-
rCTCTCCTCIGCCrGGCTGACACCAGGAACGAGGAGTTTTCTTTTATTTAGArAAAAAAAAGTTGAGAGGAGGCAGCICCAGAAATGTGG -360-
GAIACTCACCACTGGAGACATTTGGGCTGGAATTC -395-
FIG. 6. DNA sequence analysis of cDNA ba 4.1 and cDNA 8E and the corresponding chromosomal exons. Sequence strategies and 
methods are as indicated in the legend to Fig. 4. A , ( i )The nucleotide sequence of the 468-base-pair £C<JRI fragment of cDNA ba 4.1 : b2. b3. 
a l , and a2 indicate the bcr and c-abl exons included in ba 4 .1 ; brackets mark the boundaries of the exons. The synthetic c-abl primer used 
for the cDNA synthesis is underlined and indicated by arrows. The amino acids encoded by the cDNA sequence are shown. The v-abl 
homologous sequences start at position 373. The amino acid sequence of c-abl is aligned with that of v-src amino acids (36). Symbols: *, the 
position and number of amino acids deleted from v-src: — . gap in v-src to align the sequences. A solid underline indicate* an exact match 
between v-.src and c-abl amino acids, a dashed underline indicates a match between v-src and c-abl amino acids with similar structure or 
identical charge, (ii) The nucleotide sequence of ùcrexon b3 (19). followed by the 3' intron sequence. Brackets indicate the boundaries of 
the exon. as defined by the cDNA sequence, (iii) The nucleotide sequence of c-abl exon a l . preceded and followed by intron sequences. 
Brackets indicate the boundaries of the exon as defined by the ba 4.1 cDN A sequence, (iv) The nucleotide sequence of the 5' half of c-abl 
exon a2. preceded by intron sequences. Bracket indicates the boundary of the exon as defined by the ba 4.1 cDNA sequence. B: (i) The 
nucleotide sequence of the chimeric 3' end of cDNA 8E: b l . b2. b3, and x l indicate the /« rand chromosome 9 exons included in 8E. Brackes 
mark exon boundaries. The amino acid sequence encoded by this cDNA is shown: 21 codons 3' of the breakpoint a stopcodon are 
encountered, (ii) The nucleotide sequence of the exon x l preceded by the intron sequence. Bracket indicates the 5' exon boundary as defined 
by the 8E cDNA sequence. 
t ion terminat ion signals in all reading frames inc lud ing the Since the sizes o f the R N A s detected by this 0.3-kb BamHl-
f rame predicted by the bcr sequence (F ig . 6B) . Hyb r i d i za - EvoRl probe in K562 di f fer f r o m those o f the normal c-abl 
t ion o f the exon x l B E probe to N o r t h e r n blots conta in ing t ranscr ipts, we conclude that 8E represents the product o f an 
p o l y ( A ) * R N A o f K562 and He la cel ls showed two hybr id - a l ternat ively spl iced precursor m R N A , resul t ing in a ch i -
iz ing bands o f 9.5 and 5.5 kb in K562 R N A (F ig . 8 A ) , meric nonfunct iona l m R N A that contains chromosome 9 
whereas no signal cou ld be detected in H e L a R N A (F ig . 8B) . sequences not belonging to the c-abl gene. 
124 
GROSVELD ET AL. MOL. CELL. BIOL. 
17^ 
1 6 - » 
i-m » 
2.9-
remain on the Ph1 chromosome, whereas exons to the 3' side 
most probably were translocated to the 9q+ chromosome in 
the original recombination event in the patient from whose 
cells K562 was established, 
K.562 contains an increased level of the abnormal 8.5-kb 
c-abl mRNA as compared with other CML cell lines (6). 
Since c-ttbl is amplified in K562», it is likely that this higher 
expression is caused by the higher copy number of the 
oncogene. In addition. 5' bcr, located on the same amplifi-
cation unit and present in approximately the same copy 
number, exhibits high expression of an abnormal 8.5-kb 
mRNA. 
Direct proof that both probes hybridize to the same 
molecule was given by Shtivelman et al. (34) and by cloning 
of cDNA ba 4.1 containing the chimeric portion of the 
ber/c-abl mRNA. 
Translation of the chimeric cDN A sequence of ba 4.1 into 
protein shows one open reading frame (Fig. 6A) that is 
compatible with both the predicted bcr and the known v-abl 
reading frames (37). Comparison of the human c-abl amino 
acid sequence of ba 4.1 with the protein sequence of homol-
ogous regions in v-abl and mouse c-abl shows complete 
amino acid conservation between exon a2 and v-abl And one 
difference with mouse c-abl (Fig. 6A). Amino acid 117 of ba 
4.1 is a tyrosine, and in mouse c-abl it is a cystine. Extensive 
amino acid sequence homology has been described between 
v-src (36), v-abl, and mouse c-abl (37). The homology 
between v-src and human c-abl does not stop at the 5' side of 
FIG. 7. Hybridization of cDNA ba 4.1 to chromosomal DNA of 
K562 and GM3344 cells. Southern blot of EcoRl digests of 10 jig of 
DNA from the cell line K562 and cell line GM3344. Both lanes were 
hybridized to the >3P-labeled EcoR\ insert ot'cDNA ba 4.1. Molec-
ular masses are indicated at the side of the gel. 
DISCUSSION 
The present findings demonstrate that the CML cell line 
K562. like all Ph'-positive CML patient material examined 
to date, contains a breakpoint on chromosome 22 within the 
breakpoint cluster region on chromosome 22. However, in 
contrast with the leukemic cells of patients, the K.562 cell 
line contains amplified remnants of the Ph' chromosome, 
including CX. a part of bcr, and c-abl. These amplified 
regions do not represent multiple copies of intact Ph1 chro-
mosomes, but rather are present on one acrocentric marker 
chromosome (33). Most probably, the regions originate from 
a multiplication of a large region of DNA from the original 
Ph1 chromosome: all copies of the bcr breakpoint region 
contain identically sized breakpoint fragments with the re-
striction enzymes tested. 
K562 cells also differ from other CML cells in that the 9q* 
chromosome cannot be detected by Southern blot analysis, 
in concordance with results of cytogenetical analysis in 
which the 9q* chromosome was found to be absent from 
K562 (33); the absence of the 9q* chromosome strengthens 
the hypothesis that the 22q~ chromosome is critical to the 
malignant proliferation of these leukemic cells. 
The breakpoint cluster region on chromosome 22 was 
found to be part of a gene; in K.562. the chromosomal break 
leading to the formation of the Ph1 chromosome has oc-
curred within an intron of this gene; exons 5' of this point 
Kb 
95 
8.5-
70 -
6 0 - n 
Kb 
95-
60-
2 8 s -
FIG. 8. Hybridization of exon xl probe to Northern blots of 
K562 and HeLa poly(A)* RNA. Northern blots with K562 and 
HeLa poly(A)' RNA were prepared as described in the legend of 
Fig. 3. A, In the left lane, K562 RNA was hybridized with a 0.6-kb 
EcoRl-BttmHl c-abl probe (Fig. 5); in the right lane. K562 RNA was 
hybridised with a 0.3-kb BamHl-EvoRl exon xl probe (Fig. 5). B, 
K562 RNA (left lane) and HeLa RNA (right lane) were hybridized 
with the 0.3-kb BaniHl-EcoRl xl probe. The probe was labeled with 
"Pby the oligo-labeling method of Feinberg and Vogelstein (9). The 
molecular masses and the position of the 28S rRNA are indicated at 
the side of the gel. 
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c-abl exon a2 (Wang et al. [37] have compared the homolo-
gous mouse c-abl exon to v-src), but extends further 5' into 
c-abl exon al (Fig. 6A); 15 of the 57 amino acids of a l are 
homologous with v-src. Although exon a l is absent in the 
v-abl gene it apparently belongs to part of the protein that is 
as conserved between v-src and c-abl as the 3' adjoining 
kinase domains (as defined by v-abl [30]). These results 
further underline the supposition that c-src and c-abl have a 
common ancestor. 
From the ba 4.1 sequence (Fig. 6A), it is clear that bcr 
exon b3 and c-abl exon a l are compatible, although the 
splice takes place within a codon. Mapping experiments and 
sequencing of several Ph1 breakpoint clones from different 
patients indicated that breakpoints occur in introns between 
bcr exons b2 and b3 or b3 and b4 (19; unpublished results). 
Since these two exons have the 3' splice donor site after the 
first nucleotide of the codon, both can be spliced to c-abl 
exon a l , resulting in mRNAs that can differ in the presence 
or absence of one bcr exon, i.e., 75 nucleotides in size, 
dependent on the position of the Ph1 breakpoint in bcr. 
Whether the proteins encoded by these two mRNAs will 
have different characteristics remains to be elucidated. This 
splicing pattern would also explain why the same 8.5-kb 
mRNA is detected in different patients (4, 11, 35a) although 
the distance between the Ph1 breakpoint and v-abl hybridiz-
ing sequences varies from 14 to at least 101 kb. 
As shown by Shtivelman et al. (34), we have strong 
evidence that exon a l does not represent the 5' end of the 
c-abl gene. Moreover we have also isolated a normal c-abl 
cDNA clone that contains sequences further 5' of c-abl exon 
al (unpublished results). So at least one or more c-abl exons 
must be located further 5' of exon a l . Whether these exons 
can also be included in the K.562 splicing event is unknown 
and leaves the possibility that ba 4.1 represents only one of 
several translatable chimeric mRNAs that could be pro-
duced in K562. However, if this indeed is the case then it 
seems unlikely that the 5' end of the c-abl gene can be 
included in a protein-coding chimeric mRNA, since no splice 
acceptor site will be available and frameshift mutations and 
stop codons are probably introduced by the nontranslated 
region of the 5' end of the gene. 
Splices over large and varied distances such as those 
found between bcr and c-abl on the Ph1 chromosome open 
the possibility that exons from other genes not belonging to 
c-abl could be included in the pre-mRNA and therefore end 
up in a mature mRNA. In fact, cDNA 8E represents an 
example of this possibility. Although the chromosome 9-
specific exon xl was spliced to bcr exon b3 following the 
GT-AG rule (Fig. 68), it does not contain an open reading 
frame. Employing the bcr reading frame, a protein termina-
tion signal in 8E is encountered at 21 codons 3' of the 
breakpoint. Hybridization of exon xl to Northern blots of 
K562 and HeLa RNA results in the detection of two RNAs 
of different size than the c-abl RNAs for K562, whereas in 
HeLa cells no RNA at all could be detected. This strongly 
suggests that exon xl does not belong to the c-abl gene. 
Because 8E is clearly a chimeric cDN A, hybridization of bcr 
probe A (Fig. 3) to K562 Northern blots should show up the 
same 9.5 and 5.5 kb RNAs as probe xl . For reasons we do 
not understand, this does not seem to be the case, but we are 
confident that 8E represents an aberrant chimeric RNA 
because a second, independently picked cDNA clone has the 
same chimeric structure. Unfortunately, both clones have 
been truncated at their 3'-end £coRI site, so no information 
ts available concerning the nature of the 3' region of these 
mRNAs. The possibility remains that xl is spliced at its 3' 
side to c-abl sequences, although hybridization of c-abl 
probes to K.562 Northern blots does not show up the 9.5- and 
5.5-kb mRNAs. Why this differential splice occurs in the 
K562 bcric-abl pre-mRNA remains an open question. 
The implications of the translocation of c-abl to the 3' side 
of bcr on the Ph1 chromosome are as follows. Transcription 
is likely to be initiated from the bcr promoter and probably 
stops at the 3' end of the c-abl gene. By splicing of the 
precursor RNA the 8.5-kb mRNA is produced, in which the 
versatility of the splicing system accomodates for the large 
variation in intron size that links bcr and c-abl in different 
patients. From the data now available, we know that the 
variation in this chimeric 8.5-kb mRNA can comprise one 
bcr exon, i.e., 75 nucleotides (19). Translation of the 8.5-kb 
mRNA into protein seems almost certain, since the chimeric 
part of the molecule contains an open reading frame that 
links the predicted bcr and c-abl reading frames. A likely 
candidate for such a protein is the abnormally sized 210-
kilodalton c-abl protein found in K562 cells, which in con-
trast to normal c-abl has in vitro tyrosine kinase activity (24), 
very similar to that of the v-abl gene product (7). The bcr 
moiety of this hybrid molecule could unmask the c-abl 
tyrosine kinase activity, raising the question whether bcr is 
sufficiënt or necessary for this effect. The bcric-abl hybrid 
protein may have transforming activity; since the chimeric 
8.5-kb mRNA is also found in Ph^positive CML patients 
(35a), the protein is likely to be present in all cases of 
Ph'-positive CML, but it remains to be established whether 
this plays an essential role in the generation or maintenance 
of CML. 
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In chronic myelocytic leukemia, the human c-oW oncogene is translocated from chromosome 9 to a region on 
chromosome 22 designated as the breakpoint cluster region (bcr) (A. de Klein, A. Geurts van Kessel, G. 
Grosveld, C. R. Bartram, A. Hagemeyer, D. Bootsma, N. K. Spurr, N. Heisterkamp, J. Groffen, and J. R. 
Stephenson, Nature (London) 300:765-767, 1982; J. Groffen, J. R. Stephenson, N. Heisterkamp, A. de Klein, 
C. R. Bartram, and G. Grosveld, Cell 36:93-99.) Abnormal c-abl homologous mRNA and protein have been 
detected in the leukemic cells of patients with chronic myelocytic leukemia (E. Canaani, D. Steîn-Saltz, E. 
Aghai, R. P . Gale, A. Berrebi, and E. Januszewicz, Lancet 1:593-595, 1984; S. J . Collins and M. T. 
Groudine, Proc. Natl. Acad. Sei. USA 80:4813-4817,1983; R. P. Gale and E. Canaani, Proc. Natl. Acad. Sei. 
USA 81:5648-5652, 1984; J . B. Konopka, S. M. Watanabe, J. W. Singer, S. J. Collins, and O. N. Witte, 
Proc. Natl. Acad. Sei. USA 82:1810-1814, 1985). The abnormal mRNA represents a chimeric transcript 
consisting of 5 ' bcr and 3 ' c-abl sequences (G. Grosveld, j . Verwoerd, T. van Agthoven, A. de Klein, K. L. 
Ramachandran, N. Heisterkamp, K. Stam, and J . Groffen, Mol. Cell. Biol. 6:607-616, 1986; E. Shtivelman, 
B. Lifshitz, R. B. Gale, and E. Canaani, Nature (London) 315:550-554, 1985; K. Stam, N. Heisterkamp, G. 
Grosveld, A. de Klein, R. S. Verma, M. Coleman, H. Dosik, and J . Groffen, N. Engl. J . Med. 313:1429-1433, 
1985). In the present study, we demonstrated that the abnormal c-abt protein is a fusion protein. In addition, 
the normal gene encompassing bcr sequences was shown to encode a 160,000-dalton phosphoprotein with an 
associated serine or threonine kinase activity. We propose that this gene be designated phi, reserving the term 
bcr for the region within the phi gene encompassing the Ph' translocation breakpoints. 
Chronic myelocytic leukemia (CML) is a malignancy of 
the pluripotent hematopoietic stem cell. A clonal expansion 
of the stem cell resulting in an increased proliferation of 
myeloid and B lymphoid lineages is characteristic of the 
chronic phase of the disease. In a later stage, the blast crisis, 
cells lose their ability to differentiate, resulting in malignant 
proliferation of myeloid or lymphoid cells. The leukemic 
cells undergo a specific chromosomal translocation (the 
Philadelphia [Ph'] translocation) affecting the long arms of 
chromosomes 9 and 22 (20). The resulting 22q" or Ph' 
chromosome characteristic of this type of neoplasia is found 
in over 95% of all CML patients. We have previously 
localized the human c-abl oncogene to chromosome 9 (10) 
and shown that the tip of the long arm of chromosome 9, 
including c-abl, is consis tent ly t ranslocated to the 
breakpoint cluster region (bcr) within the phi gene on chro-
mosome 22 (6, 8). The phi gene is oriented with its 5' end 
toward the centromere of chromosome 22. As a result of the 
Ph' translocation, 3 ' phi exons are physically removed, 
whereas 5' exons remain on chromosome 22 (11). A chro-
mosomal breakpoint was previously localized within the 
c-abl gene in one CML patient (12). Since the genomic 
sequences of the phi and abl genes are fused in a head-to-tail 
* Corresponding author. 
t Present address: Section of Molecular Genetics, Division of 
Medical Genetics, Children's Hospital of Los Angeles, Los 
Angeles. CA 90027. 
fashion, we hypothesized that an abnormal c-abl gene prod-
uct could be expressed in Ph'-positive leukemia cells (9). 
Indeed, an abnormally sized abl mRNA of 8.5 kilobases (2, 
3, and 7) and an abl protein of 210,000 molecular weight 
(P210) have been demonstrated in leukemic cells of CML 
patients (15). In subsequent experiments, the mRNA was 
found to be chimeric, consisting of 5' phi exons fused to 3 ' 
c-abl sequences (9, 21, 23). Apart from the fact that it is 
specifically involved in the Ph' translocation, little is known 
regarding the phi gene and its translationai product. More-
over, sequence analysis of a phi cDNA clone did not reveal 
homology to previously identified genes (11). The present 
studies were initiated in an attempt to establish the chimeric 
character of the P210 protein and to identify and characterize 
the normal phi gene product. 
To raise antisera against the phi gene product, we selected 
two different regions of the phi cDNA Vl-3 . These were a 
486-base-pair PvulhHindlU fragment, which is retained on 
the Ph' chromosome in the CML cell line K562 (9) and thus 
is included in the chimeric phllc-abl mRNA, and a 691-base-
pair PvuW fragment originating from the 3' translated region 
of the cDNA (Fig. 1A). These latter sequences are absent 
from the chimeric mRNA detected in the leukemic cells of 
CML patients and in the CML cell line K562 (9, 23). Both 
segments were inserted into appropriate trpE expression 
vectors (22), and trpE fusion proteins were synthesized in 
Escherichia coli. Antisera (designated 486 for the Pvull-
//i/idlll fragment and 691 for the Pvull fragment) were 
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FIG. 1. Schematic representation of the regions of phi and n/»/used to raise antisera. (A)pWcDNA Vl-3. The translated region of the phi 
cDNA Vl-3 is indicated by a solid bar; 3' untranslated regions are indicated by a single line. Regions of the cDNA inserted into expression 
vectors are indicated above the restriction enzyme map of the cDNA by horizontal lines; the approximate location of the synthetic peptide 
Bl is also shown. A vertical arrow points to the chromosomal breakpoint in the CML cell line K562; all sequences 5' of this breakpoint remain 
on the Ph' chromosome and are included in the chimeric phllc-abi mRNA. (B) Schematic representation of Abelson murine leukemia virus 
(MuLV). The acquired cellular sequences iy-abf) of Abelson murine leukemia virus are indicated by the cross-hatched box; the long terminal 
repeats, gag portion, and putative phosphoiyrosine acceptor region are also shown. Fragments inserted into the expression vectors are 
indicated above the restriction enzyme map. Restriction enzymes include: Bg, Bglll; He. HincU; H, ////idlll; P. Pstl; PU, Pvutt, Sm, Smal. 
Abbreviations: An, poly(A) tail; P-tyr, putative phosphoiyrosine acceptor region; bp, base pair; LTR, long terminal repeat. 
FIG. 2. In vivo and in vitro labeling of P21Ü with n P and sequential immunoprecipitalion of P210in K562 ceils. (A) Labeling of K.562 CML 
cells in vivo. Immunoprecipitations include sera BgS abl (lane 1). HcPs abl (lane 2), 486 5' phi (lane 3). Bl 5' phi (lane 4), and normal mouse 
serum (lane 5). (B) In vitro phosphorylation. Cell extracts were prepared from either K.562 celts (lanes 2. 4, 6. 7. and 10) or A498 cells (lanes 
1.3.5, 8, and 9) with normal mouse serum (lanes 1 and 2). 5' phi 486 antiserum (lanes 3 and 4), 5' phi Bl antiserum (lanes 5 and 6), abl BgS 
antiserum (lanes 7 and 8) or abl HcPs antiserum (lanes 9 and 10). (C) Double immunoprecipitation of the P210 in K562 cells; proteins were 
precipitated with a first antiserum, labeled in vitro, eluled from the immune complex, and precipitated with a second antibody. The following 
antisera were used: normal mouse serum and normal mouse serum (lane 1); 5' phi 486 antiserum and normal mouse serum (lane 2); abl HcPs 
antiserum and normal mouse serum (lane 3); 5' phi 486 and abl HcPs antisera (lane 4): abl HcPs and 5' phi 486 antisera (lane 5); abl HcPs 
and abl HcPs antisera (lane 6); and 5' phi and 5' phi antisera (lane 7). The immunoprecipitated proteins were analyzed on a 7.5% 
Polyacrylamide gel. The phosphorylated proteins were detected by autoradiography. Exposure time was 4 h. The molecular masses of three 
protein standards (in kilodaltons) are indicated to the left or right of each panel. 
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obtained from immunized mice. In addition, a synthetic 
peptide originating from the 5' region of the phi cDN A which 
is included within the Pvull-HbailU fragment was used to 
immunize a rabbit (Bl antiserum; Fig. 1A). Two different 
bacterially expressed regions of v-abi, a 1,214-base-pair 
Hincll-Pstl fragment and a 294-base-pair BgM-Smal frag-
ment, were also used as immunogens; these antisera were 
designated HcPs and BgS, respectively. 
K562 cells were labeled in vivo with 32Pj, and analyzed for 
immunoprecipitation with 5' p/i/-specific antisera 486 and 
B l . Cells (10") were labeled with 32Pj (12 mCi) for 4 h and 
disrupted in 10 ml of RIPA buffer (19). Cell extracts were 
clarified by centrifugation (13), and a 1-ml extract was 
incubated overnight at 4°C with 5 JJLI of antiserum. Protein A 
agarose (Bethesda Research Laboratories) was used as an 
immunoadsorbant. The immune complexes were washed, 
suspended in loading buffer, and analyzed on a 7.5% Poly-
acrylamide gel. The phosphorylaled proteins were detected 
by autoradiography. Both sera immunoprecipitated a 3 : P-
labeled phosphoprotein of a molecular mass of approxi-
mately 210 kilodaltons (210K. phosphoprotein) (Fig. 2A, 
lanes 3 and 4). A 3:P-labeled phosphoprotein of the same size 
was similarly detected by two independent abl antisera, BgS 
and HcPs (Fig. 2A, lanes 1 and 2). In contrast, normal mouse 
serum did not immunoprecipitate detectable amounts of 
phosphoprotein in K562 (Fig. 2A, lane 5). 
To confirm that the above-described 210K protein (P210) 
represents the abnormal c-abl gene product found in K562 
cells (16), extracts were subjected to an immune complex 
kinase assay. The immune complexes collected with protein 
A agarose were washed and suspended in 20 mM PIPES 
[piperazine-yv,iV'-bis(2-ethanesulfonic acid)) (pH 7.0)-2O 
mM MnCl;. The reactions were initiated by addition of 10 
M-Ci of [-y-32P]ATP (5,000 Ci/mmol). Reactions (10 min at 
30°C) were terminated by the addition of cold RIPA buffer 
and analyzed as described above. Both abl antisera BgS and 
HcPs immunoprecipitated P210, which autophosphorylated 
upon addition of [-v-32P]ATP in vitro (Fig. 2B, lanes 7 and 
10). Our results with the BgS antiserum are in contrast to 
results of others, who used a Bglll-Sstl fragment of v-abl 
(encompassing the BgM-Smal fragment) to produce protein 
in bacteria and to raise antiserum (14). The BglU-Sstl 
antiserum inhibited the in vitro kinase activity of P210 (5). 
P210 precipitated with both phi 5'-specific antisera 486 and 
Bl and also exhibited autophosphorylation activity in vitro 
(Fig. 2B. lanes 4 and 6). Morever, P210 precipitated by abl. 
as well as 5' phi antisera, phosphorylated exogenously added 
substrate, enolase, in vitro. Upon treatment of the gel 
containing 32P-labeled enolase with KOH, the enolase re-
mained labeled, demonstrating that it contains phospho-
tyrosine or phosphothreonine (4; results not shown). 
The above findings demonstrate the recognition by both 5' 
phi and abl antisera of a 21ÖK phosphoprotein with both 
protein kinase and autophosphorylation activity in vitro. To 
demonstrate the chimeric nature of P210. we performed 
sequential (double) immunoprecipitations. Protein was im-
munoprecipitated from K.562 cell extracts with an antiserum. 
labeled in vitro with 32P as described above, eluted from the 
immune complex with sodium dodecyl sulfate sample buffer 
by incubating at 80°C for 5 min, and precipitated with a 
second antiserum after a 30-fold dilution in RIPA buffer. To 
ascertain that the first antibody was completely inactivated 
before addition of the second antibody, we did control 
experiments with either normal mouse, 5' phi 486, or abl 
HcPs antiserum first and normal mouse serum subsequently. 
The inactivation treatment was effective in that P210 was not 
detected in these controls (Fig. 2C, lanes 2 and 3). Subse-
quently, P210 was immunoprecipitated with 5' phi antiserum 
486 and labeled in vitro. The first antiserum was inactivated, 
and abl HcPs antiserum was added. Conversely, P210 was 
precipitated with abl HcPs antiserum and labeled in vitro; 
the antiserum was inactivated, and the proteins were incu-
bated with 5' phi 486 antiserum. In both experiments, the 
presence of P210 could be demonstrated unambiguously 
(Fig. 2C, lanes 4 and 5). Thus, the P210 protein recognized 
by both antisera is the same molecule, a phl/c-abt fusion 
protein. 
Since K562 also contains a normal, nonrearranged phi 
allele which is transcribed, albeit at low levels (9), normal 
phi gene products should be present in this cell line. How-
ever, even P210 is difficult to detect in [35S]methionine-
labeled extracts of K562 cells (data not shown). To find a 
more abundant source of the phi gene product, we prepared 
poIy(A) RNA from different human cell lines and subjected 
them to Northern blotting and hybridization with a phi 
cDNA probe (23). Of the cell lines tested, a kidney carci-
noma cell line, A498, was found to express the highest levels 
of the approximately 7.0- and 4.5-kilobase (7, 8) phi mRNAs 
(data not shown). However, phi gene protein products were 
not detectable with phi 486 antiserum in [35S]methionine-
Iabeled A498 cell extracts (data not shown). 
Upon reexamination of proteins immunoprecipitated from 
32Pi-labeled K562 cells, it was evident that a phosphoprotein 
of around 160,000 molecular weight (P160) is im-
munoprecipitated with the 5' phi antisera 486 and Bl but not 
with abl or normal mouse antiserum (Fig. 2A). As this 
protein perhaps represents the normal phi gene product, 
A498 and K562 ceils were labeled in vivo with 32Pj. The 5' 
phi Bl antiserum specifically precipitated the P160 in A498 
cells (Fig. 3A, lane 2). In K562 cells, P210 was detected in 
addition to the P160 (Fig. 3A, lane 1). To further demon-
strate that P160 is the phi gene product, a second, indepen-
dent antiserum • was utilized. This antiserum was raised 
against a trpE fusion protein containing the 3' region of the 
phi cDNA expressed in E. coli (Fig. 1A; 691 antiserum). As 
expected, this antiserum did not detect P210 in K562 (Fig. 
3A, lane 3), as the region against which it is directed is not 
included in the chimeric phl/c-abl mRNA (9). However, it 
did immunoprecipitate P160 both in K562 (Fig. 3A, lane 3) 
and in A498 cells (Fig. 3A, lane 4) labeled in vivo with 32P. 
These findings establish that the phi gene product is a 
phosphoprotein with a molecular mass of 160,000 daltons. 
Since P160 is a phosphoprotein, the possibility was con-
sidered that it might exhibit kinase activity. To test this, the 
phi gene product was immunoprecipitated with 691 anti-
serum from extracts prepared from K562 and A498 cells. 
Upon addition of f7-32P]ATP and MnCI; in vitro. P160 was 
labeled in complexes from both cell extracts (data not 
shown). In a second experiment, the substrate enolase was 
added to the immune complex in vitro to test whether it 
could be labeled by the P160-associated kinase activity. Both 
P160 and enolase were labeled in K562 and A498 immune 
complexes (Fig. 3B, lanes 7 and 8). This demonstrates that 
the P160-associated kinase exhibits an autophosphorylation 
activity and in addition has the ability to phosphorylate on 
exogenously added substrate. 
The phosphorylation reaction associated with P160 was 
not easily detected in immune complexes of P160 with 5' phi 
486 or Bl antiserum (Fig. 2B, lanes 3 through 6). Phosphor-
ylation of P160 precipitated with 3' phi antiserum was 
inhibited after incubation of the immune complex with Bl 
antiserum. Preincubation of Bl antiserum with the peptide 
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FIG. 3. phi gene product. (A) Immunoprecipitation of P160 labeled in vivo with "P. MP labeled cellular extracts are from K562 (107 cells; 
lanes 1, 3, and 5) or A498 (4 x 10* cells; lanes 2, 4, and 6). Antisera included 5' phi Bl (lanes 1 and 2). 3' pM 691 {lanes 3 and 4), and normal 
mouse serum (lanes 5 and 6). Exposure time was 8 h for lane 1 and 16 h for lanes 2 through 6. (B) Kinase activity associated with the P160. 
3' phi 691 antiserum was added to A498 (lane 7) or K562 (lane 8) cell extracts and phosphorylation reactions in vitro were performed in the 
presence of enolase. (C) KOH treatment of gels containing in vitro "P-labeled P210and P160. K562 cellular extracts were incubated with 5' 
phi Bl (lanes 9 and 12), 3' phi 691 (lanes 10 and 13), or normal mouse serum (lanes 11 and 14). The segment containing lanes 12 through 14 
was fixed, incubated for 2 h at 55°C in 1 N KOH, and refixed before exposure. The positions of P210, P160, and enolase are indicated to the 
left in each panel. Labeling was performed essentially as described in the text. Before its use as a substrate, the rabbit skeletal muscle enolase 
{Sigma Chemical Co.) was activated by incubation of a 5-jig/jxl solution in the presence of an equal volume of 50 mM acetic acid for 5 min 
at 30"C (14). For the in vitro phosphorylation, 5 jig of activated enolase was added to the reaction mixture. 
Bl neutralized this effect (results not shown). Thus binding 
of immunoglobulin to a specific domain of P160 may inter-
fere with its associated kinase activity in vitro. 
To characterize the P160-associated kinase activity fur-
ther, a different substrate was added to the immune complex 
of P160 and 3' phi 691 antiserum in vitro. Although enolase 
was a suitable substrate, we could not detect incorporation 
of Î2P into angiotensin I (data not shown). This is in marked 
contrast to the protein kinase activity of the chimeric phl/c-
abl P210, which phosphorylates both enolase and angioten-
sin I (5; results not shown). Angiotensin I is a small molecule 
containing only tyrosine as a putative phosphate acceptor 
(14), whereas enolase has tyrosine, serine, and threonine 
residues. Therefore, the P160-associated kinase activity 
could exhibit specificity for serine or threonine. In accord-
ance with this, the phosphoamino acids present in P160 were 
hydrolizable with KOH, indicating that they are phospho-
serine or phosphothreonine (4) (Fig. 3C, cf. lanes 10 and 13). 
The phosphoamino acids in the P210 (phosphotyrosine and 
15 to 50% phosphoserine) (5) were less affected by this 
treatment (Fig. 3C, cf. lanes 9 and 12). Final confirmation 
was obtained by phosphoamino acid analysis (17). P210 and 
P160 phosphorylated in the immune complex kinase assay 
were eluted from the gel and hydrolyzed for 1.5 h at 110°C in 
6 N HCl, as described by Davis et al. (5). Approximately 
1,000 cpm of phi pl60 and 1,500 cpm of phUc-abl P210 
hydrolysates were applied to the thin-layer cellulose plates. 
Our results show that phi P160 (Fig. 4, lane 1) was 
phosphorylated on serine (±40%) and threonine (±60%), 
whereas no labeling of tyrosine could be detected. Phospho-
amino acid analysis of P160-phosphorylated enolase showed 
a similar phosphoamino acid composition (data not shown). 
The phllz-abl P210 (Fig. 4, lane 2) was phosphorylated on 
serine and threonine, as well as on tyrosine. Preliminary 
results (data not shown) suggest that the phosphoamino acid 
composition of in vivo labeled phi P160 was similar to that of 
P210 in that the P160 is also phosphorylated on tyrosine 
(±40%). 
The juxtaposition of phi gene sequences to those of the 
t 
il 
• 
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• -P-TYR 
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FIG. 4. Phosphoamino acid analysis of in vitro phosphorylated 
plil/c-abl P210 (lane 2) and phi P160 protein (lane 1). Hydrolysates 
were applied to thin-layer cellulose plates (10 by 10 cm) and 
electrophoresed toward the anode at the top for 1.5 h at 400 V in 
TLE buffer (pyridine-acetic acid-water 5:50:945). Phosphoamino 
acid standards indicated to the left were detected by ninhydrin 
staining. Phosphoamino acid composition of the hydrolysates was 
analyzed by autoradiography. Exposure with intensifying screen 
was 8 h for lane 1. and 16 h for lane 2. Abbreviations: P-SER, 
phosphoserine: P-THR. phosphothreonine; P-TYR, phosphotyro-
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c-abl oncogene in CML has a marked influence on the 
activity of the c-abl protein. Whereas normal human c-abl 
P145 lacks high levels of phosphorylating activity in vitro 
under the extraction and reaction conditions suitable for 
phl/c-abi P210 (17), the latter protein has a pronounced 
tyrosine-specific protein kinase activity in vitro (13. 16). 
Moreover, phllc-abl P210 is phosphorylated on tyrosine in 
vivo, whereas P145 is not (17). The normal mouse c-abl 
protein has properties similar to the normal human P145 
protein (17). However, in Abelson murine leukemia virus, 
the 5' end of the murine c-abl has been removed and 
replaced by gag sequences of the virus; the gaglabl fusion 
protein (P160) exhibits a modified abl function (v-ubl) similar 
to that of P210 (5). 
Since the properties of human phllc-abl P21Ö and v-abl 
P160 seem similar (5), the specific contribution of the phi or 
gag moieties of these fusion proteins (apart from furnishing 
promoter sequences and a novel 5' end) to the in vitro 
protein kinase activity is unclear. Interestingly, the deletion 
of gag sequences in Abelson murine leukemia virus abol-
ishes its lymphoid transforming activity (18). The Ph' chro-
mosome and its novel protein product, phllc-abl P210. is 
found in a lymphoproliferative disease. CML. Quite unex-
pectedly, the normal phi gene product is a phosphoprotein 
with an associated protein kinase activity, making it entirely 
dissimilar to gag. We have not demonstrated whether this 
kinase activity is intrinsic to the phi gene product or that it is 
coprecipitated in a complex with phi P160. The fact that the 
5' phi antisera Bl and 486 inhibit the in vitro kinase activity 
does not necessarily indicate that the kinase activity is 
intrinsic to P160. The failure to detect protein kinase activity 
with these antisera could be explained if these antisera 
cannot recognize a subpopulation of phi P160 which is 
associated with the putative protein kinase. If the protein 
kinase is distinct from, yet tightly associated with phi P160, 
it would be of interest to examine its interaction with 
phllc-abl P210. Phosphoamino acids detected upon labeling 
of v-abl in vitro are predominantly phosphotyrosine; P210 is 
found to contain 15 to 50% phosphoserine in addition to 
phosphotyrosine under the same reaction conditions (5; our 
results), The phllc-abl P210 protein could combine an intrin-
sic tyrosine kinase and an associated serine kinase activity. 
In this case, the phllc-abl fusion protein would exhibit two 
protein kinase activities which possibly interact with each 
other; in addition, the normal cellular substrates of both the 
phi and the c-abl proteins could be affected by phllc-abl 
P210. 
p/i/-specific mRNAs of approximately 4.5 and 7.0 
kilobases are found in normal cells (21, 23). Since the 
apparent molecular mass of the phi protein is 160,000 
daltons, either or both of the mRNAs could encode this 
protein. We occasionally have observed a protein with a 
molecular mass of approximately 180.000 daltons im-
munoprecipitated by phi antiserum. This protein might rep-
resent the translational product of the larger mRNA; alter-
natively, both mRNAs might be translated in the 160-000-
dalton phi protein. Since the sequence of the partial phi 
cDNA bears no homology to the region conserved among 
the members of the tyrosine-specific protein kinase family. 
we did not expect the phi gene product to belong to this 
family. In fact, despite an extensive search, we could find no 
significant homology of the phi cDN A sequence to any other 
previously identified gene product (11). Therefore, its pro-
tein kinase activity was unanticipated. If the chimeric phllc-
abl P210 protein is involved in, or is contributing to CML. 
the influence of the phi moiety must now be considered in 
concert with that of the modified c-abl tyrosine kinase 
activity. However, it seems clear that the phi gene product, 
apart from its possible involvement in CML, may be inter-
esting in its own right as a phosphoprotein with associated 
kinase activity. 
After completion of this manuscript, Y. Ben-Neriah et al. 
(1) reported that P210 represents a fusion protein. In addi-
tion, they identified a 190-kilodalton phosphoprotein that 
might be a candidate for the normal phi gene product. Our 
data establish that P160 is the phi gene product; P190 could 
be identical to the P180 protein we observed in some 
experiments. 
We thank Anila Lewis for preparation of the antisera and John. R. 
Stephenson for helpful suggestions and critical reading of ihe 
manuscript. 
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ABSTRACT 
We report the evaluation of the clinical usefulness of a DNA probe 
assay for the characteristic genetic marker of human chronic 
myelogenous leukemia (CML), observed by cytogenetics and designated the 
"Philadelphia chromosome" (Ph'). This translocation activates the c-
abl oncogene, normally located on chromosome 9, by fusion to the p_h_l 
gene** on chromosome 22. The assay uses "Southern blot" hybridization 
of DNA, extracted from peripheral blood or bone marrow, with a probe, 
designated phl/bcr-210. spanning a breakpoint cluster region (bcr) 
within p_hl_. Rearrangements are revealed by the presence of one or two 
novel junction fragments. 
Clinical specimens were compared by cytogenetic and DNA probe 
analysis at seven centers in the United States and Europe. The probe 
assay identified the p_hl rearrangement in 201 of 203 cases of 
Ph'-positive CML, as well as in 12 of 29 confirmed CML specimens 
lacking a visible Ph' chromosome. DNA rearrangements also were seen in 
two of six cases of Ph'-positive acute lymphoblastic leukemia. No 
false positive results were obtained among 93 non-leukemic controls. 
Mixing experiments showed that the probe assay can detect cellular 
populations of one percent carrying the phl/abl gene fusion. The test 
revealed residual leukemic cells, often not found by cytogenetic 
analysis, in a significant fraction of CML patients in clinical 
remission after allogeneic bone marrow transplantation. 
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NOTE 
8. The fihl gene is often referred to as bçr. However, for clarity we 
prefer to reserve the designation "bcr" for the regions within the 
phi gene in which translocation breakpoints have been found to 
occur. We also find it useful to distinguish between two such 
regions in p_hl, bcr-210 and bcr-190, named after the 210 kDa and 190 
kDa phl/abl fusion proteins resulting from translocations with 
breakpoints in the respective regions. We refer to the 
corresponding chromosomal translocations as Ph'(bcr-210) and 
Ph'(bcr-190). 
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INTRODUCTION 
The activation of cellular oncogenes plays a crucial role in 
neoplastic disease (1,2). Substantial evidence shows that specific 
chromosomal abnormalities, often involving the sites of known proto-
oncogenes, are associated with various forms of leukemia (3). 
Chromosomal translocations can cause oncogenic activation both by 
altering the control of gene expression and by causing protein 
structural changes which lead to the deregulation of the enzymatic 
activities of oncogene-encoded proteins (1,2). These mutations may 
result in profound abnormalities in the control of proliferation and 
differentiation in a given cell lineage. 
The Philadelphia (Ph') chromosome offers one of the most clearly 
documented examples of a translocation which leads to the activation of 
a human cellular oncogene. The characteristic cytogenetic abnormality 
is the 22q" chromosome, usually resulting from a reciprocal 
translocation t(9;22)(q34;qll) (4). This marker chromosome is found in 
the leukemic cells of more than 95 percent of patients with chronic 
myelogenous leukemia (CML) (4,5). A Ph' chromosome indistinguishable 
by cytogenetics from that found in CML is also observed in the leukemic 
cells of about 17 to 25 percent of adults with acute lymphoblastic 
leukemia (ALL) (6,7,8). A lower incidence has been reported for 
childhood ALL (about five percent) (9,10) and acute non-lymphoblastic 
leukemia (ANLL) (less than one percent) (11,12). 
The Ph' chromosome can be used as a prognostic indicator. CML 
patients with this marker generally show increased survival compared to 
patients with Ph'-negative CML (13,14,15). By contrast, the presence 
of the Ph' chromosome in the leukemic cells of ALL patients appears to 
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correlate with decreased survival (10,16). 
The critical molecular consequence of the Ph' translocation is a 
specific gene fusion (Fig. 1). A segment of the c-abj. proto-oncogene, 
located at chromosome 9 band q34, becomes joined to a segment of the 
phi gene, located at chromosome 22 band qll (17,18,19,20). In 
Ph'-positive CML the translocation breakpoint almost invariably lies 
within a 5.8 kb "breakpoint cluster region" of p_hJL designated here as 
bcr-210 (21). Detailed mapping has revealed that translocation 
breakpoints in c-abl occur within intervening sequences (introns) 
located in the 5' region of the gene, almost always upstream of c-abl 
exon 2. The breakpoints within the bcr-210 region of p M occur in any 
of three introns separating the four small coding exons (numbered 1 to 
4) in this region. The Ph'(bcr-210) translocation diagrammed in Fig. 1 
depicts a hybrid gene with a junction between c-abl_, in the intron 
bounded by exons IB and 1A, and p_hl_, in the intron bounded by exons 3 
and 4 of the bcr-210 cluster region. Transcription of such a fused 
phl/c-abl gene, followed by RNA splicing, gives rise to an 8.5 kb 
polyadenylated RNA, with p_h_L sequences at the 5' end and ab_l sequences 
(almost invariably beginning with exon 2) at the 3' end (22,23,24). 
This mRNA encodes a fusion protein of approximately 210 kiloDalton 
(kDa), designated P210 phl/abl (25,26). Compared to the normal c-abl 
gene product, a polypeptide of 145 kDa, the hybrid P210 phl/abl 
protein exhibits elevated, constitutive tyrosine protein kinase 
activity (27,28,29). 
Molecular analysis of Ph'-positive ALL reveals two classes of 
rearrangements, both involving p_hl and c-abl- One group exhibits 
Ph'(bcr-210) translocations indistinguishable from those found in CML, 
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2 3 A 567 8 910 
*3=HHH3=fflM(]C3J 
123 IA 2 3 A 567 8 910 11 
DpolyA ?0kb phl/abt <nRNA DpoJyA 85kb pMtob/nJmA 
3COOH PI90 phl/obl 
3COOH P210 pbt/obl 
Figure 1. Molecular Basis of the Ph' Translocations. 
Generation of Ph' (22q") chromosomes by recombination between p M and 
c-abl. and structures of spliced mRNA and of protein products. 
Chromosomal localization of genes and translocation event are depicted 
at right, and schematic gene structures at left. Arrows indicate known 
positions of translocation breakpoints (individual cases for c-abl• 
representative examples for phi). Alternative regions in p M gene 
introns in which translocation breakpoints are found are labeled 
bcr-190 and bcr-210. Exons indicated by boxes, introns by double 
lines. 5' and 3' refer to chemical polarity of mRNA or sense strand of 
DNA. Wavy boxes: protein products (amino-terminal and 
carboxyl-terminal ends indicated). Open symbols: c-abj. sequences. 
Closed symbols: phi sequences. 
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as shown by chromosomal breakpoints within bcr-210, and synthesis of 
8.5 kb mRNAs and P210 phl/abl fusion proteins. The second group, here 
designated Ph'(bcr-190), has translocation breakpoints lying nearer to 
the 5' end of the p M gene, within the large intron located between 
exons pi and p2 (Fig. 1) (30). The Ph'(bcr-190) translocations are 
associated with the expression of a 7 kb chimeric phl/c-abl mRNA (30), 
encoding a 190 kDa phl/abl fusion protein (P190) with elevated tyrosine 
protein kinase activity (31,32,33,34). The P190 and P210 fusion 
proteins differ structurally only in the amount of phi-derived sequence 
at the amino-terminal end of the polypeptide. 
The precise role of the phl/abl fusion proteins in leukemogenesis is 
not knoWh. However, the consistent and specific presence of the P210 
and P190 proteins in leukemic cells argues forcefully that their 
expression is an important step in the pathogenesis of Ph'-positive CML 
and ALL. 
The molecular dissection of the Ph' translocation offers novel 
approaches to the differential diagnosis of human leukemias. In 
particular, because of the relatively small size of the bcr-210 
breakpoint cluster region in the p_h_l gene, it is possible to utilize 
hybridization with a single DNA probe to detect any rearrangement of 
genomic DNA in this region. We report here the results of the clinical 
evaluation of such a DNA probe assay. Specimens obtained from CML 
patients, patients with other leukemias, and non-leukemic controls were 
assessed for the presence of a Ph' translocation by both cytogenetic 
and molecular hybridization analysis. The results show that the DNA 
probe assay provides a highly specific and sensitive clinical 
diagnostic test for Ph'(bcr-210) translocations. 
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METHODS 
Sample source 
Bone marrow and/or peripheral blood cell specimens obtained from 
leukemic individuals and non-leukemic (NL) controls were evaluated at 
seven independent clinical trial sites by both DNA probe and 
cytogenetic (karyotype) analysis. The participating trial sites and 
the total number of patient specimens studied per site are as follows: 
Erasmus University, 25 (I); Leukaemia Research Fund Centre, 53 (II); 
Vanderbilt University Medical School, 59 (III); M.D. Anderson Hospital 
and Tumor Institute, 91 (IV); Memorial Sloan-Kettering Cancer Center, 
111 (V); University of Rochester, 24 (VI); Oncogene Science, Inc., 65 
(VII). 
The diagnosis of CML, ALL, or ANLL was based upon clinical and 
hematological criteria. Samples used in both karyotype and DNA probe 
procedures were obtained from patients on the same day. 230 samples 
were obtained from 218 CML patients with active disease. In 12 cases 
both blood and marrow specimens were obtained simultaneously from the 
same patient and tested by DNA probe analysis. In 14 additional cases, 
samples were obtained from patients after extensive chemotherapeutic 
treatment immediately prior to bone marrow transplantation. 141 of the 
CML specimens were from peripheral blood and 103 were from bone marrow 
aspirates. An additional 34 bone marrow specimens were obtained from 
CML patients in clinical remission after allogeneic bone marrow 
transplantation. 
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Cytogenetics 
Bone marrow samples were cultured overnight, in the absence of 
mitogenic stimulation, in Ham's F10 media supplemented with 10% fetal 
calf serum. Standard cytogenetic procedures were used. Slide 
preparations were pre-treated with trypsin and either stained with 
Giemsa to yield G-banded chromosomes, or stained with quinacrine 
dihydrochloride to yield Q-banded chromosomes. At least 25 metaphase 
spreads were analyzed from each sample (35). The karyotype was 
reported according to the International System for Human Cytogenetic 
Nomenclature (35). 
DNA probe construction 
A DNA probe, designated phl/bcr-210. was designed to detect all 
Ph'(bcr-210) translocations (37, Fig. 2). The probe consists of 
genomic sequences which span the entire 5.8 kb bcr-210 region of the 
phi gene, as well as an additional 5' flanking segment, but lacks an 
internal Hind III restriction fragment of 1.6 kb containing repetitive 
sequences. The probe was assembled using DNA fragments obtained from 
two genomic clones. One clone contained an 11.0 kb Hind III fragment 
including the 5' portion of the bcr-210 region, while the second 
contained a 5.2 kb Hind III fragment including the 3' portion of this 
region. A 2.3 kb Sal I - Hind III fragment and a 2.2 kb Hind III-
BamH I fragment (Fig. 2) were excised by restriction endonuclease 
digestion from the 5' and 3' clones, respectively, and these fragments 
were purified by gel electrophoresis in low melting point agarose. 
The plasmid pSP65 (Promega) was digested with restriction 
endonucleases Sal I and BamH I, and the linearized vector DNA was 
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mixed together with the two purified p M fragments described above. 
The DNA was incubated with T4 DNA ligase under conditions described by 
the supplier (BRL) (38). The ligated preparation was introduced into 
E. coli K12 strain HB101 (39), and transformants were selected by 
growth on ampicillin plates. Plasmid DNA was isolated from individual 
transformed clones, selected randomly, and analyzed for the presence of 
the desired 4.5 kb ßhl insert (resulting from joining of the 2.3 kb Sal 
I - Hind III fragment to the 2.2 kb Hind III - BamH I fragment) by 
digestion with Sal I» BamH I, Hind III, and combinations of these 
restriction endonucleases. 
A clone with the structure shown in Fig. 2, designated T47-1-8, was 
identified and used in all subsequent studies. For purification of the 
phl/bcr-210 probe, circular plasmid DNA was digested with Sal I and 
BamH I, and fragments were separated by electrophoresis on a 1% low 
melting point agarose gel. The 4.5 kb phl/bcr-210 fragment was excised 
from the gel and the agarose was melted by heating at 65° C for 30 
minutes. DNA was extracted twice with phenol, equilibrated with 0.3 M 
sodium acetate (pH 5.0), then once with phenol/chloroform/isoamyl 
alcohol (25:24:1). The extracted DNA fragment was precipitated with 
ethanol (70% final v/v) and 0.2 M sodium acetate (pH 5.6) in the 
presence of 20 g/ml Dextran T-500 as carrier. The precipitated DNA 
was rinsed two times with 70% ethanol, and dissolved in Tris-EDTA 
buffer. 
Isolation of cellular DNA 
High molecular weight DNA was isolated from cells of peripheral 
blood or bone marrow aspirates. Nucleated cells were obtained from 
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peripheral blood by centrifugation on Ficoll-Hypaque (Pharmacia) 
according to manufacturer's recommendations. White blood cells were 
lysed with sodium dodecyl sulfate (38), and DNA was obtained by 
extraction with phenol/chloroform (1:1) and precipitation with two 
volumes of ethanol. RNA and protein were removed from the DNA by 
digestion with RNAse A (final concentration 20 g/ml) for 30 minutes at 
37° C followed by proteinase K (final concentration 100 g/ml) for at 
least 30 minutes at 37° C. The DNA was extracted again with 
phenol/chloroform (1:1), followed by ethanol precipitation as 
described (39). The yield of DNA was determined by absorbance at 260 
nm. 
Hybridization analysis 
The purified cellular DNA was digested with BgT II or another 
restriction endonuclease, and the resulting fragments were separated by 
electrophoresis on an agarose gel (0.7 to 0.8% w/v), and transferred to 
a nitrocellulose or nylon filter by the method of Southern, with minor 
modifications (39,40). The phl/bcr-210 DNA probe was labelled with 3 2P 
to a specific activity of 2 x 10** to 1 x 10^ cpm/ g by either nick 
translation (41) or the random primer method of Feinberg and Vogel stein 
(42,43). Filter hybridization with at least 2.5 x 106 cpm/ml of 
labeled probe was performed overnight at 65° C in a solution 
containing 10 percent dextran sulphate as described elsewhere (44). 
Filters were subjected to several consecutive washing steps for 30 
minutes at 65° C under increasingly stringent conditions (2.5-strength 
SSC to 0.1-strength SSC; SSC = 0.15 M NaCl, 0.015 M sodium citrate). 
After the final wash filters were dried, and hybridized probe was 
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detected by autoradiography using XAR-2 film (Kodak) at -70° C with 
intensifying screens (Dupont Lightning Plus) for four hours or longer. 
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RESULTS 
The Ehl/bcr-210 probe test 
As a consequence of a reciprocal Ph' translocation, two novel 
junctions should be present in genomic DNA, corresponding to the 22q~ 
and 9q+ chromosomes, respectively. If the breakpoint in p_hl lies 
within the bcr-210 region (Fig. 1), then molecular hybridization with a 
DNA probe spanning this region should reveal two rearranged fragments 
in genomic DNA digested with an appropriate restriction endonuclease. 
The pJil/bcr-210 probe (Fig. 2 and Methods) encompasses the entire 
bcr-210 region, with the exception of an internal 1.6 kb Hind III 
fragment found to contain repetitive sequences. Figure 2 indicates the 
human genomic DNA fragments, generated by several restriction 
endonucleases, that hybridize with this probe. For example, digestion 
with Bgl II normally yields three detectable fragments of 4.8, 2.3 and 
1.1 kb (Fig. 2). A translocation involving bcr-210 would disrupt one 
of these fragments and generate two new fragments. Because only one 
copy of chromosome 22 is generally rearranged in Ph'-positive leukemic 
cells, DNA from such cells would be expected to yield up to five DNA 
fragments that can hybridize with the phl/bcr-210 probe, i.e. the three 
germ line DNA fragments and two junction fragments. 
We have found Bgl II to be a suitable restriction enzyme for the 
identification of rearranged p M bcr-210 regions using the phl/bcr-210 
probe (37), because of the excellent electrophoretic resolution of the 
three hybridizable fragments generated by this enzyme, and the apparent 
absence of polymorphism of the four relevant Bgl II target sites in 
human genomic DNA. BamH I, Xba I, and EcoR I can be used as well. A 
149 
Bg Bg X S Bg 
bcr 
H H BgE Bg 
lkb 
i 1 
H H Bg 
_ l I 
1 2 . 3 4 
S Bg H BgE 
phl/ bcr -210 probe 
NORMAL FRAGMENTS GENERATED 
2.3 kb 
I 1 -
11 kb 
13kb 
4.8 kb 1.1 kb 
-H 1 
4.3kb 
3.2 kb 
H 1 
Bgll 
-i Hind 11 
BomHI 
Figure 2. Restriction Hap of phi and Construction of the 
phl/bcr-210 Probe. 
The position of the bcr-210 breakpoint cluster region (labeled bcr), 
and regions of genomic DNA present in the phl/bcr-210 probe 
(cross-hatched boxes) are indicated. Small boxes labeled 1-4 indicate 
positions of coding exons in bcr-210 region of p_h_l gene. Fragments in 
normal genomic DNA generated by digestion with several restriction 
endonucleases, and detectable by the probe are indicated (size in kb) 
at bottom. Restriction endonuclease cleavage sites: E « EcoR I, B -
BamH 1, Bg - Bgl II, X - Xbâ 1, S - Sal I. H = Hind III. 
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rare polymorphism has been observed affecting one of the BamH I sites, 
which may complicate the analysis using this enzyme. Hind III is a 
poor choice of enzyme for the identification of Ph'(bcr-210) 
translocations using the phl/bcr-210 probe, because breakpoints lying 
within the genomic 1.6 kb Hind III fragment, absent from the probe, 
will not be detected (Fig. 2). 
The results of DNA probe analysis to detect Ph'(bcr-210) 
rearrangements in the K562 cell line and in cells of five 
representative Ph'-positive CML patients are shown in Figure 3. The 
HL-60 cell line, derived from a human promyelocytic leukemia with no 
Ph' chromosome, and bone marrow cells of a Ph'-negative CML patient 
served as controls lacking bcr-210 rearragements. Genomic DNA was 
digested with Bgl II, and Southern blot hybridization with the 
phl/bcr-210 probe was carried out as described (Methods). The three 
germ line fragments (4.8, 2.3 and 1.1 kb) are present in every case. 
No additional DNA fragments can be detected in DNA from either HL-60 
cells (lane 1) or from leukemic cells of the Ph'-negative CML patient 
(lane 3). In DNA from the CML cell line K562, one novel band is 
observed (lane 2). This presumably represents a 22q~ fragment, since 
cytogenetic analysis revealed no 9q+ chromosome in these cells (23). 
The intensity of the rearranged band confirms the finding that the 
chimeric phl/c-abl gene is amplified in K562 (23). In three of the 
samples from Ph'-positive CML patients, two novel bands can be seen, 
corresponding to the junctions present in the 22q" and 9q+ chromosomes 
(lanes 4,6,8). Another CML patient sample (lane 5) also appears to 
have two rearranged DNA fragments, but one co-migrates with the 2.3 kb 
germ line fragment, as judged by the intensity of the corresponding 
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Figure 3. Assay for Ph'(bcr-210) Translocations by 
Hybridization with pM/bcr-210 Probe 
DNA from control cell lines or patient specimens was digested with Bgl 
II and analyzed for the Ph'(bcr-210) translocation by DNA probe assay 
as described (Methods). Sources of DNA: (1) HL-60 cell line (human 
acute promyelocyte leukemia); (2) K562 cell line (human CHL); (3) Ph'-
negative CML patient specimen; (4 - 8) Ph'-positive CHL patient 
specimens. Positions of germ line bands (sizes in kb) are indicated at 
left. 
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autoradiographic band. In the analysis of one of the Ph'-positive 
leukemic DNA samples, only a single extra DNA fragment is apparent 
(lane 7). It is possible that a small rearranged fragment ran off the 
gel or that a 9q+ fragment is not present in these cells. 
Assay sensitivity 
In order to determine the minimal fraction of leukemic cells 
detectable by the probe test, we performed mixing experiments using DNA 
samples obtained from peripheral blood of a CML patient and from a 
non-leukemic individual. By cytogenetic analysis, all dividing bone 
marrow cells analyzed from the CML patient were found to contain a Ph' 
chromosome. Normal and leukemic DNA were mixed in varying ratios, the 
DNA was digested with Bgl II restriction endonuclease, and a total of 
15 g DNA per slot was separated by gel electrophoresis and analyzed by 
Southern hybridization with ^^p_-|
 abel ed phl/bcr-210 probe. The 
results of this experiment are shown in Figure 4. The anticipated germ 
line fragments (4.8, 2.3, 1.1 kb) are present in both the normal and 
leukemic DNA samples. A single novel junction fragment (labeled Ph') 
of approximately 4 kb is observed in the CML patient DNA. The 
intensity of the corresponding band is roughly proportional to the 
fraction of leukemic DNA in the input sample, a conclusion supported by 
densitometric scanning, and ten percent Ph'-positive DNA is readily 
detectable in a short autoradiographic exposure (Fig. 4A). We repeated 
the analysis using smaller percentages of leukemic DNA, and a longer 
exposure time (Fig. 4B). The results of this and comparable 
experiments indicate that the phl/bcr-210 probe assay can routinely 
detect less than five percent leukemic DNA, and that as little as one 
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Figure 4. Sensitivity of j>hl/bcr-210 DNA Probe Analysis. 
DNA from a CML patient and a normal donor were mixed and analyzed by 
digestion with BgJ. II and blot hybridization with the pM/bcr-210 
probe, by the method of Southern, as described in the text. (A) and 
(B) show independent experiments using DNA from the same individuals. 
Percentage of leukemic DNA is denoted above each lane. Positions of 
normal germ line DNA fragments (sizes in kb) are indicated at left. 
Arrow labeled Ph' indicates position of the rearranged DNA fragment 
from the CHL patient. Autoradiographic exposure times: (A) 4 hours; 
(B) 20 hours. 
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percent leukemie DNA can be observed under favorable conditions. 
Reconstruction experiments in which leukemic and normal cells were 
mixed in varying ratios prior to DNA isolation demonstrated a similar 
assay sensitivity (data not shown). 
The sensitivity of the probe assay would be expected to show some 
dependence on the size of the rearranged DNA fragments, since smaller 
fragments give a less intense hybridization signal. However, to date, 
all Ph'(bcr-210) samples have shown at least one rearranged Bgl II 
restriction fragment larger than 2.3 kb. Thus, the reconstruction 
experiment of Fig. 4 should accurately represent the situation in the 
vast majority of clinical specimens. 
Clinical application 
The DNA probe assay was compared with cytogenetic analysis 
in the diagnosis of Ph'-positive leukemia in over 400 leukemic 
patients and control individuals tested at seven trial sites. 
Karyotyping was carried out on cells obtained from bone marrow 
aspirates, while the probe analysis was carried out on DNA extracted 
from peripheral blood or bone marrow. Most specimens for the two 
assays were obtained at the time of initial presentation at a clinic. 
In all cases Bgl II restriction endonuclease was used to digest genomic 
DNA. If the results obtained with this enzyme were ambiguous, or in 
cases of apparent discrepancy between cytogenetic observations and the 
DNA probe assay, the probe analysis was repeated using DNA digested 
with at least one other restriction endonuclease (usually BamH I). The 
results of the study are summarized in Table 1. 
Both the cytogenetic and DNA hybridization assays revealed Ph' 
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translocations only in samples from patients with leukemia, and not in 
any of 93 non-leukemic controls. This confirms the specificity of the 
probe test. 
Among 232 cases of clinically diagnosed CML, 203 were Ph'-positive 
by cytogenetic analysis. 218 of the patients had clinically active 
disease, while 14 were in apparent clinical remission induced prior to 
bone marrow transplantation. Among the latter group, karyotype 
analysis revealed a population of residual Ph'-positive cells in 12. 
Hybridization with the phl/bcr-210 probe showed definitive evidence 
of DNA rearrangement in 201 of the 203 Ph'-positive CML patients (99%). 
In neither of the two apparently discrepant cases (both tested at site 
V) was the probe analysis confirmed using a restriction endonuclease 
other than Bgl II, so it remains to be determined whether these 
represent examples of rearrangements occurring within or outside of the 
bcr-210 region. Furthermore, in one case in which the probe analysis 
failed to confirm a positive karyotype, the patient was sampled during 
induced clinical remission immediately prior to transplantation. 
The DNA probe assay revealed novel p M junction fragments in an 
additional 12 clinically CML cases in which karyotype analysis failed 
to detect a Ph' chromosome. In two of these cases, cytogenetic 
analysis showed the presence of a complex rearrangement, while in 10 
cases a normal diploid karyotype was reported. 
Among six cases of cytogenetically Ph'-positive ALL, only two showed 
bcr-210 rearrangements using the DNA probe test. It seems very likely 
that in each of the four remaining cases the breakpoint on chromosome 
22 was located within the bcr-190 region of p M (Fig. 1), and therefore 
could not be detected by hybridization with the phl/bcr-210 probe. In 
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Table 1. Comparison of phl/bcr-210 DNA Probe Assay and 
Cytogenetic Analysis in Clinical Diagnosis of 
Ph'-positive Leukemia 
DIAGNOSIS KARYOTYPE DNA PROBE POSITIVE / NUMBER TESTED 
(NUMBER) PH' CELL SOURCE TOTAL 
PB BM 
CML (232) + 121 / 121* 80 / 82 201 / 203* 
4 / 8 8 / 2 1 1 2 / 2 9 
ALL 
ANLL 
NL 
(24) 
(33) 
(93) 
+ 
-
+ 
-
-
2 / 4 
0 / 6 
0 / 1 
1 / 21 
0 / 7 0 
0 / 2 
1 / 12 
0 / 1 1 
0 / 2 3 
2 / 6 
1 / 18 
0 / 1 
1 / 32 
0 / 9 3 
PB = peripheral blood; BM = bone marrow; CML = chronic myelogenous 
leukemia; ALL = acute lymphocytic leukemia; ANLL = acute non-
lymphocytic leukemia; NL = non-leukemic. 
*From 12 Ph'-positive CML patients DNA was obtained from both PB and BM 
with consistent probe test results. For these 12 patients only the BM 
data are included in the Table. 
In the two apparently discrepant cases, probe analysis was carried out 
only on DNA digested with Bgl II. 
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one additional case the probe test disclosed a Ph'(bcr-210) 
rearrangement that was not detected by cytogenetics. 
Only one example of a visible Ph' chromosome was reported among 33 
cases of clinically diagnosed ANLL, and this specimen was negative by 
DNA probe analysis. Conversely, in another case the probe test 
revealed a bcr-210 rearrangement in the absence of an obvious Ph' 
karyotypic abnormality. 
A diagnostic test for the Ph'(bcr-210) rearrangement has potential 
utility in monitoring patients during the course of therapy. At two 
test sites (III and V) specimens were analyzed from CML patients in 
clinical remission, immediately prior to or several months after 
undergoing allogeneic bone marrow transplantation. In 11 of 12 samples 
obtained prior to transplantation (site V), residual Ph'-positive 
leukemic cells could be detected by both cytogenetic and DNA probe 
analysis, while in one specimen a cytogenetically observed Ph' 
chromosome was not confirmed by the DNA probe test. 
A total of 34 specimens from 31 different patients were sampled from 
post-transplant CML patients in clinical remission (Table 2). In about 
one-half of these cases, both cytogenetic and DNA probe analysis were 
negative. However, in the remaining cases either one or both assays 
revealed a Ph' translocation, indicative of residual leukemic cells. 
The DNA probe test was more successful than cytogenetic analysis in 
detecting these Ph'-positive cells (15 versus 10 positive specimens), 
but there were three cases in which hybridization with the phl/bcr-210 
probe did not corroborate positive karyotypic results. 
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Table 2. Detection of Ph' Translocation in CML Patients in 
Clinical Remission after Bone Marrow Transplantation 
TEST RESULTS NUMBER OF SAMPLES 
KARYOTYPE DNA PROBE 
16 
+ + 7 
+ - 3 
+ 8 
During this study a few CML patients were tested sequentially at 
intervals before and after allogeneic bone marrow transplantation. Two 
cases proved of particular interest. 
From one patient at site V an initial specimen of splenic tissue was 
obtained just prior to transplantation, and the presence of a 
Ph'(bcr-210) chromosome was verified by both karyotype and DNA probe 
analysis. Eight months after allogeneic transplantation the patient's 
disease was in remission, and both cytogenetic and probe assays were 
negative. A specimen taken at fifteen months after transplantation 
still showed a normal diploid karyotype, and the patient remained in 
clinical remission. However, DNA probe analysis carried out at this 
time revealed a rearranged bcr-210 DNA fragment, suggesting the 
presence of a population of Ph'-positive leukemic cells. This patient 
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is still being followed. 
In the second case (studied at site III) the diagnosis of 
Ph'-positive CML was confirmed at presentation by both cytogenetic and 
DNA probe assays. The patient was brought into remission and received 
a bone marrow transplant. Several months later the patient was 
clinically disease-free, and the karyotype appeared normal, but the 
phl/bcr-210 probe test revealed a rearranged DNA fragment. 
Densitometrie analysis suggested that this represented a population of 
no more than five percent cells with a Ph' translocation. Several 
months later the patient developed a clinical relapse resembling an 
acute lymphoblastic crisis. At this time cytogenetic analysis was 
attempted, but adequate chromosome spreads were not obtained. However, 
the DNA probe test showed a high level of a rearranged bcr-210 DNA 
fragment in bone marrow cells. Comparison of the mobility of the 
junction fragments obtained by restriction endonuclease digestion with 
Bgl II showed that the same rearrangement was present in DNA obtained 
during the chronic phase of CML, during apparent remission after 
transplantation, and at the time of the clinical relapse. This implies 
that the lymphoblastic cells observed at relapse were derived from the 
same leukemic clone that was present in the patient during the chronic 
phase of CML prior to transplantation. The patient has subsequently 
died, and no additional karyotyping could be done for confirmation. 
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DISCUSSION 
Elucidation of the molecular structure of the Ph' translocation has 
resulted in the first oncogene-based assay for the diagnosis of a 
specific form of human cancer, CML. We have constructed an improved 
DNA probe, phl/bcr-210. to detect rearrangements in the bcr-210 segment 
of the p_hl gene which are associated with activation of the c-abl 
oncogene. The assay entails Southern blot hybridization of the probe 
to genomic DNA fragments generated by digestion with Bgl II or another 
restriction endonuclease. In the clinical study described here the 
probe test correctly identified 99 percent of confirmed cases of 
Ph'-positive CML. Furthermore, no false positive results were 
obtained among 93 samples from non-leukemic individuals. This 
indicates that the four Bgl II restriction sites critical to the assay 
are highly conserved and that extraneous Bgl II sites in this region 
occur rarely, if at all, in the human population. 
The DNA probe test also revealed rearrangements of the 
characteristic breakpoint cluster region of the p_hl gene (bcr-210) in 
12 out of 29 cases (41%) of karyotypically Ph'-negative CML, only two 
of which showed complex chromosomal rearrangements. In agreement with 
this observation, others have demonstrated both a bcr-210 rearrangement 
and the expression of a P210 phl/abl tyrosine protein kinase in some 
CML cases lacking a marker chromosome (45-49). Wiedemann and 
colleagues (45) recently reported that in Ph'-negative CML the presence 
or absence of the DNA rearrangement correlates with clinical and 
morphological features. Among 12 such cases reviewed in their study, 
five were clinically indistinguishable from Ph'-positive CML, and these 
were marked by molecular rearrangements of bcr-210 and, where tested, 
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expression of P210 phl/abl. The remaining seven cases involved no bcr 
rearrangement detectable by the phl/bcr-210 probe test. Upon 
independent review, these leukemias were reclassified on the basis of 
cellular morphology and clinical features as either atypical CML (aCML; 
6 cases) or chronic myelomonocytic leukemia (CMML; 1 case). Thus, 
irrespective of the presence of a visible Ph' chromosome, CML 
involving a breakpoint in the bcr-210 region appears to define a 
distinct clinical entity. 
Among 203 patients with Ph'-positive CML, as judged by karyotype, 
only two did not appear to have a DNA rearrangement in bcr-210. One of 
these probe-negative specimens was obtained from a patient after 
radical chemotherapeutic treatment, shortly before bone marrow 
transplantation, and might have contained very few leukemic cells. 
Neither discrepant case was confirmed by analysis of DNA using a second 
restriction endonuclease, and it remains possible that a breakpoint was 
present in the bcr-210 region, but was not detected. Alternatively, 
although almost all translocation breakpoints in Ph'-positive CML lie 
within bcr-210 (21,37,50,51), a small minority may lie outside of this 
cluster region (52,53; our data would indicate a frequency of one 
percent or less). 
A somewhat higher frequency (3/34) of specimens from patients in 
clinical remission after allogeneic bone marrow transplantation were 
Ph'-positive by cytogenetic analysis, but showed no evidence for a 
bcr-210 rearrangement by DNA probe test with a single restriction 
endonuclease (Bgl II). A partial explanation for this observation may 
be that leukemic cells were infrequent in these samples, so that both 
cytogenetic and DNA probe assays were pushed near to their thresholds 
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of sensitivity, leading to some discrepant results due to sampling 
variation. For example, in some cases Ph'-positive cells might have 
grown out selectively during in vitro culture for cytogenetic 
analysis. It is also possible that secondary deletions or entirely new 
translocations are selected preferentially in this group of patients. 
However, in the one case in which specimens from a single patient were 
studied sequentially during chronic phase CML, during a post-transplant 
clinical remission, and at the time of a lymphoblastic relapse, the 
same bcr-210 rearrangement was observed at each point. Similarly, 
Ganesan et al. reported four CML cases cases in which leukemic cells 
present before allogeneic bone marrow transplantation and after relapse 
were derived from the same clone, as judged by identity of the bcr-210 
rearrangement (54). 
The chromosomal rearrangements in Ph'-positive ALL recently 
have come under intense scrutiny. Two classes of phl/c-abl gene 
fusions are found. One group has molecular characteristics 
indistinguishable from those in Ph'-positive CML, and may represent 
cases in which clinically silent CML progresses to a lymphoblastic 
crisis. For this group the phl/bcr-210 probe can be used to diagnose 
the presence of the Ph'(bcr-210) translocation. The second group is 
distinguished by rearrangements with breakpoints in a ßhl gene intron 
located upstream of those typically involved in CML, defining a region 
we call bcr-190. The Ph'(bcr-190) translocations cannot be identified 
utilizing the assay described here, although the phl/bcr-210 probe 
would detect such rearrangements if sufficiently large DNA restriction 
endonuclease fragments were generated and resolved, for example by 
pulsed field gel electrophoresis (55,56). In ALL the Ph' chromosome is 
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generally associated with extremely poor prognosis (10,16,57). It will 
be of interest to determine the particular clinical implications of 
the Ph'(bcr-210) and Ph'(bcr-190) rearrangements, which give rise to 
similar but distinct phl/c-abl fusion proteins (P210 and P190, 
respectively) with elevated tyrosine protein kinase activity. 
The same molecular heterogeneity in the precise location of 
breakpoints may be involved in Ph'-positive ANLL as in Ph'-positive ALL 
(58,59). In our study only two of 33 ANLL specimens showed evidence 
for a Ph' translocation. In one sample cytogenetic analysis 
established the presence of a Ph' chromosome, but no rearrangement of 
bcr-210 could be found by DNA probe assay. Assays for activated abj. 
kinase might suggest whether such cases involve rearrangements in 
bcr-190, or elsewhere on chromosome 22. In the second example the 
probe test revealed a bcr-210 rearrangement, although a Ph' chromosome 
was not apparent in the karyotype. As in Ph'(bcr-210)-positive ALL, 
such cases of ANLL may progress from clinically unrecognized CML. 
In summary, the phl/bcr-210 DNA probe assay compares very favorably 
with karyotype analysis as a specific diagnostic test for CML. The 
probe assay can be carried out on peripheral blood specimens as well as 
bone marrow aspirates, identifies the translocation in at least 99 
percent of cases of cytogenetically Ph'-positive CML, and reveals a 
significant number of phl/c-abl translocations not detected by 
karyotype analysis. Furthermore, the test offers useful information, 
that cannot be obtained from cytogenetics, in the differential 
diagnosis of atypical CML, CMML, and those cases of Ph'-positive ALL 
and ANNL involving bcr-210 rearrangements. As treatment of the 
leukemias becomes increasingly sophisticated, it seems highly probable 
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that the precise diagnosis of these diseases, at the molecular level, 
will be accompanied by the development of distinct therapeutic 
strategies for each identifiable class. 
The DNA probe test is likely to find a second major use in 
monitoring CML patients, particularly to determine the response to 
therapy. A key consideration for this application is assay 
sensitivity. Reconstruction experiments indicate that Southern 
hybridization with the pjil/bcr-210 probe test can reveal leukemic 
cells present at one percent in a peripheral blood or bone marrow 
cellular population. The threshold for detection of Ph'-positive 
cells by karyotype analysis depends on the number of metaphase spreads 
studied per sample, but is usually in the range of ten percent of the 
cell population. Thus, under routine laboratory conditions the probe 
assay appears several to ten-fold more sensitive than conventional 
cytogenetic analysis. 
Recent reports demonstrate that hematological remission of CML can 
be induced by recombinant human interferon alpha-A, and possibly 
interferon-gamma (60,61,62). In some patients the fraction of bone 
marrow cells containing the Ph' chromosome drops significantly. This 
has been demonstrated most convincingly by molecular hybridization 
analysis (63,64). Similarly, the DNA probe assay should have utility 
in monitoring the response of CML patients to other biological response 
modifiers, such as granulocyte colony-stimulating factor (65). 
Recent advances in bone marrow transplantation suggest that this 
approach will play an increasingly important role in the treatment of 
CML (54,66-69). Although the systematic study of allogeneic transplant 
recipients was outside the main focus of the present work, we found 
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that the phl/bcr-210 DNA probe assay readily revealed residual leukemic 
cell populations in nearly half of such patients sampled during 
clinical remission after transplantation (Table 2). The superior 
sensitivity of the probe test, and its precision in the identification 
of Ph'(bcr-210) translocations clearly make it a powerful tool to 
supplement clinical observation and cytogenetic analysis in following 
the complex biology of bone marrow transplantation. 
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Concluding remarks 
The experiments described in this thesis show that as a 
consequence of the Ph' translocation, a new P210 phl/c-abl fusion-
protein is expressed in the leukemic cells of Ph' chromosome positive 
CML patients. The results demonstrate that translocation of a cellular 
oncogene c-abl. can result in the activation of its gene product. The 
phl/c-abl protein has an increased tyrosine specific protein kinase 
activity. 
The specific contribution of the p M moiety to the P210 phl/c-abl 
protein kinase activity is unclear. No homology of p M to sequences of 
known proteins have been found. Although experiments have suggested 
that the loss of amino terminal abl sequences can result in activation 
of the abj. kinase, a change in protein configuration, or phospho-
rylation of the p M domain may affect the kinase activity as well. It 
has been demonstrated that the In vitro phosphorylation patterns of the 
P145 c-abl. P210 phl/c-abl and P190 phl/c-abl differ. This different 
manner in which the abl proteins utilize themselves as substrates in 
vitro suggest that they may interact differently with substrate in 
vivo; they may have different substrate specificities. Deletion of p M 
amino acids in P190 phl/c-abl compared to P210 phl/c-abl removes a part 
of the p M protein, which may be involved in controlling the action of 
the c-abl moiety of the protein. This may explain why the presence of 
P190 is associated with an acute leukemia, in which there is autonomous 
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growth of immature invasive lymphoid blast cells, while P210 in CML is 
present in an initially non-aggressive tumor with an excess of 
apparently normal myeloid cells of all differentiation stages. It is 
not clear whether the presence of the phi domain has an effect on the 
location of the abj. protein. The NH2 terminal p M sequences do not 
provide a myristilation site for association to the membrane. This 
site is indispensable for the transforming capacity of P160 qag/abl. 
Apart from the fact that the phi gene is involved in the Ph' 
translocation little is known regarding its translational product. The 
identification of the normal ph_l gene product is of importance, since 
it may give us insight into whether the part of the phi protein 
appended to the truncated c-abl protein plays any role in the 
properties of P210 phl/c-abl. In this thesis we present evidence that 
the p M gene encodes an 160 K phosphoprotein with an associated kinase 
activity. However, it is not shown whether this activity is intrinsic. 
The evidence does not distinguish whether this activity is inherent or 
due to a protein kinase activity tightly associated with P160 phi. 
Many questions as to what is the primary event that causes CML and ALL, 
what is responsible for initiation of the blastcrisis in CML, and what 
is the role of P210 and P190 in tumorigenesis still remain to be 
elucidated. Introduction of full length 7 kb and 8.5 kb phl/c-abl 
cDNAs in in vitro hematopoietic culture systems and in transgenic mice 
will be necessary to define the precise role of these proteins and 
hence of the Ph' translocation in the pathogenesis of CML and ALL. 
Molecular analysis of the Ph' chromosome demonstrated the 
possibility of the use of DNA probe analysis in diagnostics. A probe 
test specific for translocations in bcr has been developed and has been 
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shown to overcome several of the limitations of karyotypic detection of 
the Ph' chromosome in CML. The present DNA based test requires the 
isolation of DNA from the patients leukemic cells, restriction enzyme 
digestion, electrophoresis and Southern blot analysis with a 3^P 
labeled probe. However, the probe does not allow the detection of the 
c-abl translocation in the Ph'-positive, bcr negative ALL patients. It 
will be necessary to identify the breakpoint of a larger number of Ph'-
positive, bcr negative ALL patients to establish the possibility of 
another breakpoint cluster region in the EJLL gene. The presence of 
such a region will initiate efforts to develop a probe specific for 
translocation in this region. Specific probe tests for Ph' positive 
CML and ALL would contribute to the accurate diagnosis of these 
diseases. As treatment of the leukemias becomes increasingly 
sophisticated, it is highly probable that the differential diagnosis of 
ALL at the molecular level will be accompanied by the development of 
distinct therapeutic strategies for each identifiable class. 
The use of DNA probes to diagnose specific chromosomal 
rearrangements associated with human cancer presents several general 
advantages, which are exemplified by studies of the Ph' translocations. 
The tests should be more accurate than cytogenetic analysis, 
particularly because complex rearrangements are frequently difficult to 
resolve by chromosome banding techniques. The tests may also be more 
sensitive than karyotyping with respect to the detection of a small 
percentage of abnormal cells, and thus should have particular utility 
in the monitoring of patients during disease remission for early 
indication of relapse. As noted above, DNA probes can discriminate 
between related forms of cancer which have minor differences at the 
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molecular level, and which cannot be distinguished by cytogenetics or 
histopathology. In the case of CML and other leukemia, DNA tests can 
be performed on peripheral blood cells, obviating the need for bone 
marrow biopsy. Finally, the probe tests should prove considerably less 
expensive than karyotyping, and, especially if non-isotopic methodology 
can de developed, should be easier to implement in typical clinical 
laboratories. 
Although DNA probe analysis is faster than cytogenetic methods, 
the procedure is still relatively complex and takes five days to 
perform. Since the Ph' chromosome is, besides a diagnostic marker, a 
prognostic marker as well, early diagnosis is required. The 
development of immunological assays could allow a rapid, convenient and 
accurate diagnosis of Ph' positive CML and ALL. Antisera specific for 
abl and p_h_l sequences or antisera made against the junction domain of 
the P210 and P190 proteins could be used for the detection of the 
aberrant abj. proteins in patients sera, plasma or lysates of peripheral 
blood. 
Early diagnosis plays an important role in leukemia research. 
However, the ultimate goal is to find ways to cure patients with this 
disease. CML is in most cases incurable. The presence of an activated 
tyrosine protein kinase implicated in CML could be a target for drugs 
inhibiting its activity. Another equally valid approach is to find 
drugs activating the tyrosine specific protein phosphatases. 
Establishment of normal phosphorylation levels in the cell may be a 
novel approach with regard to cancer chemotherapy. 
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Samenvatting 
Cytogenetisch onderzoek heeft aangetoond dat een aanzienlijk aantal 
humane tumoren, vooral leukemieen en lymfomen geassocieerd is met 
consistente specifieke chromosomale afwijkingen. Het Philadelphia (Ph') 
chromosoom, aanwezig in meer dan 95 procent van de patiënten met 
chronische myeloide leukemie (CML), is een van de meest karakteristieke 
en best gedokumenteerde voorbeeld van zo'n afwijking. Dit chromosoom is 
gewoonlijk het resultaat van een reciproke translokatie tussen 
chromosoom 9 en 22 (t(9;22)(q34;qll)). Hierbij ontstaat een kleiner 
chromosoom 22 (22q- of Ph') en een groter chromosoom 9 (9q+). Met 
behulp van somatische celhybriden en in situ hybridisatie werd 
aangetoond dat het oncogen c-abl, gelegen op chromosoom 9, verhuist 
naar het Ph' chromosoom, abl blijkt ook in de gevallen waar chromosoom 
9 niet zichtbaar betrokken is in de translokatie, naar chromosoom 22 te 
verhuizen. Deze gegevens en de vinding dat in een CML patient het 
breukpunt 14 kb van de v-abj. homologe c-abl sequenties gelegen is, 
suggereren een rol voor c-abl in CML. Dit idee wordt gesteund door de 
ontdekking dat in de CML cellijn K562 een groter c-abl mRNA en eiwit 
aanwezig is. 
De isolatie van het breukpunt fragment van een CML patient maakte 
het mogelijk om een chromosoom 22 specifieke DNA probe te construeren. 
Met deze probe kan worden aangetoond dat op chromosoom 22 een gebied 
aanwezig is waarin de breukpunten van de verschillende CML patiënten 
geklusterd voorkomen. Dit gebied wordt breakpoint cluster region (bcr) 
genoemd, bcr bleek deel uit te maken van een gen, genaamd p_hl 
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(Hoofdstuk 3). Dit ghl gen wordt overgeschreven in een 4,5 en 7 kb 
raRNA molecuul (Hoofdstuk 4,5 ). In immunoprecipitaties met ßhl 
antiserum werd een 160K fosfo-proteine geprecipiteerd waarmee kinase 
activiteit geassocieerd is (Hoofdstuk 6). Niet aangetoond kon worden 
echter of deze activiteit intrinsiek is. De cellulaire functie van het 
phl eiwit is tot nu toe onbekend. 
Het ßh_l gen is gelegen met het 5' uiteinde gericht naar de 
centromeer en met het 3' uiteinde naar de telomeer van chromosoom 22 
(Hoofdstuk 3). Als gevolg van de Ph' translokatie gaat een deel van 
het ßhl gen, het 3' uiteinde, naar chromosoom 9 terwijl het 5' uiteinde 
op het Ph'chromosoom blijft. De achterblijvende ßhl sequenties fuseren 
met het c-abj. gen. Northern blot analyse van het RNA uit de leukemie 
cellen van CML patiënten laat zien dat deze genomische configuratie 
resulteert in de transcriptie in een 8,5 kb hybride RNA waarvan het 5' 
uiteinde afkomstig is van het ßhj. gen en het 3' uiteinde van het c-abl 
gen (Hoofdstuk 4). Dit RNA komt ook voor in de CML cellijn K562. Een 
direct bewijs hiervoor word geleverd door de klonering van een cDNA 
overeenkomend met het chimaere RNA (Hoofdstuk 5). Aangezien in K562 en 
in alle Ph' chromosoom positieve CML patiënten het 8,5 kb chimère 
transcript wordt aangetroffen ondanks dat de breukpunten op chromosoom 
9 verspreid zijn over een gebied dat varieert van 5 kb tot meer dan 175 
kb, lijkt het splicing systeem erg flexibel te zijn en geen moeite te 
hebben met de grote variatie in intron grootte tussen de ßh_l en c-abl 
genen. 
Translatie van het 8,5 kb transcript resulteert in de synthese van 
een 210K fusie-eiwit met een amino terminaal ßhl en een carboxy 
terminaal c-abl uiteinde (Hoofdstuk 6). Dit eiwit heeft in vergelijking 
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met het normale c-abl eiwit hogere tyrosine kinase activiteit en is in 
vivo gefosforyleerd op tyrosine. Het is nog niet duidelijk wat de 
preciese rol van dit eiwit is. Thans wordt verder onderzocht met behulp 
van transfectie experimenten of dit eiwit transformerende eigenschappen 
heeft, en indien dit het geval is welke rol de tyrosine kinase 
activiteit daarbij speelt. 
De kennis van de genetische basis van CML kan gebruikt worden in 
de diagnostiek. Naast detectie van het Ph' chromosoom door middel van 
cytogenetische methoden is het nu ook mogelijk deze translokatie te 
detecteren door hybridiseren van Southern blots van genomisch DNA met 
een geschikte DNA probe. Deze toets heeft het voordeel boven 
karyotypering dat het niet noodzakelijk is uit te gaan van actief 
delende cellen. Bovendien kan in plaats van beenmergcellen ook bloed 
worden gebruikt. Het klinische onderzoek naar de toepassingsmogelijk-
heden van deze methode is uitgevoerd in 7 verschillende onderzoeks 
centra. Aangetoond word dat er in CML patiënten met het Ph' chromosoom 
de correlatie tussen karyotypering en probe analyse 99% is (Hoofdstuk 
7). Met de probe kunnen meer complexe translokaties worden aangetoond 
die met karyotypering niet of zeer moeilijk te detecteren zijn. Daarbij 
is ook de detectiegrens, waarbij de aanwezigheid van leukemie cellen 
nog kan worden aangetoond bij DNA probe analyse lager dan bij 
karyotypering, respectievelijk 1 en 10 procent. Gevoeligheid van de 
detectie methode is van belang voor het volgen van de patient tijdens 
de remissie en voor de vroege detectie van relapse. 
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